Direct genome editing

The CRISPR-guided DNA ligase system provides a self-contained solution for precise gene editing in non-dividing cells by replacing DNA without double-strand breaks, addressing inefficiencies and toxicity in existing methods.

JP2024543481APending Publication Date: 2024-11-21REPLACE THERAPEUTICS LLC
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
JP2024528467
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-05-12
Filing Date
2022-11-09
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Existing gene editing methods rely on endogenous cellular machinery, such as HDR and NHEJ, which are inefficient in non-dividing cells and can introduce unintended mutations and toxicity, limiting precision and efficiency.

Method used

A self-contained gene editing system using CRISPR-guided DNA ligases and guide nucleic acids that target genomic regions without creating double-strand breaks, allowing precise replacement of DNA through a donor strand, independent of endogenous repair mechanisms.

Benefits of technology

Enables efficient and precise gene editing in non-dividing cells by eliminating reliance on cellular repair systems, reducing unintended mutations and enhancing editing efficiency.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024543481000001_ABST
    Figure 2024543481000001_ABST
Patent Text Reader

Abstract

Described herein are compositions, systems, and methods for nucleic acid editing. Editing can be accomplished using a ligase coupled to an endonuclease. Nucleic acid editing can include ligating an integrating nucleic acid to a target nucleic acid. Nucleic acid editing can include replacing a portion of a target nucleic acid with an integrating nucleic acid.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] cross reference This application claims the benefit of U.S. Provisional Patent Application No. 63 / 278,886, filed November 12, 2021, and U.S. Provisional Patent Application No. 63 / 341,200, filed May 12, 2022, each of which is incorporated by reference in its entirety.

[0002] Sequence Listing This application contains a Sequence Listing that has been submitted electronically in XML file format and is incorporated herein by reference in its entirety. The XML copy created on November 9, 2022 is named Replace Therapeutic 62942-701601(PCT).xml, and is 703,891 bytes in size. [Background technology]

[0003] Improved gene editing methods are needed to modify nucleic acids. Summary of the Invention

[0004] Disclosed herein, in some embodiments, is a system or composition comprising a DNA binding protein coupled to a DNA ligase. The DNA binding protein may comprise an endonuclease. The endonuclease may comprise an RNA-guided endonuclease. In some embodiments, the coupling is a covalent bond. Some embodiments include a fusion protein comprising a DNA binding protein (e.g., an endonuclease, such as an RNA-guided endonuclease) and a DNA ligase. Some embodiments include a composition comprising a cell containing a DNA binding protein (e.g., an endonuclease, such as an RNA-guided endonuclease) and a DNA ligase, both of which are heterologous to the cell. In some embodiments, the DNA binding protein is amino (N)-terminal to the DNA ligase in the fusion protein. In some embodiments, the DNA binding protein is carboxy (C)-terminal to the DNA ligase in the fusion protein. In some embodiments, the connection comprises a linker comprising 1-100 amino acids. In some embodiments, the coupling is a non-covalent bond. In some embodiments, the composition comprises a first polypeptide comprising at least a portion of a DNA binding protein and a second polypeptide comprising at least a portion of a DNA ligase, the first and second polypeptides being non-covalently coupled. In some embodiments, the first polypeptide comprises a first heterodimerization domain that binds to a second heterodimerization domain, and the second polypeptide comprises a second heterodimerization domain. In some embodiments, the heterodimerization domain comprises a leucine zipper, a PDZ domain, streptavidin, a streptavidin binding protein, a foldon domain, a hydrophobic portion, or a functional binding fragment thereof. In some embodiments, the first polypeptide comprises a first intein that binds to a second intein, and the second polypeptide comprises a second intein. In some embodiments, the ligase comprises a hairpin binding motif, and the DNA binding protein and the DNA ligase are coupled to a nucleic acid comprising a scaffold that binds to the DNA binding protein and a hairpin that binds to the hairpin binding motif.In some embodiments, the hairpin binding motif comprises an MS2 coat protein (MCP) peptide and the hairpin comprises an MS2 hairpin. In some embodiments, the DNA binding protein and the DNA ligase are coupled to a heterobifunctional molecule comprising an endonuclease binding domain and a DNA ligase binding domain. In some embodiments, the heterobifunctional molecule comprises a small molecule. In some embodiments, the DNA binding protein comprises a class II CRISPR / Cas endonuclease. In some embodiments, the DNA binding protein comprises a Cas9 endonuclease. In some embodiments, the DNA binding protein comprises a nickase. In some embodiments, the DNA binding protein comprises an amino acid sequence at least 80% identical to the amino acid sequence of any one of SEQ ID NOs: 1-13, or a functional fragment thereof. In some embodiments, the DNA ligase ligates DNA strand bases paired to the DNA splint. In some embodiments, the DNA ligase ligates DNA strand bases paired to the RNA splint. In some embodiments, the DNA ligase comprises an amino acid sequence at least 80% identical to the amino acid sequence of any one of SEQ ID NOs: 55-96, or a functional fragment thereof. In some embodiments, the DNA binding protein or DNA ligase comprises a nuclear localization signal, a chromatin modifying domain, a cell penetrating peptide, or a tag polypeptide. Some embodiments include a guide RNA and an integrating nucleic acid. Some embodiments include one or more nucleic acids encoding the composition. Some embodiments include a cell comprising the composition or comprising one or more nucleic acids.

[0005] Disclosed herein are methods of editing that, in some embodiments, include contacting a target nucleic acid in a cell with an endonuclease at a predetermined locus of the target nucleic acid, thereby introducing a nick at the predetermined locus of the target nucleic acid, introducing a pre-synthesized integrating nucleic acid into the cell, and ligating the 5' end of the pre-synthesized integrating nucleic acid to the 3' end of the nick at the predetermined locus of the target nucleic acid. In some embodiments, the endonuclease comprises a class II CRISPR / Cas endonuclease. In some embodiments, the endonuclease comprises a Cas9 nickase. Some embodiments include contacting the endonuclease and the predetermined locus of the target nucleic acid with a guide nucleic acid. In some embodiments, said ligation is performed by a ligase coupled to the endonuclease. In some embodiments, the pre-synthesized integrating nucleic acid comprises a mutation with respect to the target nucleic acid. In some embodiments, the nick comprises a single phosphodiester strand break in an otherwise double-stranded target nucleic acid. In some embodiments, the nick comprises a non-sticky, non-blunt end of a strand of the target nucleic acid. In some aspects, the target nucleic acid comprises a chromosome of the cell. In some aspects, the cell is eukaryotic.

[0006] Disclosed herein is an editing system that includes, in some embodiments, a ligase, an endonuclease that introduces a nick at a predetermined locus of a target nucleic acid, and a pre-synthesized integrating nucleic acid that includes a 5' end that is ligated by the ligase to the 3' end of the nick at the predetermined locus of the target nucleic acid. In some embodiments, the endonuclease includes a class II CRISPR / Cas endonuclease. In some embodiments, the endonuclease includes a Cas9 nickase. Some embodiments include a guide nucleic acid that brings the endonuclease into proximity with the predetermined locus of the target nucleic acid. In some embodiments, the ligase is coupled to the endonuclease. In some embodiments, the pre-synthesized integrating nucleic acid includes a mutation with respect to the target nucleic acid. In some embodiments, the nick includes a single phosphodiester strand break in an otherwise double-stranded target nucleic acid. In some embodiments, the nick includes a non-sticky non-blunt end of a strand of the target nucleic acid. In some embodiments, the target nucleic acid includes a chromosome of a cell. In some embodiments, the cell is eukaryotic.

[0007] Disclosed herein in some embodiments is a system of nucleic acids comprising a guide nucleic acid comprising (a) a spacer complementary to a region of a genomic locus of a genomic strand, (b) a scaffold for complexing with a DNA binding protein, (c) an optional donor binding site at least partially complementary to the integrating nucleic acid, and (d) a flap binding site at least partially identical to or complementary to a genomic flap at or adjacent to the genomic locus, and an integrating nucleic acid comprising a 5' end that is ligated to the 3' end of the genomic strand generated by the DNA binding protein. The DNA binding protein may comprise an endonuclease. The endonuclease may comprise an RNA-guided endonuclease. Disclosed herein, in some embodiments, is a system of nucleic acids comprising a guide nucleic acid comprising (a) a spacer complementary to a region of a genomic locus of a genomic strand, (b) a scaffold for complexing with a DNA binding protein, and (c) an optional donor binding site at least partially complementary to the splint nucleic acid; an integrating nucleic acid comprising a 5' end ligated to the 3' end of the genomic strand generated by the DNA binding protein; and a splint nucleic acid comprising a flap binding site at least partially identical or complementary to a genomic flap at or adjacent to the genomic locus and an optional guide binding site at least partially complementary to the guide nucleic acid. In some embodiments, the genomic strand is within a cell. In some embodiments, the splint nucleic acid further comprises a donor binding site at least partially identical or complementary to a portion of the integrating nucleic acid. In some embodiments, the guide nucleic acid comprises a sequence of a binding nucleic acid between the scaffold and the donor binding site. In some embodiments, the guide nucleic acid or the integrating nucleic acid comprises a modified internucleoside linkage. In some embodiments, the modified internucleoside linkage comprises a phosphorothioate linkage. In some embodiments, the modified internucleoside linkage is between any of the four terminal nucleosides at the 5' or 3' end of the guide or embedding nucleic acid. In some embodiments, the guide or embedding nucleic acid comprises a modified nucleoside.In some embodiments, the modified nucleoside comprises a locked nucleic acid (LNA), 2'fluoro, 2'O-alkyl, or a combination thereof. In some embodiments, the modified nucleoside is any of the three terminal nucleosides at the 5' or 3' end of the guide or embedding nucleic acid. The modified nucleoside may comprise an LNA, 2'fluoro, 2'O-alkyl, methylated cytosine, inverted thymidine, or a combination thereof.

[0008] Disclosed herein is a composition comprising, in some embodiments, a DNA binding protein connected to a DNA ligase. The DNA binding protein may comprise an endonuclease. The endonuclease may comprise an RNA-guided endonuclease. In some embodiments, the connection between the DNA binding protein and the DNA ligase is a covalent bond. Some embodiments include a fusion protein comprising a DNA binding protein upstream of the DNA ligase. Some embodiments include a fusion protein comprising a DNA binding protein downstream of the DNA ligase. In some embodiments, the connection comprises a linker comprising 1-100 amino acids. In some embodiments, the composition comprises a first polypeptide comprising at least a portion of a DNA binding protein and a second polypeptide comprising at least a portion of a DNA ligase, wherein the first and second polypeptides are covalently or non-covalently linked. In some embodiments, the first polypeptide comprises a first heterodimerization domain that binds to a second heterodimerization domain, and the second polypeptide comprises a second heterodimerization domain. In some embodiments, the heterodimer domain comprises a leucine zipper, a PDZ domain, streptavidin, a streptavidin binding protein, a foldon domain, a hydrophobic portion, or a functional binding fragment thereof. In some embodiments, the first polypeptide comprises a first intein that binds to a second intein, and the second polypeptide comprises a second intein. In some embodiments, the DNA binding protein and the DNA ligase are bound together by a small molecule. In some embodiments, the DNA binding protein comprises a class II CRISPR / Cas endonuclease. In some embodiments, the DNA binding protein comprises a Cas9 endonuclease. In some embodiments, the DNA binding protein comprises a nickase. In some embodiments, the DNA binding protein comprises an amino acid sequence at least 80% identical to the amino acid sequence of any one of SEQ ID NOs: 1-13, or a functional fragment thereof. In some embodiments, the DNA ligase ligates DNA strand bases paired to the DNA splint. In some embodiments, a DNA ligase ligates DNA strand bases paired to the RNA splint.In some embodiments, the DNA ligase comprises an amino acid sequence at least 80% identical to any one of the amino acid sequences of SEQ ID NOs: 55-96, or a functional fragment thereof. In some embodiments, the DNA binding protein or DNA ligase comprises a nuclear localization signal, a chromatin modifying domain, a cell membrane permeable peptide, or a tag polypeptide. Some embodiments include a guide RNA and an integrating nucleic acid. Some embodiments relate to a cell comprising the composition. Some embodiments include a nucleic acid encoding the composition. Some embodiments include one or more nucleic acids encoding a first or second polypeptide. Some embodiments include an editing method (e.g., a nucleic acid) using the composition. Some embodiments include a therapeutic method using the composition. Some embodiments include administering the composition to a subject.

[0009] Disclosed herein, in some embodiments, is a fusion protein comprising a DNA binding protein fused to a DNA ligase. The DNA binding protein may comprise an endonuclease. The endonuclease may comprise an RNA-guided endonuclease. Disclosed herein, in some embodiments, is a protein complex comprising a DNA binding protein bound to a DNA ligase. In some embodiments, the endonuclease and the DNA ligase are bound together via a heterodimerization domain. In some embodiments, the heterodimerization domain comprises a leucine zipper, a PDZ domain, streptavidin and a streptavidin binding protein, a foldon domain, a hydrophobic polypeptide, an antibody that binds to a Cas nickase, or an antibody that binds to a DNA ligase, or one or more binding fragments thereof. Disclosed herein, in some embodiments, is a cell comprising the fusion protein or protein complex. Disclosed herein, in some embodiments, is a cell comprising a heterologous DNA binding protein and a DNA ligase introduced into the cell. Some embodiments comprise a nuclease distinct from the DNA binding protein. Disclosed herein in some embodiments is a guide nucleic acid comprising a spacer at least partially complementary to a first region of a target nucleic acid, a scaffold configured to bind an endonuclease, a flap binding site at least partially reverse-complementary to the nucleic acid flap, and an integrating nucleic acid binding site. Disclosed herein in some embodiments is an integrating nucleic acid comprising a single-stranded or double-stranded DNA region inserted into a target nucleic acid, the single-stranded or double-stranded DNA region being adjacent to at least one additional single-stranded region comprising a guide binding site. Disclosed herein in some embodiments is an editing system comprising a DNA binding protein, a guide nucleic acid, and an integrating nucleic acid. Disclosed herein in some embodiments is an editing method comprising contacting a target nucleic acid with an editing system and a DNA ligase.

[0010] Disclosed herein in some embodiments is a system comprising at least one DNA binding protein, at least one guide nucleic acid comprising a spacer at least partially complementary to a genomic locus in a cell, a scaffold for complexing with the at least one DNA binding protein, and an optional donor binding site at least partially complementary to the integrating nucleic acid, at least one DNA ligase, and an integrating nucleic acid comprising a flap binding site at least partially reverse complementary to a nucleic acid flap, and optionally comprising a guide binding site at least partially complementary to the at least one guide nucleic acid, wherein the at least one DNA binding protein cuts or nicks at least one strand of the genomic locus, and the at least one DNA ligase ligates an end of the integrating nucleic acid to the genomic flap site, thereby replacing a region of the locus with the integrating nucleic acid in the cell. The DNA binding protein may comprise an endonuclease. The endonuclease may comprise an RNA-guided endonuclease. In some embodiments, the integrating nucleic acid comprises single-stranded DNA. In some embodiments, the integrating nucleic acid comprises double-stranded DNA.

[0011] Disclosed herein, in some aspects, is a system comprising at least one DNA binding protein, including a first DNA binding protein and an optional second DNA binding protein, and at least one guide nucleic acid, including a first guide nucleic acid and a second guide nucleic acid, wherein the first guide nucleic acid comprises a first spacer complementary to a first region of a genomic locus in a cell, a first scaffold for complexing with the first DNA binding protein, an optional first donor binding site at least partially complementary to the integrating nucleic acid, and a first flap binding site that is at least partially identical or complementary to a first genomic flap at or adjacent to the genomic locus, and the second guide nucleic acid comprises a second spacer complementary to a second region of a genomic locus in a cell, a second scaffold for complexing with the first or second DNA binding protein, an optional second donor binding site at least partially complementary to the integrating nucleic acid, and a first flap binding site that is at least partially identical or complementary to a first genomic flap at or adjacent to the genomic locus. at least one DNA ligase comprising a first DNA ligase and an optional second DNA ligase; and at least one integrating nucleic acid comprising a first strand and a second strand, wherein the first strand comprises an optional first guide binding site that is at least partially complementary to the first guide nucleic acid and the second strand comprises an optional second guide binding site that is at least partially complementary to the second guide nucleic acid, wherein the first DNA binding protein and / or the second DNA binding protein each cleave or nick at least one strand of a genomic locus in the cell, the first DNA ligase ligates an end of the first strand of the integrating nucleic acid to the first genomic flap and the first or second DNA ligase ligates an end of the second strand of the integrating nucleic acid to the second genome, thereby replacing a region of the genomic locus with the integrating nucleic acid in the cell. In some embodiments, the integrating nucleic acid comprises a double stranded DNA duplex region. The DNA binding protein may comprise an endonuclease. The endonuclease may comprise an RNA-guided endonuclease.In some embodiments, the integrating nucleic acid optionally comprises a 5' overhang that includes a first guide binding site. In some embodiments, the integrating nucleic acid optionally comprises a 5' overhang that includes a second guide binding site.

[0012] Disclosed herein, in some embodiments, is a system comprising at least one DNA binding protein, at least one guide nucleic acid comprising a spacer complementary to a genomic locus in a cell, a scaffold for complexing with the at least one DNA binding protein, and an optional donor binding site at least partially complementary to the integrating nucleic acid, at least one DNA ligase, and an integrating nucleic acid comprising an optional guide binding site at least partially complementary to the at least one guide nucleic acid and a flap binding site at least partially identical or complementary to a genomic flap at or adjacent to the genomic locus, wherein the at least one DNA binding protein cuts or nicks at least one strand of the genomic locus, and the at least one DNA ligase ligates an end of the integrating nucleic acid to the genomic flap, thereby replacing a region of the genomic locus with the integrating nucleic acid in the cell. The DNA binding protein may comprise an endonuclease. The endonuclease may comprise an RNA-guided endonuclease. In some embodiments, the integrating nucleic acid comprises a DNA comprising a 3' overhang. In some embodiments, the 3' overhang comprises a guide binding site. In some embodiments, the 3' overhang comprises a flap binding site. In some embodiments, at least one DNA ligase ligates a strand of the integrated nucleic acid to a genomic nucleic acid sequence.

[0013] Disclosed herein, in some aspects, is a system comprising at least one DNA binding protein, comprising a first DNA binding protein and an optional second DNA binding protein; at least one guide nucleic acid, comprising a first guide nucleic acid and a second guide nucleic acid, wherein the first guide nucleic acid comprises a first spacer complementary to a first region of a genomic locus in the cell, a first scaffold for complexing with the first DNA binding protein, and an optional first donor binding site at least partially complementary to the integrating nucleic acid, and the second guide nucleic acid comprises a second spacer complementary to a second region of a genomic locus in the cell, a second scaffold for complexing with the first or second DNA binding protein, and an optional second donor binding site at least partially complementary to the integrating nucleic acid; at least one DNA ligase, comprising a first DNA ligase and an optional second DNA ligase; and an integrating nucleic acid comprising a first strand and a second strand, wherein the first strand is ligated to the first guide nucleic acid. the first strand comprises an optional first guide binding site that is at least partially complementary to a first genomic flap at or adjacent to the genomic locus, the second strand comprises an optional second guide binding site that is at least partially complementary to a second guide nucleic acid, the first strand comprises a first flap binding site that is at least partially identical or complementary to a first genomic flap at or adjacent to the genomic locus, the second strand comprises a second flap binding site that is at least partially identical or complementary to a second genomic flap at or adjacent to the genomic locus, the first DNA binding protein and / or the second DNA binding protein each cleave or nick at least one strand of a genomic locus in the cell, the first DNA ligase ligates an end of the first strand of the integrating nucleic acid to the first genomic flap, and the first or second DNA ligase ligates an end of the second strand of the integrating nucleic acid to the second genomic flap, thereby replacing a region of the genomic locus with the integrating nucleic acid in the cell. The DNA binding protein may comprise an endonuclease. The endonuclease may comprise an RNA-guided endonuclease. In some embodiments, the integrating nucleic acid comprises a double-stranded DNA duplex region.In some embodiments, the double stranded DNA optionally comprises a first guide binding site and a 3' overhang that comprises a first flap binding site. In some embodiments, the double stranded DNA optionally comprises a second guide binding site and a 3' overhang that comprises a second flap binding site.

[0014] The DNA binding protein may comprise an endonuclease. The endonuclease may comprise an RNA-guided endonuclease. In some embodiments, the at least one DNA binding protein comprises a Cas protein or a functional fragment thereof. In some embodiments, the Cas protein or a functional fragment thereof comprises a nickase activity. In some embodiments, the at least one DNA binding protein comprises a Cas9 nickase or a functional fragment thereof. In some embodiments, the at least one DNA ligase ligates a nucleic acid bound to DNA. In some embodiments, the at least one DNA ligase ligates a nucleic acid bound to RNA. In some embodiments, the at least one DNA ligase comprises a PBCV-1 DNA ligase. In some embodiments, the at least one DNA ligase is operably coupled to the at least one DNA binding protein. In some embodiments, the at least one DNA ligase is fused to the at least one DNA binding protein as a fusion polypeptide. In some embodiments, the at least one DNA binding protein and the at least one DNA ligase each comprise a heterodimerization domain. In some embodiments, the at least one DNA binding protein and the at least one DNA ligase form a heterodimer via a heterodimer domain. In some embodiments, the at least one DNA binding protein comprises a linker. In some embodiments, the linker connects the Cas protein or a functional fragment thereof to the heterodimer domain. In some embodiments, the at least one DNA binding protein comprises a localization signal sequence. In some embodiments, the at least one DNA ligase comprises a localization signal sequence. In some embodiments, the localization signal sequence comprises a nuclear localization sequence (NLS). In some embodiments, the at least one DNA binding protein or the at least one DNA ligase is directed to the nucleus of the cell by the NLS. In some embodiments, the at least one integrating nucleic acid corrects at least one genetic mutation in at least one locus. In some embodiments, the at least one integrating nucleic acid inserts a coding sequence.In some embodiments, the coding sequence encodes a full-length protein. In some embodiments, the at least one integrating nucleic acid inserts a non-coding sequence. In some embodiments, the non-coding sequence knocks out an endogenous gene. In some embodiments, the non-coding sequence comprises a regulatory element. Some embodiments further comprise a nuclease. In some embodiments, the nuclease comprises an exonuclease for digesting genomic flaps. In some embodiments, the nuclease comprises human flap endonuclease 1 (hFEN1), human exonuclease 5 (hEXO5), T5 exonuclease, T7 exonuclease, exonuclease VIII, flap endonuclease domain of E. coli PolI, RecJF, lambda exonuclease, Xni (ExoIXI), SaFEN (Staphylococcus aureus FEN), nuclease BAL-31, or a fragment thereof. In some embodiments, the heterologous nuclease comprises an endonuclease for digesting the genomic flap, and the endonuclease is different from the at least one DNA binding protein. In some embodiments, the at least one DNA binding protein comprises at least one additional functional domain. In some embodiments, the at least one additional functional domain comprises a chromatin modification domain. In some embodiments, the at least one additional functional domain comprises a cell penetrating peptide. In some embodiments, the at least one guide nucleic acid comprises at least one nucleic acid modification. In some embodiments, the at least one nucleic acid modification comprises a modification to the backbone, sugar, base, or combination thereof. In some embodiments, the at least one DNA binding protein is complexed with the at least one guide nucleic acid. In some embodiments, the at least one guide nucleic acid is complexed with an integrating nucleic acid. In some embodiments, the at least one DNA binding protein, the at least one guide nucleic acid, the at least one DNA ligase, the integrating nucleic acid, or combination thereof are encoded by a polynucleotide. In some embodiments, the polynucleotide comprises an mRNA. In some embodiments, the polynucleotide comprises a vector.In some embodiments, the vector comprises a viral vector. In some embodiments, the at least one DNA binding protein, the at least one guide nucleic acid, the at least one DNA ligase, the integrating nucleic acid, or a combination thereof is encapsulated by at least one lipid nanoparticle. In some embodiments, the cell comprises a bacterial cell, a eukaryotic cell, or a plant cell. In some embodiments, the eukaryotic cell comprises a mammalian cell. Some embodiments comprise a composition comprising the system. Some embodiments comprise a cell comprising the system. Some embodiments comprise a cell line comprising the cell. Some embodiments comprise a pharmaceutical composition comprising the system. Some embodiments comprise a pharmaceutical composition comprising the composition. Some embodiments comprise a pharmaceutical composition comprising the cell. Some embodiments comprise a pharmaceutically acceptable excipient, carrier, or diluent. In some embodiments, the pharmaceutical composition is formulated for administration to a subject in need thereof intrathecally, intraocularly, intravitreally, retina, intravenously, intramuscularly, intracerebroventricularly, intracerebrally, intracerebellarly, intraventricularly, intraparenchymal, subcutaneously, intratumorally, intrapulmonary, intratracheal, intraperitoneally, intravesically, intravaginally, intrarectally, orally, sublingually, transdermally, by inhalation, by inhaled aerosol form, by intraluminal GI route, or by combinations thereof. Some embodiments include a system, composition, or kit comprising the pharmaceutical composition and a container. Some embodiments include a method for modifying a cell, comprising contacting the cell with the system. Some embodiments include a method for modifying a cell, comprising contacting the cell with the composition. Some embodiments include a method for modifying a cell, comprising contacting the cell with the pharmaceutical composition. In some embodiments, the cell is not a dividing cell. In some embodiments, the integrated nucleic acid is inserted into the genomic locus of the cell that is independent of endogenous non-homologous end joining (NHEJ) and independent of endogenous homology-directed repair (HDR).Some embodiments include a method for treating disease or condition in a subject that requires it, comprising contacting the cell or subject with the system, composition, or pharmaceutical composition, and replacing the genomic locus in the cell with the integrated nucleic acid, thereby treating the disease or condition in the subject.In some embodiments, the cell is not a dividing cell.In some embodiments, the integrating nucleic acid is inserted into a genomic locus of the cell that is independent of endogenous non-homologous end joining (NHEJ) and independent of endogenous homology directed repair (HDR).

[0015] Disclosed herein in some embodiments is a guide nucleic acid comprising a spacer that is at least partially complementary to a genomic locus in a cell, a scaffold for complexing with a DNA-binding protein, and a donor binding site that is at least partially complementary to an integrating nucleic acid. The DNA-binding protein may comprise an endonuclease. The endonuclease may comprise an RNA-guided endonuclease. In some embodiments, the guide nucleic acid comprises a flap binding site that is at least partially complementary to a genomic sequence of the genomic locus. In some embodiments, the guide nucleic acid comprises at least one nucleic acid modification. In some embodiments, the at least one nucleic acid modification comprises a modification to the backbone, sugar, base, or a combination thereof. In some embodiments, the guide nucleic acid comprises an RNA sequence. [Brief description of the drawings]

[0016] [Figure 1A] The guide nucleic acid, endonuclease, ligase, and donor strand at the genomic locus are shown. [Figure 1B] Continuing from FIG. 1A, the figures show a donor strand integrated on one side of a genomic locus, where the donor strand displaces a genomic flap. [Figure 1C] Continuing from FIG. 1B , there is shown the donor strand integrated on one side of the genomic locus, and the nick that appears where the genomic flap was removed. [Figure 2A] Shown are two guide nucleic acids, two endonucleases, two ligases, and a donor strand at a genomic locus. [Figure 2B] Continuing from FIG. 2A, there is shown a donor strand integrated into a genomic locus, which displaces two genomic flaps. [Figure 2C]Continuing from FIG. 2B, the donor strand is shown integrated into the genomic locus, and two nicks appear where the genomic flap was removed. [Figure 3A] The guide nucleic acid, endonuclease, ligase, and donor strand at the genomic locus are shown. [Figure 3B] Continuing from FIG. 3A, a donor strand is shown integrated on one side of a genomic locus, where the donor strand displaces a genomic flap. [Figure 3C] Continuing from FIG. 3B, there is shown the donor strand integrated on one side of the genomic locus, and the nick that appears where the genomic flap was removed. [Figure 4A] Shown are two guide nucleic acids, two endonucleases, two ligases, and a donor strand at a genomic locus. [Figure 4B] Continuing from FIG. 4A, there is shown a donor strand integrated into a genomic locus, where the donor strand has displaced two genomic flaps. [Figure 4C] Continuing from FIG. 4B, the donor strand is shown integrated into the genomic locus, and two nicks appear where the genomic flap was removed. [Figure 5A] The guide nucleic acid, endonuclease, ligase, and donor strand at the genomic locus are shown. [Figure 5B] Continuing from FIG. 5A, there is shown a donor strand integrated into a genomic locus, where the donor strand displaces a genomic flap. [Figure 5C] Continuing from FIG. 5B, there is shown the donor strand integrated on one side of the genomic locus, and the nick that appears where the genomic flap was removed. [Figure 6A] Shown are two guide nucleic acids, two endonucleases, two ligases, and a donor strand at a genomic locus. [Figure 6B] Continuing from FIG. 6A, there is shown a donor strand integrated into a genomic locus, where the donor strand has displaced two genomic flaps. [Figure 6C]Continuing from FIG. 6B, the donor strand is shown integrated into the genomic locus, and two nicks appear where the genomic flap was removed. [Figure 7] Some examples of fusion protein sequences are shown below. [Figure 8A] 1 shows exemplary nicking and ligation patterns of integrating nucleic acids. [Figure 8B] A DNA gel showing the patterns associated with one-sided replacer 2 performed in vitro using 30nt GBS / DBS and thermostable T4 ligase. Using the combination of 30nt GBS / DBS, a donor containing a protospacer adjacent motif (PAM) mutation, and thermostable T4 ligase (Hi-T4, NEB), we were able to generate a final replacer product (lane 3) that corresponded in size to our control product (lane 1). No replacer product was detected in the absence of nicking Cas9 (Cas9n) (lane 2) or in the absence of a bottom donor acting as a splint (lanes 4 and 5). [Figure 8C] 1 shows an exemplary nucleic acid gel showing the patterns associated with in vitro one-sided replacer 2 using variable length GBS / DBS combinations and T4 ligase. Using regular T4 ligase (NEB), multiple GBS / DBS combinations, including no GBS / DBS, 20nt GBS / DBS, and 30nt GBS / DBS, were used to generate final replacer products corresponding in size to the control. Furthermore, in this experiment, the recoded dsDNA donor containing the PAM mutation was more efficient in generating the final replacer product compared to the PAM mutant dsDNA donor that was not recoded. [Figure 9] Measurement of the percentage of cells expressing green fluorescent protein (GFP) is shown, demonstrating gene editing of BFP to GFP by nicking Cas9 and one-sided replacer 2 with DNA ligase. [Figure 10]Shown are sequencing reads that were merged and aligned to the amplicon of interest via one-sided replacer 2 with nicking Cas9 and T4 DNA ligase, as well as the percentage of total reads that matched the intended edit. [Figure 11] Shown are sequencing reads that were merged and aligned to the amplicon of interest via double-sided replacer 2 with nicking Cas9 and T4 DNA ligase, as well as the percentage of total reads that matched the intended edits. [Figure 12] Measurement of the percentage of cells expressing green fluorescent protein (GFP) is shown, demonstrating gene editing of BFP to GFP via one-sided replacer 2 with nicking Cas9 and T4 DNA ligase. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0017] preface Recent advances in gene editing tools have enabled precise editing of genomes for therapeutic, agricultural, industrial, and research purposes. Some nuclease-based tools, such as CRISPR-Cas9, use guide RNA to target Cas9 protein to specific DNA sequences specified by spacer sequences within the guide RNA. Cas9 nuclease activity then cleaves DNA, resulting in double-strand breaks (DSBs). DSBs are typically repaired via endogenous DNA repair mechanisms, including non-homologous end joining (NHEJ) or homology-directed repair (HDR). However, NHEJ results in a spectrum of nucleotide insertions and deletions (indels), which hinders its utility for precision editing. HDR efficiency is very low in non-dividing cells and may require DNA replication. Even when HDR editing is detectable, DSB-induced indels are often prevalent, meaning that HDR may not be feasible when precision editing is desired.

[0018] Homology-independent targeted insertion (HITI) exploits the NHEJ DNA repair machinery active in non-dividing cells for CRISPR-induced transgene integration in non-dividing cells such as primary neurons, retinal pigment epithelial cells, and HSPCs. However, due to the generation of DSBs from Cas9, HITI generates a high frequency of indels, resulting in unintended mutations in addition to the toxicity associated with DSBs.

[0019] Other methods for gene editing have further limitations. Tools that use fusions of nicking Cas nucleases with nucleotide deaminases (e.g., base editors) can perform certain nucleotide mutations, for example, cytosine base editors can convert C to T. Although some base editors can perform precision editing with high efficiency, they are essentially limited to specific edits determined by the deaminase variant, so they are only applicable to specific substitution mutations and cannot perform precise insertion or deletion edits. Furthermore, base editors are generally limited to small editing windows within a subset of protospacer regions and are therefore significantly limited by the availability of protospacer adjacent motifs (PAMs). Finally, base editors can exhibit bystander mutations within the edited region (e.g., when two Cs are present), demonstrating DNA and RNA off-target deaminase activity.

[0020] Existing precision editing techniques have limitations that prevent their practical use in various ways. In particular, they may rely on endogenous cellular machinery for editing, such as HDR machinery for nuclease-based editing and mismatch repair for base editing. No system has been reported that is independent of all endogenous factors. Reliance on endogenous factors is problematic because different cell types have different activity levels of these endogenous factors, and in many cases the activity is not sufficient to provide a useful level of editing. An example where this reliance is particularly problematic is non-dividing cells, which constitute the majority of cells in adults and therefore cannot be accommodated by many existing precision editing tools.

[0021] Therefore, there remains a need for a system or method for effective gene editing or for modifying gene expression by gene editing. In particular, there remains a need for a system or method for gene editing or modifying gene expression, which system or method does not rely on endogenous components or mechanisms of the cell. There also remains a need for a system or method for correcting genetic mutations in cells. In some cases, the correction of genetic mutations can be performed in subjects who need to treat a disease or condition. As seen below, the systems, methods, and compositions disclosed herein can be useful for addressing these needs or limitations.

[0022] overview Described herein is a self-contained gene editing system. Some such self-contained systems may control all aspects of gene editing. Some such systems do not rely on host cell machinery to perform editing functions or to replace or repair any aspect of a target nucleic acid, such as a genomic locus. Some such systems may perform editing without the use of polymerases, and therefore are not affected by cellular nucleotide triphosphate (dNTP) concentrations. For example, an integrated nucleic acid may be delivered and inserted into a locus without transcribing a template. Editing may eliminate the need to rely on cellular repair systems, such as HDR or NHEJ. Editing may be performed without cell cycling. Gene editing may be performed inside a cell or in vitro. For example, gene editing may be performed in a test tube or outside a cell.

[0023] Described herein are systems and methods for editing DNA in a donor strand without generating double-strand breaks in the genome using CRISPR-guided DNA ligase and a guide nucleic acid targeted to a genomic region of interest. DNA ligase is an enzyme that chemically joins two DNA molecules together via a phosphodiester bond. DNA ligase may or may not require hybridization of the DNA molecule to a DNA or RNA scaffold or "sprint" that is reverse-complementary to the DNA sequence to be ligated. Targeting of the ligase to the genome nick generated by the CRISPR nuclease allows for precise replacement of the genomic DNA with the donor strand that is optionally recruited to the target locus by the guide nucleic acid. The CRISPR-guided DNA ligase may be composed of a DNA ligase that is fused, recruited, or unfused to an RNA-guided endonuclease by utilizing a peptide linker, a heterodimerization domain, or two separate peptides, respectively.

[0024] Some embodiments include cells that contain or include an RNA-guided endonuclease and a DNA ligase, both of which are introduced into the cell. The endonuclease or ligase can be heterologous to the cell. The endonuclease and ligase can be heterologous to the cell. The ligase can be endogenous to the cell. In some embodiments, the cell includes an RNA-guided endonuclease and a DNA ligase, both of which are heterologous to the cell. The cell can include a composition or system described herein. The cell can be used or included in the systems, compositions, or methods described herein.

[0025] The systems described herein may include heterologous endonucleases, including RNA-guided endonucleases such as nicking Cas9, and heterologous ligases (e.g., DNA ligases) that can utilize an RNA splint. The guide nucleic acid optionally recruits the donor strand to a site targeted by the endonuclease (e.g., a targeted genomic locus) and also generates a splint across the donor strand (donor strand) and the genomic flap generated by nicking Cas9, resulting in ligation of the donor strand and the genomic flap by DNA ligase. In some embodiments, the ligase is or includes an endogenous ligase. The systems may utilize one or more guide nucleic acids that may include the following components together, optionally in the following order: 5' spacer-scaffold-donor binding site (optional)-flap binding site 3'. The donor strand (donor strand) may include the following sequence components: 5' guide binding site-donor strand 3'. The guide binding site of the donor strand is at least partially reverse-complementary to the donor binding site of the guide nucleic acid such that the donor hybridizes to the guide and localizes to the target site of the RNA-guided endonuclease. The 5' end of the donor sequence and the 3' end of the genomic flap generated by the nuclease nicking activity are ligated by DNA ligase and splinted by the donor binding site and the flap binding site of the guide nucleic acid(s).

[0026] 1A-1C show a non-limiting example of the system (one-sided replacer 1). The example includes a guide nucleic acid that includes a spacer for targeting a genomic locus, a scaffold for complexing and recruiting an endonuclease described herein, a donor binding site for complexing with a donor strand, and a flap binding site for complexing with a genomic flap of the genomic locus. The guide nucleic acid is shown complexed with an endonuclease (e.g., Cas9 nickase, nCas9) operably coupled to a ligase. The guide nucleic acid can direct the endonuclease to a genomic locus bound by the spacer of the guide nucleic acid. The guide nucleic acid is also shown to be partially complementary to the donor strand (complexing between the donor binding site of the guide nucleic acid and the guide binding site of the donor strand). The endonuclease, when directed by the guide nucleic acid, can cleave or nick at least one strand of the genomic locus, and the ligase can ligate one end of the donor strand to the cut or nicked end of the genomic locus, thus integrating the donor strand into the genomic locus. Integration of the donor strand into the genomic locus can generate a genomic flap that can be digested and removed by the nuclease.

[0027] 2A-2C show a non-limiting example of the system (two-sided replacer 1). Similar to the guide nucleic acid of FIG. 1A, the example guide nucleic acid includes a spacer for targeting the genomic locus, a scaffold for complexing and recruiting an endonuclease described herein, a donor binding site for complexing with a donor strand, and a flap binding site for complexing with a genomic flap of the genomic locus. In FIG. 2A, a first guide nucleic acid is shown complexed with a first endonuclease operably coupled to a first ligase, and a second guide nucleic acid is shown complexed with a second endonuclease operably coupled to a second ligase. The first endonuclease and the second nuclease can each cleave at least one strand of the genomic locus. The two cleaved ends of the genomic locus can be ligated to the two ends of the donor strand, thereby incorporating the donor strand into the genomic locus. Insertion of the donor strand at a genomic locus can generate two genomic flaps that can be digested and removed by nucleases.

[0028] 3A-3C show a non-limiting example of the system (one-sided replacer 2). In the examples, the guide nucleic acid includes a spacer for targeting the genomic locus, a scaffold for complexing and recruiting an endonuclease as described herein, and a donor binding site for complexing with the donor strand. Also shown in FIG. 3A is a donor strand including at least one overhang, the overhang including a flap binding site for complexing with a genomic flap of the genomic locus, and a guide binding site for complexing with the guide nucleic acid (via the donor binding site of the guide nucleic acid). The guide nucleic acid can be complexed with an endonuclease (e.g., nCas9) operably coupled to a ligase. The guide nucleic acid in the examples directs the endonuclease and ligase to the genomic locus bound by the spacer of the guide nucleic acid. The guide nucleic acid in the examples is also partially complementary to the donor strand (complexing between the donor binding site of the guide nucleic acid and the guide binding site of the donor strand). The endonuclease, when directed by the guide nucleic acid, can cleave at least one strand of the genomic locus, and the ligase can ligate one end of the donor strand to the cut end of the genomic locus, thus integrating the donor strand into the genomic locus. Integration of the donor strand into the genomic locus can generate a genomic flap that can be digested and removed by the nuclease.

[0029] Figures 4A-4C show non-limiting examples of the system (two-sided replacer 2). In an example, similar to the guide nucleic acid of Figure 3A, the guide nucleic acid includes a spacer for targeting a genomic locus, a scaffold for complexing and recruiting an endonuclease as described herein, and a donor binding site for complexing with a donor strand. Also shown in Figure 4A is a donor strand that includes two overhangs, each of which includes a flap binding site for complexing with a genomic flap of the genomic locus and a guide binding site for complexing with the guide nucleic acid (through the donor binding site of the guide nucleic acid). The flap binding site of the donor strand can bring the donor strand into close proximity to the genomic locus after the endonuclease cleaves at least one strand of the genomic locus to generate a genomic flap. In FIG. 4A, the first guide nucleic acid is shown complexed with a first endonuclease operably coupled to a first ligase, and the second guide nucleic acid is shown complexed with a second endonuclease operably coupled to a second ligase. In this example, the first endonuclease and the second nuclease can each cleave at least one strand of the genomic locus. The two cleaved ends of the genomic locus can be ligated to the two ends of the donor strand, thereby integrating the donor strand into the genomic locus. In this example, the insertion of the donor strand at the genomic locus can generate two genomic flaps that can be digested and removed by nucleases.

[0030] The system (replacer 3) described herein may include a heterologous endonuclease, including an RNA-guided endonuclease such as nicking Cas9, and a ligase (e.g., DNA ligase) that can utilize a DNA splint. The guide nucleic acid optionally recruits the donor strand to a site targeted by the endonuclease (e.g., a targeted genomic locus) and also generates a splint across the donor strand (donor strand) and the genomic flap generated by nicking Cas9, resulting in ligation of the donor strand and the genomic flap by DNA ligase. At least a portion of the flap binding site and donor binding site on the guide nucleic acid is DNA such that the ligase utilizing the DNA splint can catalyze the intended reaction. The system may utilize one or more guide nucleic acids that may include the following components together, optionally in the following order: 5' spacer-scaffold-donor binding site (optional)-flap binding site 3'. The donor strand may comprise the following sequence components: 5' guide binding site - donor strand 3'. The guide binding site of the donor strand is at least partially reverse-complementary to the donor binding site of the guide nucleic acid, such that the donor hybridizes to the guide and localizes to the target site of the RNA-guided endonuclease. The 5' end of the donor sequence and the 3' end of the genomic flap generated by the nuclease nicking activity are ligated by DNA ligase and splinted by the donor binding site and the flap binding site of the guide nucleic acid(s).

[0031] 5A-5C show a non-limiting example of the system (one-sided replacer 3). The example includes a guide nucleic acid comprising a spacer for targeting a genomic locus, a scaffold for complexing and recruiting an endonuclease as described herein, a donor binding site for complexing with a donor strand, and a flap binding site for complexing with a genomic flap of the genomic locus, where at least a portion of the flap binding site and the donor binding site are comprised of DNA. The guide nucleic acid is shown complexed with an endonuclease (e.g., Cas9 nickase, nCas9) operably coupled to a ligase (e.g., an endogenous ligase or an exogenous ligase). The guide nucleic acid can direct the endonuclease to the genomic locus bound by the spacer of the guide nucleic acid. The guide nucleic acid is also shown to be partially complementary to the donor strand (complexing between the donor binding site of the guide nucleic acid and the guide binding site of the donor strand). The endonuclease, when directed by the guide nucleic acid, can cleave at least one strand of the genomic locus, and the ligase can ligate one end of the donor strand to the cut end of the genomic locus, thus integrating the donor strand into the genomic locus. Integration of the donor strand into the genomic locus can generate a genomic flap that can be digested and removed by the nuclease.

[0032] 6A-6C show a non-limiting example of the system (two-sided replacer 3). The guide nucleic acid in this example, similar to the guide nucleic acid in FIG. 5A, includes a guide nucleic acid including a spacer for targeting a genomic locus, a scaffold for complexing and recruiting an endonuclease described herein, a donor binding site for complexing with a donor strand, and a flap binding site for complexing with a genomic flap of the genomic locus, where at least a portion of the flap binding site and the donor binding site are composed of DNA. In FIG. 6A, a first guide nucleic acid is shown complexed with a first endonuclease operably coupled to a first ligase, and a second guide nucleic acid is shown complexed with a second endonuclease operably coupled to a second ligase. The first endonuclease and the second nuclease can each cleave at least one strand of the genomic locus. The two cleaved ends of the genomic locus can be ligated to the two ends of the donor strand, thereby integrating the donor strand into the genomic locus. Insertion of the donor strand at the genomic locus can generate two genomic flaps that can be digested and removed by nucleases.

[0033] Ligation may be performed using a DNA ligase that can utilize an RNA splint, such as SplintR ligase, also known as PBCV-1 DNA ligase from Chlorella virus. In some embodiments, the system utilizes two guide nucleic acids that target the CRISPR-guided ligase to target sites on opposite strands that flank the genomic region of interest. In some embodiments, each guide nucleic acid interacts with the corresponding donor strand in the manner described above, resulting in ligation of both donor strands that are reverse-complementary to each other within the donor strand region.

[0034] A ligase fused or recruited to an endonuclease or supplied in trans can utilize DNA as a splint, with the donor strand acting as a splint for the genomic flap generated by the endonuclease and another donor strand. In some embodiments, the donor strand comprises 5' donor strand-flap binding site-guide binding site (optional) 3'. The flap binding site on one donor strand (donor 2) can be reverse-complementary to the genomic flap, while the optional guide binding site on donor 2 is reverse-complementary to the optional donor binding site of the guide nucleic acid (guide 1), and the donor strand can be at least partially reverse-complementary to a different donor strand (donor 1). The 5' end of donor 1 and the 3' end of the genomic flap can be ligated using the flap binding site of donor 2 and the donor strand as a splint. Such a two-sided approach utilizing dual guide nucleic acids with different spacer sequences can be employed with Donor 2, which provides a splint at a first genomic site, and can be ligated on its 5' end to the 3' end of a different genomic flap at a nick created using a second Replacer 2 guide nucleic acid (Guide 2) with a spacer sequence targeting a second site. The Donor binding site on the second guide nucleic acid system can optionally recruit Donor 1 via hybridization with its optional Guide binding site, with Donor 1 serving as a DNA splint to ligate Donor 2 to the 3' end of the genomic flap at the target site of the second guide nucleic acid.

[0035] After ligation, the remaining flap of the native genomic DNA can be excised through exogenous delivery or endogenous flap endonucleases or exonucleases.Examples of exogenous nucleases that can be introduced into cells include human flap endonuclease 1 (hFEN1), human exonuclease 5 (hEXO5), T5 exonuclease, T7 exonuclease, exonuclease VIII, flap endonuclease domain of E. coli PolI, RecJF, lambda exonuclease, Xni (ExoIXI) from Escherichia coli, SaFEN (Staphylococcus aureus FEN), nuclease BAL-31, or fragments thereof. The endonuclease or exonuclease may optionally be fused, recruited to an RNA-guided endonuclease or DNA ligase, or may be unfused, by utilizing a peptide linker, a heterodimerization domain, or two separate peptides, respectively.

[0036] In some embodiments, the systems, compositions, or methods described herein utilize additional proteins that bind to the cleavage or nick site. For example, the systems, compositions, or methods described herein can include a Ku protein or a Gam protein from bacteriophage Mu, and the binding of the Ku protein or the Gam protein can increase the ligation efficiency of the integrated nucleic acid at the cleavage or nick site.

[0037] The systems or methods described herein may use nicking endonucleases and therefore do not generate double-strand breaks. Furthermore, the systems described herein address the problem of reduced editing efficiency in non-dividing cells through a mechanism of action that relies solely on exogenous components delivered to cells using mRNA, viral vectors, guide nucleic acids, DNA, or peptides, or any other modality. Thus, the system does not require the presence of cell cycle-dependent endogenous cellular processes or components, such as HDR or dNTPS. Thus, the systems described herein allow for unhindered efficiency in non-dividing cells. Furthermore, the system allows for replacement of both strands of the target region of the genome, which can increase editing efficiency.

[0038] The donor strand may contain a high degree of homology with the replaced genomic DNA. These donors may contain mutations to the genomic DNA, such as correcting a pathogenic mutation, disabling a CRISPR protospacer adjacent motif (PAM) site, disrupting the spacer sequence of the guide, other substitution mutations, or combinations thereof. Additional substitution mutations may be included to increase donor-donor homology versus donor-genome homology to facilitate hybridization and integration of the donor strand into the genome. The donor strand may also code for deletions or insertions of nucleotides, or combinations of the above complexes that replace the target genomic DNA. Optionally, the guide strand and donor strand may be chemically modified using nucleic acid chemistry, such as phosphorothioate bonds or 2'-O-methylation. Optionally, the guide nucleic acid may contain a hairpin sequence. Optionally, any combination of guide nucleic acid, donor strand, and protein may be complexed using, for example, an annealing reaction (gradual temperature reduction) before delivering the editing components to the cell.

[0039] Protein components (e.g., nicking Cas9, ligase) can be modified with nuclear localization signals, cell penetrating peptides, or chromatin disrupting peptides to improve delivery efficiency to genomic targets.

[0040] The predominant cellular DNA repair pathway for resolving small (less than 13 nt) mismatches between genomic DNA strands is mismatch repair (MMR). In the case of single-stranded donor ligation, the ligated donor strand forms a DNA heteroduplex with the reverse-complementary genomic DNA strand. This can also occur in competitive hybridization between the ligated donor strand and the genomic DNA strand. In these cases, MMR activity can use the genomic strand as a template to excise and restore the mismatch in the donor strand, resulting in reduced editing. Expression of dominant-negative versions of MMR proteins has been shown to inhibit the MMR pathway and improve editing outcomes when similar DNA heteroduplexes are generated. In some embodiments, dominant-negative MMR peptides such as MSH2(G674A) and MLH1(del754-756) may be delivered as part of the system described herein to improve genome editing capabilities, especially in cells that overexpress the MMR pathway. In some embodiments, these dominant negative MMR peptides may be delivered as fusions (e.g., fused to any component of the system described herein), mobilized, or delivered as separate peptides.

[0041] Endonucleases Disclosed herein are endonucleases. The endonucleases may be included in the compositions, systems or methods disclosed herein. The endonucleases may be recombinant. The endonucleases may be linked to ligases. The endonucleases may be directly or indirectly coupled to ligases. The coupling may be covalent or non-covalent. The endonucleases may be bound or connected to ligases. The endonucleases may be recruited to ligases, may be part of a fusion protein, or may be used in conjunction with ligases. The endonucleases may be heterologous. Heterologous may refer to a source from outside the cell. Where a heterologous endonuclease is described, a non-heterologous (e.g., endogenous) endonuclease may be used in some instances. The endonuclease may be encoded within the cell. The endonuclease may be delivered to the cell in trans. The endonuclease can catalyze the cleavage of a phosphate bond in the integrating nucleic acid. The endonuclease can be guided by the guide nucleic acid to cleave or nick the target nucleic acid for ligation of the integrating nucleic acid at the cleavage or nick site. The endonuclease can include any of the embodiments included in Figures 1A-6C.

[0042] The endonuclease may be non-naturally occurring. The endonuclease may be engineered. The endonuclease may be synthetic. The endonuclease may be presynthesized. The endonuclease may be added to a subject or cell. The endonuclease may be encoded by a nucleic acid. The encoding nucleic acid may be engineered, synthetic, or added to a subject or cell.

[0043] At least a portion of the endonuclease may be included in the first polypeptide. At least a portion of the endonuclease may be included in the second polypeptide. The endonuclease may be split into two or more polypeptides that are joined together. The first polypeptide may include the N-terminal portion of the endonuclease. The first polypeptide may include the C-terminal portion of the endonuclease. The second polypeptide may include the N-terminal portion of the endonuclease. The second polypeptide may include the C-terminal portion of the endonuclease. The first or second polypeptide that includes a portion of the endonuclease may be fused to at least a portion or the entirety of the ligase.

[0044] Described herein is a system that includes, in some embodiments, at least one endonuclease. In some embodiments, the endonuclease is a programmable endonuclease, where the endonuclease can be complexed with a guide nucleic acid as described herein and thereby guided to a genomic locus. The endonuclease can bind to DNA. In some embodiments, the endonuclease is an RNA-guided endonuclease. In some embodiments, the endonuclease can introduce a single-strand break. An example of an RNA-guided endonuclease can include a CRISPR / Cas endonuclease (e.g., a class 2 CRISPR / Cas endonuclease, e.g., a type II, type V, or type VI CRISPR / Cas endonuclease). A CRISPR / Cas endonuclease is also referred to as a CRISPR / Cas effector polypeptide. A suitable endonuclease is a CRISPR / Cas endonuclease (e.g., a class 2 CRISPR / Cas endonuclease, such as a type II, type V, or type VI CRISPR / Cas endonuclease). In some cases, a suitable RNA-guided endonuclease is a class 2 CRISPR / Cas endonuclease. In some cases, a suitable RNA-guided endonuclease is a class 2 type II CRISPR / Cas endonuclease (e.g., a Cas9 protein). In some cases, the endonuclease comprises a class 2 type V CRISPR / Cas endonuclease (e.g., a Cpf1 protein, a C2c1 protein, or a C2c3 protein). In some cases, a suitable RNA-guided endonuclease is a class 2 type VI CRISPR / Cas endonuclease (e.g., a C2c2 protein, also referred to as a "Cas13a" protein). Also suitable for use is a CasX protein. Also suitable for use is the CasY protein. In some cases, the endonuclease can include any one of the Cas described herein complexed with a guide nucleic acid (e.g., gRNA) as an RNP complex.

[0045] In some cases, the endonuclease is a type II CRISPR / Cas endonuclease. In some cases, the endonuclease is Cas9. Cas9 functions as an RNA-guided endonuclease that uses dual guide RNAs with crRNA and transactivating crRNA (tracrRNA) for target recognition and cleavage by a mechanism that involves two nuclease active sites in Cas9 that together can generate double-stranded DNA breaks (DSBs) or individually can generate single-stranded DNA breaks (SSBs). The type II CRISPR endonuclease Cas9 and engineered dual (dgRNA) or single guide RNA (sgRNA) form a ribonucleoprotein (RNP) complex that can target a desired DNA sequence. Guided by the dual RNA complex or chimeric single guide RNA, Cas9 generates site-specific DSBs or SSBs in double-stranded DNA (dsDNA) target nucleic acids, which are modified by either non-homologous end joining (NHEJ) or homology-directed recombination (HDR). Cas9 can be guided to a target site within a target nucleic acid sequence (e.g., stabilized at the target site) by association with an RNA-binding segment of Cas9 to guide the RNA. The Cas9 protein can bind to and / or modify (e.g., cleave, nick, methylate, demethylate, etc.) the target nucleic acid and / or a polypeptide associated with the target nucleic acid (e.g., methylate or acetylate histone tails) (e.g., if the Cas9 protein comprises a fusion partner with which it has activity). In some cases, the Cas9 protein is a naturally occurring protein (e.g., naturally occurring in bacterial and / or archaeal cells). In other cases, the Cas9 protein is not a naturally occurring polypeptide (e.g., the Cas9 protein is a variant Cas9 protein, a chimeric protein, etc.).

[0046] Naturally occurring Cas9 proteins can bind to Cas9 guide RNAs and thereby be directed to specific sequences within a target nucleic acid (target site) and cleave the target nucleic acid (e.g., cleave dsDNA to generate double-stranded breaks, cleave ssDNA, cleave ssRNA, etc.). Chimeric Cas9 proteins can include fusion proteins that include a Cas9 polypeptide fused to a heterologous protein (referred to as a fusion partner), where the heterologous protein provides an activity (e.g., one not provided by the Cas9 protein). The fusion partner can provide an activity, e.g., an enzymatic activity (e.g., a nuclease activity, an activity of DNA and / or RNA methylation, an activity of DNA and / or RNA cleavage, an activity of histone acetylation, an activity of histone methylation, an activity of RNA modification, an activity of RNA binding, an activity of RNA splicing, etc.). In some cases, a portion of the Cas9 protein (e.g., the RuvC domain and / or the HNH domain) exhibits reduced nuclease activity compared to the corresponding portion of a wild-type Cas9 protein (e.g., in some cases, the Cas9 protein is a nickase). In some cases, the Cas9 protein is enzymatically inactive or has reduced enzymatic activity compared to a wild-type Cas9 protein (e.g., compared to Streptococcus pyogenes Cas9). In some cases, the Cas9 is a Cas9 nickase. The Cas9 nickase can be generated by mutating the Cas9 nuclease domain. Non-limiting examples of Cas9 nickases can include SpCas9, SaCas9, CjCas9, GeoCas9, HpaCas9, and NmeCas9. In some aspects, the endonucleases described herein include any one of the Cas9s in Table 1. In some embodiments, the endonucleases described herein comprise a polypeptide sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99% or more identical to the polypeptide sequence of any one of the Cas9s in Table 1. [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4] [Table 1-5] [Table 1-6] [Table 1-7] [Table 1-8] [Table 1-9] [Table 1-10] [Table 1-11] [Table 1-12] [Table 1-13]

[0047] Some embodiments include an endonuclease, such as an RNA-guided endonuclease. The RNA-guided endonuclease may include a class II CRISPR / Cas endonuclease. The RNA-guided endonuclease may include a Cas9 endonuclease. The RNA-guided endonuclease may include a nickase. The RNA-guided endonuclease may include an amino acid sequence at least 80% identical to the amino acid sequence of any one of SEQ ID NOs: 1-13, or a functional fragment thereof.

[0048] The endonuclease may introduce a single-stranded break in the target nucleic acid. The endonuclease may introduce a single-stranded break in the target nucleic acid without cleaving the strand opposite the single-stranded break. The endonuclease may include a nickase. In some cases, the endonuclease may exclude an endonuclease that introduces a double-stranded break. The endonuclease may exclude a restriction enzyme.

[0049] The endonuclease may be included as part of a fusion protein. In some cases, the endonuclease is a fusion protein fused to a heterologous polypeptide, such as a heterologous ligase described herein. The heterologous polypeptide may include a fusion partner. The fusion protein may include a fusion partner, such as a DNA ligase, a nuclear localization signal, a chromatin modification domain, a cell-penetrating peptide, or a tag polypeptide. The fusion protein may include one or more fusion partners. The fusion protein may include a ligase. The fusion protein may include a nuclear localization signal, a chromatin modification domain, a cell-penetrating peptide, or a tag polypeptide.

[0050] The fusion partner may be connected to the N-terminus of the endonuclease. The fusion partner may be connected to the C-terminus of the endonuclease. The endonuclease may be connected to the linker at the N-terminus or C-terminus. The fusion partner may be connected by the N-terminus or C-terminus of the fusion partner. The fusion partner may be connected to the endonuclease by the N-terminus of the fusion partner. The fusion partner may be connected to the endonuclease by the C-terminus of the fusion partner. The fusion partner may be connected to the linker at the N-terminus or C-terminus.

[0051] In some cases, the endonuclease includes a linker, which covalently connects the endonuclease to the heterologous polypeptide. The linker may connect the endonuclease to any fusion partner. The linker may also connect any fusion partner to another fusion partner. The linker polypeptide may have any of a variety of amino acid sequences. The proteins may be joined by a generally flexible spacer peptide, but other chemical bonds are not excluded. Suitable linkers include polypeptides from 4 amino acids to 40 amino acids in length, or from 4 amino acids to 25 amino acids in length. These linkers can be generated by coupling the proteins using synthetic oligonucleotides that code for the linker, or can be encoded by a nucleic acid sequence that codes for the fusion protein. Peptide linkers that have some degree of flexibility can be used. The linking peptide can have virtually any amino acid sequence, with the preferred linkers having sequences that result in generally flexible peptides. The use of small amino acids such as glycine and alanine is useful for creating flexible peptides. Creating such sequences is routine for those skilled in the art. A variety of different linkers are commercially available and deemed suitable for use. Examples of linker polypeptides include glycine polymers (G)n, glycine-serine polymers (e.g., (GS)n, (GSGGS)n, (GGSGGS)n, and (GGGS)n, where n is an integer of at least 1), glycine-alanine polymers, and alanine-serine polymers. Exemplary linkers may include amino acid sequences including, but not limited to, GGSG, GGSGG, GSGGG, GGGSG, GGSSG, and the like. Also suitable are linkers having the sequence (GGGGS)n, where n is an integer between 1 and 10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10). One of skill in the art will recognize that the design of a peptide conjugated to any desired element can include a fully or partially flexible linker, thereby allowing the linker to include not only a flexible linker, but also one or more moieties that confer a less flexible structure.

[0052] One or more linkers may be included in the fusion protein. 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 linkers, or a range of linkers defined by any two of the preceding integers, may be included in the fusion protein. The linker may be connected to the N-terminus of at least a portion of the endonuclease. The linker may be connected to the N-terminus of at least a portion of the fusion partner. The linker may be connected to the N-terminus of at least a portion of the fusion ligase. The linker may be connected to the N-terminus of the nuclear localization signal. The linker may be connected to the N-terminus of the chromatin modification domain. The linker may be connected to the N-terminus of the cell penetrating peptide. The linker may be connected to the N-terminus of the tag polypeptide. The linker may be connected to the C-terminus of at least a portion of the endonuclease. The linker may be connected to the C-terminus of at least a portion of the fusion partner. The linker may be connected to the C-terminus of at least a portion of the fusion ligase. The linker may be connected to the C-terminus of the nuclear localization signal. The linker may be attached to the C-terminus of the chromatin-modifying domain. The linker may be attached to the C-terminus of the cell-penetrating peptide. The linker may be attached to the C-terminus of the tag polypeptide.

[0053] The linker may comprise several or ranges of amino acids or residues. The linker may comprise at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 12, at least 13, at least 14, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60, at least 65, at least 70, at least 75, at least 80, at least 85, at least 90, at least 95, or at least 100 amino acid residues. A linker, in some embodiments, may comprise 1 or less, 2 or less, 3 or less, 4 or less, 5 or less, 6 or less, 7 or less, 8 or less, 9 or less, 10 or less, 12 or less, 13 or less, 14 or less, 15 or less, 20 or less, 25 or less, 30 or less, 35 or less, 40 or less, 45 or less, 50 or less, 55 or less, 60 or less, 65 or less, 70 or less, 75 or less, 80 or less, 85 or less, 90 or less, 95 or less, or 100 or less amino acid residues. A linker may comprise 1 to 10 amino acids, 1 to 25 amino acids, or 1 to 100 amino acids.

[0054] The linker may be included anywhere within the polypeptide chain or protein described herein.For example, the linker may separate the endonuclease from the ligase.The linker may separate the endonuclease from a nuclear localization signal, a chromatin modification domain, a cell penetrating peptide, or a tag polypeptide.

[0055] In some cases, the endonuclease comprises a nuclear localization sequence (e.g., one or more nuclear localization signals or NLSs for targeting to the nucleus). In some embodiments, the NLS described herein comprises any one of the NLSs in Table 2. In some embodiments, the NLS described herein comprises a polypeptide sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99% or more identical to the polypeptide sequence of any one of the NLSs in Table 2. [Table 2]

[0056] A polynucleotide encoding an NLS polypeptide may be used. An example of such a polynucleotide may be SGGSx2-bpNLS-SGGSx2:TCCGGCGGAAGCTCTGGTGGCAGCAAGCGGACCGCCGACGGCTCTGAATTCGAGAGCCCTAAGAAGAAAAGAAAGGTGAGCGGAGGCTCTAGCGGCGGAAGC (SEQ ID NO: 25).

[0057] In some embodiments, the endonuclease comprises a dimerization domain. The dimerization domain can be located at the N-terminus or C-terminus of the endonuclease. In some embodiments, the dimerization domain allows the endonuclease to form a heterodimer with another polypeptide (e.g., a heterologous ligase). In some embodiments, the dimerization domain allows the endonuclease to be functionally coupled with another polypeptide. Non-limiting examples of dimerization domains can include leucine zipper, FKBP, FRB, calcineurin A, CyP-Fas, GyrB, GAI, GID1, SNAP tag, Halo tag, Bcl-xL, Fab, LOV domain, or SpyTag / SpyCatcher. Other examples of dimerization domains can include antibodies such as heavy chain domain 2 (CH2) of IgM (MHD2) or IgE (EHD2), immunoglobulin Fc regions, heavy chain domain 3 (CH3) of IgG or IgA, heavy chain domain 4 (CH4) of IgM or IgE, Fab, Fab2, leucine zipper motif, barnase-barstar dimer, miniantibody, or ZIP miniantibody. In some embodiments, the dimerization domains described herein comprise any one of the dimerization domains in Table 3. In some embodiments, the dimerization domains described herein comprise a polypeptide sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99% or more identical to the polypeptide sequence of any one of the dimerization domains in Table 3. [Table 3]

[0058] In some embodiments, the endonuclease comprises at least one additional domain. In some embodiments, the at least one additional domain is a functional domain. For example, the functional domain can comprise a chromatin modification domain or a cell penetrating peptide. In some embodiments, the chromatin modification domain described herein comprises any one of the chromatin modification domains in Table 4. In some embodiments, the chromatin modification domain described herein comprises a polypeptide sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99% or more identical to the polypeptide sequence of any one of the chromatin modification domains in Table 4. [Table 4]

[0059] In some embodiments, the cell penetrating peptides described herein include any one of the cell penetrating peptides in Table 5. In some embodiments, the cell penetrating peptides described herein include a polypeptide sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99% or more identical to the polypeptide sequence of any one of the cell penetrating peptides in Table 5. [Table 5]

[0060] In some embodiments, the endonuclease comprises a tag, and the tag can be used to increase expression, identify, or purify the endonuclease. In some embodiments, the tag described herein comprises any one of the tag sequences in Table 6. In some embodiments, the tag described herein comprises a polypeptide sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99% or more identical to the polypeptide sequence of any one of the tag sequences in Table 6. [Table 6]

[0061] In some embodiments, endonucleases can be expressed as split constructs, as one or more exteins fused to one or more inteins. Intein technology can be used to deliver large proteins into cells by expressing the protein as two or more shorter peptide segments (exteins). Each extein can be expressed as a fusion with an intein peptide (e.g., Npu C intein or Npu N intein). Inteins can autocatalyze the fusion of two or more exteins and can autocatalyze the excision of an intein from the corresponding extein. The result can be a protein complex that includes a first extein fused to a second extein and lacking an intein. An intein can be positioned at the N-terminus of an extein, or an intein can be positioned at the C-terminus of an extein. An extein can include a cysteine ​​residue positioned adjacent to the intein (e.g., at the C-terminus of an extein with an intein fused to the C-terminus of the extein). Cas nickases can be expressed as two or more segments. The first segment of the Cas nickase segment may comprise an N-terminal portion of the Cas nickase. The first segment of the Cas nickase may comprise a first intein. The second segment of the Cas nickase may comprise a C-terminal portion of the Cas nickase. The second segment of the Cas nickase may comprise a second intein. The intein may be fused to the C-terminus of the N-terminal portion of the Cas nickase. The intein may be fused to the N-terminus of the C-terminal portion of the Cas nickase. The nucleic acid sequence encoding the extein-intein fusion may be compatible with a delivery vector (e.g., an adeno-associated virus (AAV) vector).

[0062] DNA ligase Disclosed herein is a ligase. The ligase may be or include a DNA ligase. The ligase may be included in the compositions, systems or methods disclosed herein. The ligase may be recombinant. The ligase may be coupled to an endonuclease. The ligase may be directly or indirectly coupled to an endonuclease. The coupling may be covalent or non-covalent. The ligase may be bound or connected to an endonuclease. The ligase may be recruited to an endonuclease, may be part of a fusion protein with an endonuclease, or may be used in conjunction with an endonuclease. The ligase may be heterologous. The ligase may be endogenous. Where a heterologous ligase is described, a non-heterologous (e.g., endogenous) ligase may be used in some cases. The ligase may be encoded within the cell. The ligase may be delivered to the cell in trans. The ligase can form a phosphodiester bond by joining two nucleic acid ends together. The ligase can join an end of a target nucleic acid (e.g., a 5' or 3' end) to an incorporating nucleic acid (e.g., a 3' or 5' end of an incorporating nucleic acid). The ligase ligates an incorporating nucleic acid to a cleaved or nick end of a target nucleic acid, where the cleaved or nick end has been generated by an endonuclease, such as an RNA-guided endonuclease. The ligase can include any of the embodiments included in Figures 1A-6C.

[0063] The ligase may be non-naturally occurring. The ligase may be engineered. The ligase may be synthetic. The ligase may be presynthesized. The ligase may be added to a subject or cell. The ligase may be encoded by a nucleic acid. The encoding nucleic acid may be engineered, synthetic, or added to a subject or cell.

[0064] At least a portion of the ligase may be included in the first polypeptide. At least a portion of the ligase may be included in the second polypeptide. The ligase may be split into two polypeptides that are joined together. The first polypeptide may include the N-terminal portion of the ligase. The first polypeptide may include the C-terminal portion of the ligase. The second polypeptide may include the N-terminal portion of the ligase. The second polypeptide may include the C-terminal portion of the ligase. The first or second polypeptide that includes a portion of the ligase may be fused with at least a portion or the entire endonuclease.

[0065] Examples of DNA ligases are hLIG1, T4 ligase, T7 ligase, and ligases from Aquifex aeolicus VF5, Neisseria meningitidis serogroup A strain Z2491, Neisseria meningitidis serogroup B strain MC58, Pseudomonas aeruginosa PA01, Vibrio cholerae El Tor N1696, vaccinia virus, and Emiliania huxleyi virus.

[0066] The ligase may include a ligase capable of ligating a substrate comprising DNA. In some embodiments, the ligase includes a ligase capable of ligating a substrate comprising a DNA splint. For example, the DNA ligase may ligate a 5' phosphate to the 3' hydroxyl of two DNA strands hybridized to another DNA strand. The splint DNA strand may include an RNA portion. For example, the DNA ligase may ligate a 5' phosphate to the 3' hydroxyl of two DNA strands hybridized across a DNA portion of an RNA / DNA hybrid strand. In some embodiments, the ligase includes a ligase capable of ligating a substrate comprising DNA / RNA. In some embodiments, the ligase includes a ligase capable of ligating a substrate comprising an RNA splint. For example, the DNA ligase may ligate a 5' phosphate to the 3' hydroxyl of two DNA strands hybridized to an RNA strand. The RNA strand may include a DNA portion. For example, DNA ligase may ligate the 5' phosphate to the 3' hydroxyl of two DNA strands that are hybridized across the RNA portion of an RNA / DNA hybrid strand.

[0067] In some embodiments, the ligases described herein comprise any one of the ligases in Table 7. In some embodiments, the ligases described herein comprise a polypeptide sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99% or more identical to the polypeptide sequence of any one of the ligases in Table 7. [Table 7-1] [Table 7-2] [Table 7-3] [Table 7-4]

Table 7-5

Table 7-6

Table 7-7

Table 7-8

Table 7-9

Table 7-10

Table 7-11

Table 7-12

Table 7-13

Table 7-14

Table 7-15

Table 7-16

Table 7-17

Table 7-18

Table 7-19

Table 7-20

Table 7-21

[0068] Some aspects include a DNA ligase that ligates DNA strand bases paired to a DNA splint. In some embodiments, the DNA ligase ligates DNA strand bases paired to an RNA splint. In some embodiments, the DNA ligase comprises an amino acid sequence at least 80% identical to the amino acid sequence of any one of SEQ ID NOs: 55-96, or a functional fragment thereof.

[0069] In some embodiments, the ligase comprises at least one NLS (e.g., any one of the NLSs in Table 2). In some embodiments, the ligase comprises at least one additional domain. In some embodiments, the at least one additional domain is a dimerization domain (e.g., any one of the dimerization domains in Table 3). In some embodiments, the ligase comprising the dimerization domain can dimerize with an endonuclease to form a heterodimer. In some embodiments, the at least one additional domain is a functional domain. For example, the functional domain can comprise a chromatin-modifying domain (e.g., any one of the chromatin-modifying domains in Table 4) or a cell-penetrating peptide (e.g., any one of the cell-penetrating peptides in Table 5). In some embodiments, the ligase comprises a linker, which can covalently connect the ligase to another polypeptide (e.g., an endonuclease). In some embodiments, the linker covalently connects the ligase to at least one additional domain. In some embodiments, the ligase comprises a tag (e.g., any one of the tags in Table 6), which can be used to increase expression, identify, or purify the ligase. A linker may separate the ligase from a nuclear localization signal, a chromatin modifying domain, a cell penetrating peptide, or a tag polypeptide. Any linker described herein may be included.

[0070] The ligase may include a binding motif for binding to a nucleic acid motif (e.g., a hairpin motif). In some embodiments, the ligase (e.g., a DNA ligase) includes an MS2 coat protein (MCP) peptide. The ligase may include a hairpin binding motif, such as an MCP peptide. The MCP peptide may be useful for recruiting the ligase to a guide nucleic acid that includes an MS2 hairpin. The advantage of using an MCP peptide and an MS2 hairpin is that it separates the ligase, such as a Cas nickase (or a portion thereof), and the endonuclease, allowing for compatibility within a separate vector, such as an AAV vector. In some embodiments, the ligase includes a loop region. In some embodiments, the loop region is a 2a loop or a 3a loop. The loop region may include a 2a loop. The loop region may include a 3a loop.

[0071] Fusion proteins Disclosed herein are fusion proteins. Some embodiments include a nucleic acid (e.g., an expression vector) that encodes a fusion protein. The fusion protein may include an endonuclease. The fusion protein may include a ligase. The fusion protein may include a linker. The endonuclease and the ligase may be connected via a linker. The fusion protein may be an example of a covalently coupled endonuclease and DNA ligase. The fusion protein may include an endonuclease, such as an RNA-guided endonuclease, fused to a DNA ligase.

[0072] A fusion protein may be non-naturally occurring. A fusion protein may be engineered. A fusion protein may be synthetic. A fusion protein may be presynthesized. A fusion protein may be added to a subject or a cell. A fusion protein may be encoded by a nucleic acid. The encoding nucleic acid may be engineered, synthetic, or added to a subject or a cell.

[0073] The fusion protein may include one of a variety of orientations. For example, the fusion protein may include an RNA-guided endonuclease upstream (e.g., N-terminus or N-direction) or downstream (e.g., C-terminus or C-direction) to the DNA ligase. The fusion protein may include an RNA-guided endonuclease amino (N)-terminal to the DNA ligase. The fusion protein may include an RNA-guided endonuclease carboxy (C)-terminal to the DNA ligase. The endonuclease may be amino-directed within the fusion polypeptide relative to the ligase. The endonuclease may be carboxy-directed within the fusion polypeptide relative to the ligase. The endonuclease may be N-terminal. The endonuclease may be C-terminal. The ligase may be N-terminal. The ligase may be C-terminal.

[0074] The fusion protein may include a nuclear localization signal, a chromatin modification domain, a cell-penetrating peptide, a tag polypeptide, or an exonuclease. The fusion protein may include a nuclear localization signal. The fusion protein may include a chromatin modification domain. The fusion protein may include a cell-penetrating peptide. The fusion protein may include a tag polypeptide. The fusion protein may include an exonuclease. Any of the nuclear localization signal, chromatin modification domain, cell-penetrating peptide, tag polypeptide, or exonuclease, endonuclease, or ligase may be directly connected to another, or to an endonuclease or ligase. Any of the nuclear localization signal, chromatin modification domain, cell-penetrating peptide, tag polypeptide, or exonuclease, endonuclease, or ligase may be connected to another, or to an endonuclease or ligase by a linker. Multiple linkers may be included in the fusion protein. The fusion protein may exclude a polymerase.

[0075] The linker may comprise an amino acid linker. The amino acid linker may comprise a length of residues. The length may comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, or 100 residues, or a range of residues defined by any two of the preceding integers. The length may comprise at least 1 residue, at least 2 residues, at least 3 residues, at least 4 residues, at least 5 residues, at least 6 residues, at least 7 residues, at least 8 residues, at least 9 residues, at least 10 residues, at least 15 residues, at least 20 residues, at least 25 residues, at least 30 residues, at least 40 residues, at least 50 residues, at least 60 residues, at least 70 residues, at least 80 residues, at least 90 residues, or at least 100 residues. In some embodiments, the length may comprise less than 2 residues, less than 3 residues, less than 4 residues, less than 5 residues, less than 6 residues, less than 7 residues, less than 8 residues, less than 9 residues, less than 10 residues, less than 15 residues, less than 20 residues, less than 25 residues, less than 30 residues, less than 40 residues, less than 50 residues, less than 60 residues, less than 70 residues, less than 80 residues, less than 90 residues, or less than 100 residues. Exemplary residues include alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, or valine, or any combination thereof. The linker may be non-enzymatic or lack any enzymatic activity.

[0076] The connection can be a covalent bond. The covalent bond can include a peptide bond. The peptide bond can include an amide bond. The connection can be between an N-terminus and another N-terminus. The connection can be between a C-terminus and another C-terminus. The connection can be between an N-terminus and a C-terminus. The connection can be between a C-terminus and an N-terminus.

[0077] A fusion protein may contain connections in various orientations. An endonuclease may be connected at its C-terminus. An endonuclease may be connected at its N-terminus. A ligase may be connected at its C-terminus. A ligase may be connected at its N-terminus.

[0078] Figure 7 shows some examples of fusion proteins. The diagram includes examples of the placement and orientation of endonucleases, linkers, ligases, or nuclear localization signals. Other embodiments can be incorporated into the examples shown.

[0079] Non-covalently coupled proteins Disclosed herein are non-covalently coupled proteins. Some embodiments relate to a nucleic acid (e.g., an expression vector) that encodes the protein or encodes at least a portion of the protein. The protein may comprise an endonuclease, such as an RNA-guided endonuclease. The protein of the non-covalently coupled protein may comprise a portion of an endonuclease. The protein of the non-covalently coupled protein may comprise a portion of a ligase. The protein may comprise a ligase, such as a DNA ligase. The protein of the non-covalently coupled protein may comprise a fusion protein.

[0080] Non-covalently coupled proteins can be linked together through heterodimerization domains. Examples of heterodimerization domains can include leucine zippers, PDZ domains, streptavidin, streptavidin-binding proteins, foldon domains, hydrophobic moieties, or functional binding fragments thereof. Heterodimerization domains can include leucine zippers. Heterodimerization domains can include PDZ domains. Heterodimerization domains can include streptavidin. Heterodimerization domains can include streptavidin-binding proteins. Heterodimerization domains can include foldon domains. Heterodimerization domains can include hydrophobic moieties. Heterodimerization domains can include antibodies or antibody fragments. Non-covalently coupled proteins can be linked together through inteins.

[0081] The endonuclease and the ligase may be coupled together by a separate molecule. The separate molecule may comprise a nucleic acid (e.g., a guide nucleic acid). The ligase may comprise a hairpin binding motif in which the RNA-guided endonuclease and the DNA ligase are coupled to the nucleic acid. The nucleic acid may comprise a scaffold that binds to the RNA-guided endonuclease and a hairpin that binds to the hairpin binding motif. The hairpin binding motif may comprise an MS2 coat protein (MCP) peptide. The hairpin may comprise an MS2 hairpin.

[0082] The endonuclease and the ligase may be coupled together by a heterobifunctional molecule. The heterobifunctional molecule may comprise an endonuclease binding domain and a DNA ligase binding domain. The heterobifunctional molecule may comprise an endonuclease binding domain. The endonuclease binding domain may comprise a heterodimerization domain. The endonuclease binding domain may comprise an antibody or an antibody binding fragment. The heterobifunctional molecule may comprise a ligase binding domain, such as a DNA ligase binding domain. The DNA ligase binding domain may comprise a heterodimerization domain. The DNA ligase binding domain may comprise an antibody or an antibody binding fragment. The heterobifunctional molecule may comprise a small molecule. The small molecule may comprise a proteolysis targeting chimera (PROTAC) or related heterobifunctional molecule.

[0083] Some aspects include a protein complex comprising an RNA-guided endonuclease bound to a DNA ligase. The endonuclease and the DNA ligase can be bound together through a heterodimerization domain. The protein complex according to embodiment 75, wherein the heterodimerization domain can comprise a leucine zipper, a PDZ domain, a streptavidin and a streptavidin-binding protein, a foldon domain, a hydrophobic polypeptide, an antibody that binds to a Cas nickase, or an antibody that binds to a DNA ligase, or one or more binding fragments thereof. The protein complex can be contained within a cell. The cell can further comprise a heterologous RNA-guided endonuclease and a DNA ligase introduced into the cell. The cell can further comprise a nuclease different from the RNA-guided endonuclease.

[0084] Guide Nucleic Acid Disclosed herein are guide nucleic acids. Guide nucleic acids may be included in compositions, systems, or methods disclosed herein. Some embodiments relate to nucleic acids (e.g., DNA or expression vectors) that encode guide nucleic acids, such as guide RNAs. Provided herein are guide nucleic acids (e.g., gRNAs) that direct a programmable endonuclease (e.g., nCas9) to a target nucleic acid (e.g., a genomic locus). The guide nucleic acid may guide an RNA-guided endonuclease to a target nucleic acid locus for nucleic acid replacement or gene editing at the locus. The guide nucleic acids of the present disclosure may facilitate the insertion of a donor strand into a target site of a target nucleic acid. The guide nucleic acids of the present disclosure may facilitate editing of a nucleic acid sequence at a target site of a target nucleic acid. The guide nucleic acid may also function as a splint for a DNA ligase described herein, such as to ligate two nucleic acid strand bases paired to a portion of the guide nucleic acid in some cases. The guide nucleic acid may be single-stranded. The guide nucleic acid may include RNA. The guide nucleic acid may be RNA. The guide nucleic acid may comprise a guide RNA (gRNA). In some cases, the guide nucleic acid may comprise DNA.

[0085] A guide nucleic acid can be non-naturally occurring. A guide nucleic acid can be engineered. A guide nucleic acid can be synthetic. A guide nucleic acid can be presynthesized. A guide nucleic acid can be added to a subject or a cell. In some aspects, a guide nucleic acid does not include a template for a polymerase.

[0086] The guide nucleic acid may comprise an incorporated nucleic acid binding site, which may be referred to as a "donor binding site."

[0087] Disclosed herein is a guide nucleic acid that includes a spacer that is reverse complementary to a first region of a target nucleic acid, a scaffold configured to bind to an endonuclease, an embedded nucleic acid binding site, and optionally a flap binding site that is reverse complementary to a nucleic acid flap.

[0088] In some embodiments, the guide nucleic acid comprises a spacer complementary to a genomic locus in the cell, a scaffold for complexing with at least one endonuclease, a donor binding site at least partially complementary to the donor strand, a flap binding site at least partially identical or complementary to a genomic flap at or adjacent to the genomic locus, or a combination thereof. In some embodiments, the guide nucleic acid can direct at least one endonuclease to cleave at least one strand of the genomic locus. In some embodiments, the guide nucleic acid can be at least partially complementary to the donor strand or at least partially complementary to a genomic flap (e.g., a genomic nucleic acid sequence that is displaced and becomes single-stranded when the guide nucleic acid recruits an endonuclease to the genomic locus). In some embodiments, the guide nucleic acid that is at least partially complementary to the donor strand or at least partially complementary to the genomic flap brings the donor strand into close proximity for cleavage of the genomic locus.

[0089] Disclosed herein, in some embodiments, is a guide nucleic acid comprising a scaffold. The scaffold may bind to a nuclease. The scaffold may bind to a Cas nuclease. The scaffold may bind to a nickase. The scaffold may bind to a Cas nickase. The scaffold may bind to a S. Pyogenes Cas9 nuclease. The scaffold may bind to a S. Pyogenes Cas9 nickase. The scaffold may comprise a scaffold nucleic acid sequence. The system described herein may include a first guide nucleic acid. The system may include a second guide nucleic acid. The first guide nucleic acid may bind to a first Cas nickase. The second guide nucleic acid may bind to a second Cas nickase.

[0090] The guide nucleic acid may include any of the following aspects: (i) a spacer complementary to a region of the genomic locus of the genomic strand; (ii) a scaffold for complexing with an RNA-guided endonuclease; (iii) a donor binding site at least partially complementary to the integrating nucleic acid; or (iv) a flap binding site at least partially identical to or complementary to a genomic flap at or adjacent to the genomic locus. The guide nucleic acid may include any of the following aspects: (i) a spacer complementary to a region of the genomic locus of the genomic strand; (ii) a scaffold for complexing with an RNA-guided endonuclease; or (iii) a donor binding site at least partially complementary to the splint nucleic acid. The components of (i), (ii), or (iii) may be included in a single guide nucleic acid, or may be split among multiple guide nucleic acids, or may be included together in multiple guide nucleic acids.

[0091] In some embodiments, the guide nucleic acid comprises a modified internucleoside linkage. In some embodiments, the modified internucleoside linkage comprises a phosphorothioate linkage. In some embodiments, the modified internucleoside linkage is between any of the four terminal nucleosides at the 5' or 3' end of the guide nucleic acid. The guide nucleic acid may comprise multiple modified internucleoside linkages. For example, the guide nucleic acid may comprise modified internucleoside linkages at the 5' and 3' ends of the guide nucleic acid, for example, between the last four nucleic acids at the 5' end and between the last four nucleic acids at the 3' end. In some embodiments, the guide nucleic acid comprises a modified nucleoside. In some embodiments, the modified nucleotide comprises a locked nucleic acid (LNA), 2'fluoro, 2'O-alkyl, or a combination thereof. The modified nucleoside may comprise an LNA, 2'fluoro, 2'O-alkyl, methylated cytosine, inverted thymidine, or a combination thereof. The modified nucleoside may comprise an LNA. The modified nucleoside may include 2' fluoro. The modified nucleoside may include 2' O-alkyl. The modified nucleoside may include methylated cytosine. In some embodiments, the modified nucleoside is one of the three terminal nucleosides at the 5' or 3' end of the guide nucleic acid. The guide nucleic acid may include multiple modified nucleosides. For example, the guide nucleic acid may include modified nucleotides at the 5' and 3' end nucleic acids of the guide nucleic acid, such as the last three nucleic acids at the 5' end and the last three nucleic acids at the 3' end.

[0092] In some embodiments, the guide nucleic acid comprises at least one nucleic acid modification. In some embodiments, the at least one nucleic acid modification comprises modifying the backbone, sugar, base, or a combination thereof of the guide nucleic acid. In some embodiments, the at least one nucleic acid modification can increase the resistance of the guide nucleic acid to degradation (e.g., to nuclease degradation or hydrolysis). In some embodiments, the at least one nucleic acid modification can increase the complexation of the guide nucleic acid to at least one endonuclease. In some embodiments, the at least one nucleic acid modification can increase the complexation of the guide nucleic acid to the donor strand. In some embodiments, the at least one nucleic acid modification can increase the complexation of the guide nucleic acid to a genomic locus by being complementary to a genomic flap.

[0093] In some embodiments, the guide nucleic acid comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 or more nucleic acid modifications. In some embodiments, the nucleic acid modifications can occur at the 3'OH group, 5'OH group, backbone, sugar moiety, or nucleotide base. The nucleic acid modifications can include non-naturally occurring linker molecules of inter- or intra-strand bridges. In one embodiment, the modified nucleic acid comprises one or more modifications of the 3'OH or 5'OH group, the backbone, the sugar moiety, or the nucleotide base, or the addition of a non-naturally occurring linker molecule. In some embodiments, the modified backbone comprises a backbone other than a phosphodiester backbone. In some embodiments, the modified sugar comprises a sugar other than deoxyribose (in modified DNA) or a sugar other than ribose (in modified RNA). In some embodiments, the modified base comprises a base other than adenine, guanine, cytosine, thymine, or uracil. In some embodiments, the guide nucleic acid comprises at least one modified base. In some examples, the guide nucleic acid comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, or more modified bases. In some cases, the nucleic acid modifications to the base moiety include natural and synthetic modifications of adenine, guanine, cytosine, thymine, or uracil, and purine or pyrimidine bases.

[0094] In some embodiments, at least one nucleic acid modification of the guide nucleic acid comprises any one of the following modifications or any combination thereof: 2'-O-methyl, 2'-O-methoxyethyl (2'-O-MOE), 2'-O-aminopropyl, 2'-deoxy, 2'-deoxy-2'-fluoro, 2'-O-aminopropyl (2'-O-AP), 2'-O-dimethylaminoethyl (2'-O-DMAOE), 2'-O-dimethylaminopropyl (2'-O-DMAP), 2'-O-dimethylaminoethyloxyethyl (2'-O-DMAEOE), or 2'-O-N-methylacetamide (2'-O-NMA). ' modified nucleotides; modification of one or both of the non-linked phosphate oxygens in a phosphodiester backbone linkage; modification of one or more of the linked phosphate oxygens in a phosphoester backbone linkage; modification of a building block of the ribose sugar; replacement of a phosphate moiety with a "dephospho" linker; modification or replacement of a naturally occurring nucleobase; modification of the ribose-phosphate backbone; modification of the 5' end of a polynucleotide; modification of a polynucleotide; modification of the 3' end of a polynucleotide; modification of the deoxyribose phosphate backbone; replacement of a phosphate group; modification of the ribophosphate backbone; modification of the sugar of a nucleotide; modification of the base of a nucleotide; or stereopurity of a nucleotide. Non-limiting examples of nucleic acid modifications to a guide nucleic acid include modification of one or both of the phosphodiester backbone linkages (e.g., sulfur (S), selenium (Se), BR3 (where R can be, for example, hydrogen, alkyl, or aryl), C (e.g., alkyl, aryl, etc.), H, NR2 (where R can be, for example, hydrogen, alkyl, or aryl), or unlinked or linked phosphate oxygens; replacement of the phosphate moiety with a "dephospho" linker (e.g., replacement with methylphosphonate, hydroxylamino, siloxane, carbonate, carboxymethyl, carbamate, amide, thioether, ethylene oxide linker, sulfonate, sulfonamide, thioformacetal, formacetal, oxime, methyleneimino, methylenemethylimino, methylenehydrazo, methylenedimethylhydrazo, or methyleneoxymethylimino);Modifications or replacement of naturally occurring nucleobases with nucleic acid analogs; modifications of the deoxyribose-phosphate or ribose-phosphate backbone (e.g., modifications of the ribose-phosphate backbone to phosphorothioates, phosphonothioacetates, phosphoroselenates, boranophosphates, boranophosphate esters, hydrogen phosphates, phosphonocarboxylates, phosphoramidates, alkyl or aryl phosphonates, phosphonoacetates, or phosphotriesters; modifications of the 5' end (e.g., 5' cap or 5' cap-OH modifications) or 3' end (3' tail or 3' end-OH modifications) of the nucleic acid sequence; methyl phosphonates, hydroxylamino, siloxane, carbonate, carboxymethyl, carbamate, carboxymethyl, carbamate, amide, thioether, ethylene oxide linker, sulfonate, sulfone, replacement of the phosphate group with an amide, thioformacetal, formacetal, oxime, methyleneimino, methylenemethylimino, methylenehydrazo, methylenedimethylhydrazo, or methyleneoxymethylimino; modification of the ribophosphate backbone to incorporate morpholino (phosphorodiamidate morpholino oligomers (PMOs), cyclobutyl, pyrrolidine, or peptide nucleic acid (PNA) nucleoside surrogates; modification to the sugar of the nucleotide to incorporate locked nucleic acid (LNA), unlocked nucleic acid (UNA), ethylene nucleic acid (ENA), constrained ethyl (cEt) sugar, or bridged nucleic acid (BNA); modification of the ribose sugar (e.g., 2'-O-methyl, 2'-O-methoxy-ethyl (2'-MOE), 2'-fluoro, 2'-aminoethyl, 2'-deoxy-2'-fuloarabinou-cleic acid (FLUORABINO)); modifications to the building blocks of the nucleotide (A, T, C, G, or U); and stereopurity of the nucleotide (e.g., phosphorothioate S conformation or phosphorothioate R conformation);

[0095] In some embodiments, the nucleic acid modification comprises at least one substitution of one or both of the non-linked phosphate oxygen atoms in the phosphodiester backbone linkage of the guide nucleic acid. In some embodiments, the nucleic acid modification of at least one of the guide nucleic acid comprises one or more substitutions of the linked phosphate oxygen atoms in the phosphodiester backbone linkage of the guide nucleic acid. A non-limiting example of a nucleic acid modification of a phosphate oxygen atom is a sulfur atom. In some embodiments, the nucleic acid modification comprises at least one modification to the sugar. In some embodiments, the nucleic acid modification comprises at least one modification to the sugar comprising a modification of a sugar component, the sugar being a ribose sugar. In some embodiments, the nucleic acid modification of the guide nucleic acid comprises at least one modification to the ribose sugar component of the nucleotide of the guide nucleic acid comprising a 2'-O-methyl group. In some embodiments, the nucleic acid modification comprises at least one modification comprising replacing a phosphate moiety of the guide nucleic acid with a dephosphoryl linker. In some embodiments, the nucleic acid modification of comprises at least one modification of the phosphate backbone. In some embodiments, the modification comprises a phosphorothioate group. In some embodiments, the nucleic acid modification comprises at least one modification comprising a modification to a base of a nucleotide of the guide nucleic acid. In some embodiments, the nucleic acid modification comprises at least one modification comprising an unnatural base of a nucleotide. In some embodiments, the nucleic acid modification comprises at least one modification comprising at least one stereopure nucleic acid. In some embodiments, the at least one nucleic acid modification can be located proximal to the 5' end of the guide nucleic acid. In some embodiments, the at least one nucleic acid modification can be located proximal to the 3' end of the guide nucleic acid. In some embodiments, the at least one nucleic acid modification can be located proximal to both the 5' end and the 3' end of the guide nucleic acid.

[0096] In some embodiments, the guide nucleic acid described herein comprises a backbone comprising a plurality of covalently linked sugar and phosphate moieties. In some cases, the backbone of the guide nucleic acid comprises a phosphodiester bond linkage between the first hydroxyl group of the phosphate group on the 5' carbon of the deoxyribose of DNA or the ribose of RNA and the second hydroxyl group on the 3' carbon of the deoxyribose of DNA or the ribose of RNA. In some embodiments, the backbone of the guide nucleic acid may lack a 5' reduced hydroxyl, a 3' reduced hydroxyl, or both that can be exposed to a solvent. In some embodiments, the backbone of the guide nucleic acid may lack a 5' reduced hydroxyl, a 3' reduced hydroxyl, or both that can be exposed to a nuclease. In some embodiments, the backbone of the guide nucleic acid may lack a 5' reduced hydroxyl, a 3' reduced hydroxyl, or both that can be exposed to a hydrolytic enzyme. In some examples, the backbone of the guide nucleic acid may be represented as a polynucleotide sequence in a circular two-dimensional format, with one nucleotide following another. In some examples, the backbone of the guide nucleic acid can be represented as a looped two-dimensional format polynucleotide sequence in which one nucleotide follows another. In some cases, the 5' hydroxyl, the 3' hydroxyl, or both are joined via a phosphorus-oxygen bond. In some cases, the 5' hydroxyl, the 3' hydroxyl, or both are modified to a phosphoester with a phosphorus-containing moiety.In some embodiments, the guide nucleic acid comprises at least one nucleic acid modification, including any one of the following: 5' adenylate, 5' guanosine-triphosphate cap, 5' N7-methylguanosine-triphosphate cap, 5' triphosphate cap, 3' phosphate, 3' thiophosphate, 5' phosphate, 5' thiophosphate, cis-scinthymidine dimer, trimer, C12 spacer, C3 spacer, C6 spacer, dSpacer, PC spacer, rSpacer, spacer 18, spacer 9, 3'-3' modification, 5'-5' modification, abasic, acridine, azobenzene, biotin, biotin BB, biotin TEG, cholesteryl TEG, desthiobiotin TEG, DNP. TEG, DNP-X, DOTA, dT-biotin, dual biotin, PC-biotin, psoralen C2, psoralen C6, TINA, 3'DABCYL, black hole quencher 1, black hole quencher 2, DABCYL SE, dT-DABCYL, IRDye QC-1, QSY-21, QSY-35, QSY-7, QSY-9, carboxyl linker, thiol linker, 2' deoxyribonucleoside analogs purines, 2' deoxyribonucleoside analogs pyrimidines, ribonucleoside analogs, 2'-O-methyl ribonucleoside analogs, sugar modified analogs, wobble / universal bases, fluorescent dye labels, 2' fluoro RNA, 2' O-methyl RNA, methyl phosphonates, phosphodiester DNA, phosphodiester RNA, phosphothioate DNA, phosphorothioate RNA, UNA, LNA, cEt, pseudouridine-5'-triphosphate, 5-methylcytidine-5'-triphosphate, 2-O-methyl-phosphorothioate, or any combination thereof.

[0097] The nucleic acid modification can also be phosphorothioate substitution. In some cases, natural phosphodiester bonds may be susceptible to rapid degradation by cellular nucleases, and modification of internucleotide linkages using phosphorothioate (PS) bond substitutions may be more stable against hydrolysis by cellular degradation. The modification can increase stability in polynucleic acids. The modification can also enhance biological activity. In some cases, phosphorothioate-enhanced RNA polynucleic acids can inhibit RNase A, RNase T1, calf serum nuclease, or any combination thereof. These properties can enable the use of PS-RNA polynucleic acids in applications where exposure to nucleases is likely in vivo or in vitro. For example, phosphorothioate (PS) bonds can be introduced between the last 3-5 nucleotides at the 5′ or 3′ end of the polynucleic acid to inhibit exonuclease degradation. In some cases, phosphorothioate bonds can be added throughout the polynucleic acid to reduce attack by endonucleases. In some embodiments, the guide nucleic acid comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 50, 100 or more internucleotide linkages comprising PS linkages. In some embodiments, the guide nucleic acid comprises only PS linkages as internucleotide linkage modifications. In some embodiments, all internucleotide linkages of the guide nucleic acid herein are fully PS modified or comprise phosphorothioate internucleotide linkages.

[0098] The guide nucleic acid may comprise a hairpin. The hairpin may bind to a hairpin binding motif, such as a hairpin binding motif on a DNA ligase. The hairpin may comprise an MS2 hairpin A hairpin, such as an MS2 hairpin, which may be useful for recruiting DNA ligase that comprises an MCP peptide.

[0099] The guide nucleic acid may include any of the embodiments included in Figures 1A-6C. Table 8 provides some non-limiting examples of the guide nucleic acids described herein. Some of the guide nucleic acids in the table include nucleic acid modifications. [Table 8-1] [Table 8-2] [Table 8-3] [Table 8-4]

[0100] The guide nucleic acid may include a sequence of linking nucleic acid (e.g., linking RNA or DNA nucleotides) between components of the guide nucleic acid. For example, the guide nucleic acid may include a sequence of linking nucleic acid between any of the following components: spacer, scaffold, donor binding site, or flap binding site. The guide nucleic acid may include a sequence of linking nucleic acid between the spacer, scaffold, or donor binding site. The guide nucleic acid may include a sequence of linking nucleic acid between the scaffold and the donor binding site. The guide nucleic acid may include a sequence of linking nucleic acid between the spacer and scaffold. The guide nucleic acid may include multiple sequences of linking nucleic acid between components.

[0101] The sequence of the linked nucleic acid may include any base, such as A, U, T, G, or C, or a combination thereof. The sequence of the linked nucleic acid may include A, T, G, or C, or a combination thereof. The sequence of the linked nucleic acid may include A, U, G, or C, or a combination thereof. The sequence of the linked nucleic acid may include a run of A. The sequence of the linked nucleic acid may include a run of T. The sequence of the linked nucleic acid may include a run of U. The sequence of the linked nucleic acid may include a run of C. The sequence of the linked nucleic acid may include a run of G.

[0102] The sequence of the linked nucleic acid can include a length, such as a number of nucleotides. The length can include 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 nucleotides, or a range defined by any two of the foregoing numbers of nucleotides. The length may comprise at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60, at least 65, at least 70, at least 75, at least 80, at least 85, at least 90, at least 95, or at least 100 nucleotides. In some embodiments, the length may be less than 2, less than 3, less than 4, less than 5, less than 6, less than 7, less than 8, less than 9, less than 10, less than 11, less than 12, less than 13, less than 14, less than 15, less than 16, less than 17, less than 18, less than 19, less than 20, less than 21, less than 22, less than 23, less than 24, less than 25, less than 30, less than 35, less than 40, less than 45, less than 50, less than 55, less than 60, less than 65, less than 70, less than 75, less than 80, less than 85, less than 90, less than 95, or less than 100 nucleotides.

[0103] Some embodiments relate to a guide nucleic acid comprising a spacer that is at least partially complementary to a genomic locus in a cell, a scaffold for complexing with an RNA-guided endonuclease, and a donor binding site that is at least partially complementary to an integrating nucleic acid. The guide nucleic acid may further comprise a flap binding site that is at least partially complementary to a genomic sequence of the genomic locus. The guide nucleic acid may further comprise at least one nucleic acid modification. The at least one nucleic acid modification may comprise a modification to the backbone, sugar, base, or a combination thereof. The guide nucleic acid may comprise an RNA.

[0104] Some embodiments include a guide nucleic acid that includes a spacer at least partially complementary to a first region of a target nucleic acid, a scaffold configured to bind to an endonuclease, a flap binding site at least partially complementary to the nucleic acid flap, and an intrinsic nucleic acid binding site.

[0105] Incorporating Nucleic Acid Disclosed herein is an integrating nucleic acid. The integrating nucleic acid may be included in the compositions, systems, or methods disclosed herein. Some aspects relate to a nucleic acid encoding the integrating nucleic acid. Provided herein is an integrating nucleic acid that is inserted into a target nucleic acid, such as a host genome at a locus. For example, the integrating nucleic acid may replace a nucleic acid in the target nucleic acid. The integrating nucleic acid may be referred to as a "donor nucleic acid," "donor," or "donor strand." When a genomic locus is described, the locus may be included, or vice versa. For example, the locus may be part of the host genome or may be part of a non-genomic nucleic acid. The donor may include DNA. Similarly, the target nucleic acid may include DNA. In some cases, the donor may include RNA, for example, when the target nucleic acid includes RNA. The integrating nucleic acid may include any insert, such as a gene or regulatory element, that is inserted into the genomic locus of the target nucleic acid. The donor strand may include a sequence that is at least partially homologous to the locus. The integrating nucleic acid may also, in some instances, function as a splint for a DNA ligase as described herein, for example, to ligate two nucleic acid strand bases that are paired to a portion of the splint integrating nucleic acid. In some cases, the splint comprises one strand of the integrating nucleic acid, and the portion that is ligated may be another strand of the integrating nucleic acid. In some cases, the splint comprises a strand of the integrating nucleic acid, and the portion that is ligated may be an upstream or downstream portion of the same strand of the integrating nucleic acid. The integrating nucleic acid may be single-stranded. The integrating nucleic acid may be double-stranded. The integrating nucleic acid may be delivered as two strands. The integrating nucleic acid may be delivered as multiple strands, e.g., two strands.

[0106] An integrating nucleic acid can be a non-naturally occurring nucleic acid. An integrating nucleic acid can be engineered. An integrating nucleic acid can be synthetic. An integrating nucleic acid can be presynthesized. An integrating nucleic acid can be added to a subject or a cell. In some aspects, an integrating nucleic acid does not include a template for a polymerase.

[0107] Disclosed herein is an integrating nucleic acid that includes a double-stranded DNA region that is inserted into a target nucleic acid, where the double-stranded DNA region is adjacent to at least one overhang that includes a flap binding site and / or a guide binding site.

[0108] The integrating nucleic acid can be ligated to a target nucleic acid, such as a genomic strand. The integrating nucleic acid can include a 5' end that can be ligated to the 3' end of the genomic strand generated by the RNA-guided endonuclease.

[0109] The donor may include any of the embodiments included in Figures 1A-6C. For example, the donor may include an embodiment such as a guide binding site, a flap binding site, or an overhang. The donor may include a guide binding site. The donor may include two guide binding sites. The donor may include a flap binding site. The donor may include two flap binding sites. The donor may include an overhang. The donor may include two overhangs. The embodiments may be included at the 5' or 3' end of the donor, or at both ends. The guide binding site or flap binding site may be in an internal region of the donor.

[0110] Some embodiments include an integrating nucleic acid that includes a double-stranded DNA region that is inserted into a target nucleic acid, where the double-stranded DNA region is adjacent to at least one overhang that includes a flap binding site or a guide binding site.

[0111] In some embodiments, the incorporated nucleic acid comprises a modified internucleoside linkage. In some embodiments, the modified internucleoside linkage comprises a phosphorothioate linkage. In some embodiments, the modified internucleoside linkage is between any of the four terminal nucleosides at the 5' or 3' end of the incorporated nucleic acid. The incorporated nucleic acid may comprise multiple modified internucleoside linkages. For example, the incorporated nucleic acid may comprise modified internucleoside linkages at the 5' and 3' ends of the incorporated nucleic acid, such as between the last four nucleic acids at the 5' end and between the last four nucleic acids at the 3' end. In some embodiments, the incorporated nucleic acid comprises a modified nucleoside. In some embodiments, the modified nucleoside comprises a locked nucleic acid (LNA), 2'fluoro, 2'O-alkyl, 5'O-methyl, 2'-O-methyl, or a combination thereof. The modified nucleoside may include LNA, 2'fluoro, 2'O-alkyl, methylated cytosine, inverted thymidine, or combinations thereof. The modified nucleoside may include LNA. The modified nucleoside may include 2'fluoro. The modified nucleoside may include 2'O-alkyl. The modified nucleoside may include methylated cytosine. In some embodiments, the modified nucleoside is any of the three terminal nucleosides at the 5' or 3' end of the integrating nucleic acid. The integrating nucleic acid may include multiple modified nucleosides. For example, the integrating nucleic acid may include modified nucleotides at the 5' and 3' end nucleic acids of the integrating nucleic acid, such as the last three nucleic acids at the 5' end and the last three nucleic acids at the 3' end. The integrating nucleic acid may include any modification, such as modified nucleosides or modified internucleoside linkages, described in connection with the guide nucleic acid, so long as it does not interfere with the function of the integrating nucleic acid after it is ligated to a target nucleic acid, such as a host genome. The integrating nucleic acid can include any number or combination of modifications, such as those described in connection with the guide nucleic acid, so long as they do not interfere with the function of the integrating nucleic acid. Table 8 includes some examples of integrating nucleic acid sequences.

[0112] The incorporated nucleic acid may comprise a methylated nucleotide. The incorporated nucleic acid may comprise an unmethylated nucleotide. An example of a methylated nucleotide may comprise a nucleotide comprising a methylated cytosine. The cytosine may be methylated at the C-5 position of the cytosine ring. An example of an unmethylated nucleotide may comprise an unmethylated cytosine. An unmethylated nucleotide may comprise an unmethylated cytosine at the C-5 position of the cytosine ring.

[0113] target nucleic acid Disclosed herein are target nucleic acids. The target nucleic acid may comprise DNA. The target nucleic acid may be DNA. The target nucleic acid may comprise RNA. The target nucleic acid may be within a cell. The target nucleic acid may be methylated. The target nucleic acid may be unmethylated. The target nucleic acid may comprise a genome. The target nucleic acid may comprise genomic DNA. The target nucleic acid may comprise a chromosome. The target nucleic acid may comprise a gene.

[0114] The target nucleic acid can be in a subject. The target nucleic acid can be in a cell. The target nucleic acid can be in a test tube.

[0115] The target nucleic acid may be edited. The target nucleic acid may be edited in vitro. The target nucleic acid may be edited in vivo.

[0116] system Described herein is a system for nucleic acid editing (also known as gene editing). The editing system can include an endonuclease, such as an RNA-guided endonuclease, a guide nucleic acid, and an integrating nucleic acid. When gene editing is described, it is understood that editing can be a gene, a regulatory element, or any sequence of a nucleic acid. Also, when genome editing is described, such as genome editing at a gene locus, it is understood that nucleic acid editing can be performed without involving a genome. For example, genome editing can refer to editing the genome of an organism, or can include editing of a nucleic acid that is not part of a genome. The system described herein can be used in a gene editing method.

[0117] Described herein is a system that, in some embodiments, includes at least one endonuclease, at least one guide nucleic acid, at least one ligase, at least one donor strand, or a combination thereof. In some embodiments, the guide nucleic acid guides the endonuclease to the genomic locus to cleave at least one strand of the genomic locus, and after cleavage, the donor strand is ligated and thus integrated into the genomic locus by the ligase. In some embodiments, the system includes a first endonuclease complexed with a first guide nucleic acid (the first endonuclease can be operably coupled to the first ligase) and a second endonuclease complexed with a second guide nucleic acid (the second endonuclease can be operably coupled to the second ligase). In such a system, each of the first endonuclease and the second endonuclease can each cleave at least one strand of the genomic locus for integration of the donor strand.

[0118] In some embodiments, the system comprises one, two, three, or more endonucleases. In some embodiments, the system comprises one endonuclease. In some embodiments, the two endonucleases can each be complexed with a different guide nucleic acid. In some embodiments, the two endonucleases can each be operably coupled to a ligase. In some embodiments, the endonuclease is a programmable endonuclease. In some embodiments, the endonuclease comprises an RNA-guided endonuclease and the guide nucleic acid comprises a guide RNA. In some embodiments, the endonuclease comprises a nickase and the endonuclease only cleaves one strand (rather than making a double stranded cut). In some embodiments, the endonuclease comprises a localization signal sequence to increase accumulation of the endonuclease in the vicinity of the genomic locus (e.g., in the nucleus). In some embodiments, the endonuclease comprises at least one additional domain. In some embodiments, at least one additional domain is a dimerization domain. In some embodiments, the endonuclease comprising the dimerization domain can be dimerized with a ligase to form a heterodimer. In some embodiments, at least one additional domain is a functional domain. For example, the functional domain can comprise a chromatin-modifying domain or a cell-penetrating peptide. In some embodiments, the endonuclease comprises a linker, and the linker can covalently connect the endonuclease to another polypeptide (e.g., a ligase). In some embodiments, the linker covalently connects the endonuclease to at least one additional domain. In some embodiments, the endonuclease comprises a tag, and the tag can be used to increase expression, identify, or purify the endonuclease.

[0119] In some embodiments, the system comprises one, two, three or more guide nucleic acids. In some embodiments, the system comprises one guide nucleic acid, and the one guide nucleic acid can be complexed with at least one endonuclease. In some embodiments, the system comprises two guide nucleic acids, and the two guide nucleic acids can each be complexed with at least one endonuclease. In some embodiments, the guide nucleic acid comprises a spacer complementary to a genomic locus in the cell, a scaffold for complexing with at least one endonuclease, a donor binding site at least partially complementary to a donor strand, a flap binding site at least partially identical or complementary to a genomic flap at or adjacent to the genomic locus, or a combination thereof. In some embodiments, the guide nucleic acid can direct at least one endonuclease to cleave at least one strand of the genomic locus. In some embodiments, the guide nucleic acid may be at least partially complementary to the donor strand or at least partially complementary to a genomic flap (e.g., a genomic nucleic acid sequence that is displaced and becomes single-stranded when the guide nucleic acid recruits an endonuclease to the genomic locus). In some embodiments, the guide nucleic acid that is at least partially complementary to the donor strand or at least partially complementary to a genomic flap brings the donor strand into proximity for cleavage of the genomic locus. In some embodiments, the guide nucleic acid comprises at least one nucleic acid modification. In some embodiments, the at least one nucleic acid modification comprises modifying the backbone, sugar, base, or combination thereof of the guide nucleic acid. In some embodiments, the at least one nucleic acid modification can increase the resistance of the guide nucleic acid to degradation (e.g., to nuclease degradation or hydrolysis). In some embodiments, the at least one nucleic acid modification can increase the complexation of the guide nucleic acid to at least one endonuclease. In some embodiments, the at least one nucleic acid modification can increase the complexation of the guide nucleic acid to the donor strand.In some embodiments, at least one nucleic acid modification can increase complexation of the guide nucleic acid to a genomic locus via being complementary to a genomic flap.

[0120] In some embodiments, the system includes one, two, three, or more ligases. In some embodiments, the system includes one ligase. In some embodiments, the one ligase is operably coupled to at least one endonuclease, and the ligase can ligate at least one end of the donor strand to the cleaved genomic locus, thus incorporating the donor strand into the genomic locus. In some embodiments, the system includes two ligases. In some embodiments, the two ligases can each be operably coupled to a different endonuclease, and the genomic locus is cleaved at two or more locations. In such a scenario, the two ligases can each ligate one end of the donor strand to the cleaved genomic locus, thus incorporating the donor strand into the genomic locus. In some embodiments, the ligase includes a ligase that can ligate a substrate that includes DNA. In some embodiments, the ligase includes a ligase that can ligate a substrate that includes a DNA splint. In some embodiments, the ligase comprises a ligase capable of ligating substrates comprising DNA / RNA. In some embodiments, the ligase comprises a ligase capable of ligating substrates comprising an RNA splint. In some embodiments, the ligase comprises at least one additional domain. In some embodiments, the at least one additional domain is a dimerization domain. In some embodiments, the ligase comprising a dimerization domain can dimerize with an endonuclease to form a heterodimer. In some embodiments, the at least one additional domain is a functional domain. For example, the functional domain can comprise a chromatin-modifying domain or a cell-penetrating peptide. In some embodiments, the ligase comprises a linker, which can covalently connect the ligase to another polypeptide (e.g., an endonuclease). In some embodiments, the linker covalently connects the ligase to at least one additional domain. In some embodiments, the ligase comprises a tag, which can be used to increase expression, identify, or purify the ligase.

[0121] Disclosed herein are fusion proteins comprising an RNA-guided endonuclease fused to a ligase. Table 9 shows non-limiting examples of polypeptides and nucleic acid sequences encoding fusion polypeptides comprising components of the system described herein (e.g., an endonuclease fused to a ligase). SEQ ID NO: 125 shows a nucleic acid sequence encoding the polypeptide sequence of SEQ ID NO: 126, which shows a fusion protein comprising an N-terminal NLS, followed by an endonuclease (nCas9) covalently connected to a ligase (hLIG1, 119-919 fragment) via a linker, followed by a C-terminal NLS (NLS-nCas9-linker-hLIG1(119-919)-bpNLS). SEQ ID NO: 127 shows a nucleic acid sequence encoding the polypeptide sequence of SEQ ID NO: 128, which shows a fusion protein comprising an N-terminal NLS, followed by an endonuclease (nCas9) covalently connected via a linker to a ligase (hLIG1, 233-919 fragment), followed by a C-terminal NLS (NLS-nCas9-linker-hLIG1(233-919)-bpNLS). SEQ ID NO: 129 shows a nucleic acid sequence encoding the polypeptide sequence of SEQ ID NO: 130, which shows a fusion protein comprising an N-terminal NLS, followed by an endonuclease (nCas9) covalently connected via a linker to a ligase (SplintR), followed by a C-terminal NLS (NLS-nCas9-linker-SplintR-bpNLS). SEQ ID NO: 131 shows a nucleic acid sequence encoding the polypeptide sequence of SEQ ID NO: 132, which shows a fusion protein (NLS-nCas9-linker-T4LIG-bpNLS) comprising an N-terminal NLS followed by an endonuclease (nCas9) covalently connected to a ligase (T4LIG) via a linker followed by a C-terminal NLS. SEQ ID NO: 133 shows a nucleic acid sequence encoding an endonuclease (nCas9) comprising an N-terminal NLS and a leucine zipper (LZ) dimerization domain.SEQ ID NO: 134 shows a fusion protein (NLS1-hFEN1-linker1-nCas9-linker2-T4LIG-NLS2) comprising a first NLS (NLS1) at the N-terminus, followed by an exonuclease (hFEN1) covalently connected to an endonuclease (nCas9) via linker 1, further covalently connected to a ligase (T4LIG) via linker 2, followed by a second NLS (NLS2) at the C-terminus. SEQ ID NO: 135 shows a fusion protein (NLS1-hFEN1-linker1-T4LIG-linker2-nCas9-NLS2) comprising an N-terminal NLS1, an exonuclease (hFEN1) covalently connected to a ligase (T4LIG) via linker 1, further covalently connected to an endonuclease (nCas9) via linker 2, followed by a C-terminal NLS2. SEQ ID NO: 136 shows a fusion protein comprising an N-terminal NLS1 followed by an endonuclease (nCas9) covalently connected to an exonuclease (hFEN1) via linker 1, further covalently connected to a ligase (T4LIG) via ligase 2, followed by a C-terminal NLS2 (NLS1-nCas9-linker1-hFEN1-linker2-T4LIG-NLS2). SEQ ID NO: 137 shows a fusion protein comprising an N-terminal NLS1 followed by a ligase (T4LIG) covalently connected to an endonuclease (nCas9) via linker 1, further covalently connected to an exonuclease (hFEN1) via ligase 2, followed by a C-terminal NLS2 (NLS1-T4LIG-linker1-nCas9-linker2-hFEN1-NLS2). SEQ ID NO:138 shows a fusion protein comprising an N-terminal NLS1, an endonuclease (nCas9) covalently connected to a ligase (T4LIG) via linker 1, which is further covalently connected to an exonuclease (hFEN1) via linker 2, followed by a C-terminal NLS2 (NLS1-nCas9-linker1-T4LIG-linker2-hFEN1-NLS2).SEQ ID NO: 139 shows a fusion protein comprising an N-terminal NLS1, a ligase (T4LIG) covalently connected to an exonuclease (hFEN1) via linker 1, further covalently connected to an endonuclease (nCas9) via linker 2, followed by a C-terminal NLS2 (NLS1-T4LIG-linker1-hFEN1-linker2-nCas9-NLS2). SEQ ID NO: 140 shows a fusion protein comprising an N-terminal NLS1, followed by an exonuclease (EXO) covalently connected to an endonuclease (nCas9) via linker 1, further covalently connected to a ligase (T4LIG) via ligase 2, followed by a C-terminal NLS2 (NLS1-T5 EXO-linker1-nCas9-linker2-T4LIG-NLS2). SEQ ID NO: 141 shows a nucleic acid sequence encoding a fusion protein comprising a ligase (SplintR) and an NLS fused to a dimerization domain (LZ) (LZ-SplintR-bpNLS). SEQ ID NO: 142 shows a nucleic acid sequence encoding a fusion protein comprising a ligase (T4LIG) and an NLS fused to a dimerization domain (LZ) (LZ-T4LIG-bpNLS). SEQ ID NO: 143 shows a nucleic acid sequence encoding a fusion protein comprising a ligase (hLIG) and an NLS fused to a dimerization domain (LZ) (LZ-hLIG 233-919 polypeptide fragment-bpNLS). SEQ ID NO: 144 shows a nucleic acid sequence encoding a fusion protein comprising a ligase (hLIG) and an NLS fused to a dimerization domain (LZ) (LZ-hLIG1 119-919 polypeptide fragment-bpNLS). SEQ ID NO: 145 shows a nucleic acid sequence encoding a fusion protein (T4-LZ) comprising a ligase (T4) fused to a dimerization domain (LZ) and an NLS. SEQ ID NO: 146 shows a nucleic acid sequence encoding a fusion protein (LZ-hLIG4(1-620)) comprising a ligase polypeptide fragment (hLIG4(1-620)) fused to a dimerization domain (LZ) and an NLS. SEQ ID NO: 147 shows a nucleic acid sequence encoding a fusion protein (LZ-nCas9) comprising an endonuclease (nCas9) fused to a dimerization domain (LZ) and an NLS.SEQ ID NO: 148 shows a nucleic acid sequence encoding a fusion protein (SplintR-LZ) comprising a ligase (SplintR) fused to a dimerization domain (LZ) and an NLS. SEQ ID NO: 149 shows a nucleic acid sequence encoding a fusion protein (hLIG4(1-620)-LZ) comprising a ligase polypeptide fragment (hLIG4(1-620)) fused to a dimerization domain (LZ) and an NLS. SEQ ID NO: 150 shows a nucleic acid sequence encoding a fusion protein (nCas9-hLIG4(1-620)) comprising a ligase polypeptide fragment (hLIG4(1-620)) fused to an endonuclease (nCas9) and an NLS. SEQ ID NO: 151 shows a nucleic acid sequence encoding a fusion protein (T4-nCas9) comprising a ligase (T4) fused to an endonuclease (nCas9) and an NLS. SEQ ID NO: 152 shows a nucleic acid sequence encoding a fusion protein (SplintR-nCas9) comprising an endonuclease (nCas9) and a ligase (SplintR) fused to an NLS. SEQ ID NO: 153 shows a nucleic acid sequence encoding a fusion protein (hLIG4(1-620)-nCas9) comprising an endonuclease (nCas9) and a ligase polypeptide fragment (hLIG4(1-620)) fused to an NLS. [Table 9-1] [Table 9-2] [Table 9-3] [Table 9-4] [Table 9-5] [Table 9-6] [Table 9-7] [Table 9-8]

Table 9-9

Table 9-10

Table 9-11

Table 9-12

Table 9-13

Table 9-14

Table 9-15

Table 9-16

Table 9-17

Table 9-18

Table 9-19

Table 9-20

Table 9-21

Table 9-22

Table 9-23

Table 9-24

Table 9-25

Table 9-26

Table 9-27

Table 9-28

Table 9-29

Table 9-30

Table 9-31

Table 9-32

Table 9-33

Table 9-34

Table 9-35

Table 9-36

Table 9-37

Table 9-38

Table 9-39

Table 9-40

Table 9-41

Table 9-42

[0122] Disclosed herein is a protein complex comprising an RNA-guided endonuclease bound to a ligase.The endonuclease and the ligase can be bound together via a heterodimerization domain.The heterodimerization domain can comprise one or more of the following: leucine zipper, PDZ domain, streptavidin and streptavidin-binding protein, foldon domain, hydrophobic polypeptide, antibody that binds to Cas nickase, or antibody that binds to ligase, or one or more binding fragments thereof.

[0123] In some embodiments, the system comprises at least one donor strand. In some embodiments, the donor strand comprises a nucleic acid sequence that is at least partially homologous to the genomic locus targeted by at least one guide nucleic acid. In some embodiments, the donor strand comprises a nucleic acid sequence that is not homologous to the genomic locus targeted by at least one guide nucleic acid. In some embodiments, the donor strand is a single-stranded or double-stranded nucleic acid. In some embodiments, the donor strand that comprises a double-stranded nucleic acid comprises at least one overhang. In some embodiments, the overhang comprises a guide binding site that is at least partially complementary to the guide nucleic acid. In some embodiments, the overhang comprises a genomic flap binding site that is at least partially identical to or complementary to a genomic flap at or adjacent to the genomic locus. In some embodiments, the donor strand comprises two overhangs, the first overhang comprises a first guide binding site at least partially complementary to a first guide nucleic acid, or a first genomic flap binding site at least partially identical or complementary to a first genomic flap at or adjacent to a genomic locus, and the second overhang comprises a second guide binding site at least partially complementary to a second guide nucleic acid, or a second genomic flap binding site at least partially identical or complementary to a second genomic flap at or adjacent to a genomic locus. In some embodiments, the donor strand corrects at least one genetic mutation at at least one locus. In some embodiments, the donor strand comprises a coding sequence. In some embodiments, the coding sequence encodes a full-length protein or a fragment thereof. In some embodiments, the donor strand comprises a non-coding sequence. In some embodiments, the non-coding sequence knocks out an endogenous gene. In some embodiments, the non-coding sequence comprises a regulatory element.

[0124] In some embodiments, the system includes a nuclease. The nuclease may be heterologous. In some embodiments, the nuclease includes an exonuclease for digesting genomic flaps. In some embodiments, the exonuclease is a 5' exonuclease. Non-limiting examples of exonucleases may include human flap endonuclease 1 (hFEN1), human exonuclease 5 (hEXO5), T5 exonuclease, T7 exonuclease, exonuclease VIII, flap endonuclease domain of E. coli PolI, RecJF, lambda exonuclease, Xni (ExoIXI), SaFEN (Staphylococcus aureus FEN), nuclease BAL-31, or fragments thereof. In some embodiments, the exonuclease includes an exonuclease in Table 10. In some embodiments, the exonuclease comprises a polypeptide sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99% or more identical to the polypeptide sequence of any one of the exonucleases in Table 10. [Table 10-1] [Table 10-2] [Table 10-3]

[0125] In some embodiments, the system includes at least one additional endonuclease that is different from the at least one programmable endonuclease described herein. In some embodiments, the at least one additional endonuclease is capable of digesting a genomic flap.

[0126] In some embodiments, the system comprises a dominant negative MMR peptide to improve genome editing ability, especially in cells that overexpress MMR pathway.In some embodiments, the dominant negative MMR peptide can be delivered as a fusion (e.g., fused with any component of the system described herein), can be mobilized, or can be delivered as a separate peptide.Table 11 lists non-limiting examples of MMR peptide sequences. [Table 11-1] [Table 11-2] [Table 11-3] [Table 11-4] [Table 11-5]

[0127] The system may relate to a one-sided replacer 1. Some embodiments include a system comprising: (a) at least one RNA-guided endonuclease; (b) at least one guide nucleic acid comprising (i) a spacer complementary to a genomic locus in the cell; (ii) a scaffold for complexing with the at least one RNA-guided endonuclease; (iii) an optional donor binding site at least partially complementary to the integrating nucleic acid; (iv) a flap binding site at least partially identical or complementary to a genomic flap at or adjacent to the genomic locus; (c) at least one DNA ligase; and (d) an integrating nucleic acid, optionally comprising a guide binding site at least partially complementary to the at least one guide nucleic acid, wherein the at least one RNA-guided endonuclease cleaves at least one strand of the genomic locus, and the at least one DNA ligase ligates an end of the integrating nucleic acid to the genomic flap site, thereby replacing a region of the locus with the integrating nucleic acid in the cell. The integrating nucleic acid may comprise single-stranded DNA.

[0128] The system may relate to a two-sided replacer 1. Some embodiments include a system comprising: (a) at least one RNA-guided endonuclease, comprising a first RNA-guided endonuclease and an optional second RNA-guided endonuclease; and (b) at least one guide nucleic acid, comprising a first guide nucleic acid and a second guide nucleic acid, wherein the first guide nucleic acid comprises (i) a first spacer complementary to a first region of a genomic locus in a cell, (ii) a first scaffold for complexing with the first RNA-guided endonuclease, and (iii) an optional second scaffold at least partially complementary to an integrating nucleic acid. and (iv) a first flap binding site that is at least partially identical to or complementary to a first genomic flap at or adjacent to the genomic locus, wherein the second guide nucleic acid comprises (i) a second spacer that is complementary to a second region of the genomic locus in the cell, (ii) a second scaffold for complexing with the first or second RNA-guided endonuclease, (iii) an optional second donor binding site that is at least partially complementary to the integrating nucleic acid, (iv) a second flap binding site that is at least partially identical to or complementary to a first genomic flap at or adjacent to the genomic locus. (c) at least one DNA ligase comprising a first DNA ligase and an optional second DNA ligase; and (d) at least one integrated nucleic acid comprising a first strand and a second strand, wherein (i) the first strand comprises an optional first guide binding site that is at least partially complementary to the first guide nucleic acid, and (ii) the second strand comprises an optional second guide binding site that is at least partially complementary to the second guide nucleic acid. and at least one integrating nucleic acid comprising a nucleic acid sequence encoding a genomic locus in a cell, wherein a first RNA-guided endonuclease and / or a second RNA-guided endonuclease each cleaves at least one strand of a genomic locus in the cell, a first DNA ligase ligates an end of the first strand of the integrating nucleic acid to a first genomic flap, and the first or second DNA ligase ligates an end of the second strand of the integrating nucleic acid to a second genomic flap, thereby replacing a region of the genomic locus with the integrating nucleic acid in the cell.The integrating nucleic acid may include a double-stranded DNA duplex region. The integrating nucleic acid may optionally include a 5' overhang that includes a first guide binding site. The integrating nucleic acid may optionally include a 5' overhang that includes a second guide binding site.

[0129] The system may involve a one-sided replacer 2. Some embodiments include a system comprising: (a) at least one RNA-guided endonuclease; (b) at least one guide nucleic acid comprising (i) a spacer complementary to a genomic locus in the cell, (ii) a scaffold for complexing with the at least one RNA-guided endonuclease, and (iii) an optional donor binding site at least partially complementary to the integrating nucleic acid; (c) at least one DNA ligase; and (d) an integrating nucleic acid comprising (i) an optional guide binding site at least partially complementary to the at least one guide nucleic acid and (ii) a flap binding site at least partially identical or complementary to a genomic flap at or adjacent to the genomic locus, wherein the at least one RNA-guided endonuclease cleaves at least one strand of the genomic locus and the at least one DNA ligase ligates an end of the integrating nucleic acid to the genomic flap, thereby replacing a region of the genomic locus with the integrating nucleic acid in the cell. The integrating nucleic acid may comprise a DNA comprising a 3' overhang. The 3' overhang may comprise a guide binding site. The 3' overhang may comprise a flap binding site. At least one DNA ligase may ligate a strand of the integrating nucleic acid to a genomic nucleic acid sequence.

[0130] The system may relate to a double-sided replacer 2. Some embodiments include a system comprising (a) at least one RNA-guided endonuclease, comprising a first RNA-guided endonuclease and an optional second RNA-guided endonuclease, and (b) at least one guide nucleic acid, comprising a first guide nucleic acid and a second guide nucleic acid, wherein the first guide nucleic acid comprises (i) a first spacer complementary to a first region of a genomic locus in a cell, (ii) a first scaffold for complexing with the first RNA-guided endonuclease, and (iii) an optional spacer at least partially complementary to an integrating nucleic acid. and a second guide nucleic acid comprising (i) a second spacer complementary to a second region of a genomic locus in the cell, (ii) a second scaffold for complexing with the first or second RNA-guided endonuclease, and (iii) an optional second donor binding site at least partially complementary to the integrating nucleic acid; at least one DNA ligase comprising a first DNA ligase and an optional second DNA ligase; and an integrating nucleic acid comprising a first strand and a second strand, wherein the first strand is , an optional first guide binding site that is at least partially complementary to a first guide nucleic acid, the second strand includes an optional second guide binding site that is at least partially complementary to a second guide nucleic acid, the first strand includes a first flap binding site that is at least partially identical to or complementary to a first genomic flap at or adjacent to the genomic locus, and the second strand includes a first flap binding site that is at least partially identical to or complementary to a second genomic flap at or adjacent to the genomic locus. and an integrating nucleic acid comprising a second flap binding site, wherein the first RNA-guided endonuclease and / or the second RNA-guided endonuclease each cleaves at least one strand of a genomic locus in the cell, the first DNA ligase ligates an end of the first strand of the integrating nucleic acid to the first genomic flap, and the first or second DNA ligase ligates an end of the second strand of the integrating nucleic acid to the second genomic flap, thereby replacing a region of the genomic locus with the integrating nucleic acid in the cell.The integrating nucleic acid may comprise a double-stranded DNA duplex region. The double-stranded DNA may optionally comprise a 3' overhang that includes a first guide binding site and a first flap binding site. The double-stranded DNA may optionally comprise a 3' overhang that includes a second guide binding site and a second flap binding site.

[0131] In the system, the at least one RNA-guided endonuclease may comprise a Cas protein or a functional fragment thereof. The Cas protein or a functional fragment thereof may comprise a nickase activity. The at least one RNA-guided endonuclease may comprise a Cas9 nickase or a functional fragment thereof. The at least one DNA ligase may ligate a nucleic acid bound to DNA. The at least one DNA ligase may ligate a nucleic acid bound to RNA. The at least one DNA ligase may comprise a PBCV-1 DNA ligase. The at least one DNA ligase may be operably coupled to the at least one RNA-guided endonuclease. The at least one DNA ligase may be fused to the at least one RNA-guided endonuclease as a fusion polypeptide. The at least one RNA-guided endonuclease and the at least one DNA ligase may comprise a heterodimer domain. The at least one RNA-guided endonuclease and the at least one DNA ligase may form a heterodimer via a heterodimer domain. The at least one RNA-guided endonuclease may include a linker. The linker may connect the Cas protein or a functional fragment thereof to the heterodimer domain. The at least one RNA-guided endonuclease may include a localization signal sequence. The at least one DNA ligase may include a localization signal sequence. The localization signal sequence may include a nuclear localization sequence (NLS). The at least one RNA-guided endonuclease or the at least one DNA ligase may be guided to the nucleus of the cell by the NLS. The at least one integrating nucleic acid may correct at least one genetic mutation in at least one locus. The at least one integrating nucleic acid may insert a coding sequence. The coding sequence may code for a full-length protein. The at least one integrating nucleic acid may insert a non-coding sequence. The non-coding sequence may knock out an endogenous gene. The non-coding sequence may comprise a regulatory element. The system may further comprise a nuclease. The nuclease may comprise an exonuclease for digesting the genomic flap.The nuclease may include human flap endonuclease 1 (hFEN1), human exonuclease 5 (hEXO5), T5 exonuclease, T7 exonuclease, exonuclease VIII, flap endonuclease domain of E. coli PolI, RecJF, lambda exonuclease, Xni (ExoIXI), SaFEN (Staphylococcus aureus FEN), nuclease BAL-31, or fragments thereof. The heterologous nuclease may include an endonuclease for digesting genomic flaps, and the endonuclease may be different from the at least one RNA-guided endonuclease. The at least one RNA-guided endonuclease may include at least one additional functional domain. The at least one additional functional domain may include a chromatin-modifying domain. The at least one additional functional domain may include a cell-penetrating peptide. The at least one guide nucleic acid may include at least one nucleic acid modification. The at least one nucleic acid modification may include a modification to the backbone, sugar, base, or a combination thereof. The at least one RNA-guided endonuclease may be complexed with the at least one guide nucleic acid. The at least one guide nucleic acid may be complexed with the integrating nucleic acid. The at least one RNA-guided endonuclease, the at least one guide nucleic acid, the at least one DNA ligase, the integrating nucleic acid, or a combination thereof may be encoded by a polynucleotide. The polynucleotide may include an mRNA. The polynucleotide may include a vector. The vector may include a viral vector. The at least one RNA-guided endonuclease, the at least one guide nucleic acid, the at least one DNA ligase, the integrating nucleic acid, or a combination thereof may be encapsulated by at least one lipid nanoparticle. The cell may include a bacterial cell or a prokaryotic cell. The cell may include a prokaryotic cell. The prokaryotic cell may include a bacterial cell. The editing may occur in the cytoplasm of the bacterial cell. The cell may comprise a eukaryotic cell. The eukaryotic cell may comprise an animal cell or a plant cell. The eukaryotic cell may comprise a plant cell. The eukaryotic cell may comprise an animal cell.The eukaryotic cell may include a mammalian cell. Editing may occur in the cytoplasm of the eukaryotic cell. Editing may occur in the nucleus of the eukaryotic cell. The system or any aspect of the system may be included in a composition or may be included in a cell, such as a cell line.

[0132] Some embodiments relate to systems that include a nucleic acid. The system may include a guide nucleic acid, an integrating nucleic acid, or a combination thereof. Some embodiments relate to a nucleic acid system. The system may include a guide nucleic acid system. The system may include an integrating nucleic acid system. The nucleic acid system may further include other aspects such as additional nucleic acids or non-nucleic acid components.

[0133] The nucleic acid system may include a guide nucleic acid. The guide nucleic acid may include a spacer. The spacer may be complementary to a region of a locus (e.g., a genomic locus) of a target nucleic acid, such as a genomic strand. The target nucleic acid may be in a cell. The genomic strand may be in a cell. The target nucleic acid may be in vitro. The guide nucleic acid may include a scaffold. The scaffold may be complexed with an endonuclease, such as an RNA-guided endonuclease. The guide nucleic acid may include a flap binding site. The flap binding site may be complementary or at least partially complementary to a flap, such as a genomic flap. The flap binding site may be identical or at least partially identical to a flap, such as a genomic flap. The flap may be at a locus. The flap may be adjacent to the locus. The guide nucleic acid may include a donor binding site. The donor binding site may be complementary to an integrating nucleic acid. The donor binding site may be partially complementary to an integrating nucleic acid. The donor binding site can be complementary to the splint nucleic acid. The donor binding site can be partially complementary to the splint nucleic acid. The components of the guide nucleic acid can be included in one guide nucleic acid. Two or more guide nucleic acids can be used. The components of the guide nucleic acid can be included together in a plurality of guide nucleic acids. The components of the guide nucleic acid can be divided between a plurality of guide nucleic acids.

[0134] The nucleic acid system may include an integrating nucleic acid. The integrating nucleic acid may include a 5' end that is ligated. The 5' end may be ligated. The 5' end may be ligated to a 3' end. The 3' end may be of a target nucleic acid strand (e.g., a genomic strand). The 3' end may be generated by an endonuclease, such as an RNA-guided endonuclease. The integrating nucleic acid may include a 5' end that is ligated to a 3' end of a genomic strand generated by an RNA-guided endonuclease. The integrating nucleic acid components may be included in one or two complementary strands. The integrating nucleic acid components may be included in one integrating nucleic acid. Multiple integrating nucleic acids may be used. The integrating nucleic acid components may be included together in multiple integrating nucleic acids. The integrating nucleic acid components may be split between multiple integrating nucleic acids.

[0135] The nucleic acid system may include a splint nucleic acid (also referred to as a "sprint strand"). The splint strand may hybridize to two nucleic acids that include the ends to be ligated. The splint nucleic acid may include a flap binding site. The flap binding site may be complementary to the flap. The flap binding site may be partially complementary to the flap. The flap binding site may be identical to the flap. The flap binding site may be partially identical to the flap. The flap may be at the locus of the target nucleic acid. The flap may be adjacent to the locus of the target nucleic acid. The flap may be a genomic flap. The locus may be a genomic locus. The flap binding site may be at least partially identical to or complementary to a genomic flap at or adjacent to the genomic locus. The splint nucleic acid may include a guide binding site. The guide binding site may be complementary to the guide nucleic acid. The guide binding site may be partially complementary to the guide nucleic acid. The components of the splint nucleic acid can be included in one splint nucleic acid. Two or more splint nucleic acids can be used. The splint nucleic acid can include a donor binding site. The donor binding site can be complementary to the integrating nucleic acid. The donor binding site can be partially complementary to the integrating nucleic acid.

[0136] The splint strand may be or may include DNA. The splint strand may be or may include RNA. The splint nucleic acid may be included as part of an integrating nucleic acid. The splint nucleic acid may be included as a strand of a double stranded integrating nucleic acid. The splint nucleic acid may be included as part of an integrating nucleic acid.

[0137] The nucleic acid system may include (a) a guide nucleic acid comprising (i) a spacer complementary to a region of a genomic locus of a genomic strand, (ii) a scaffold for complexing with an RNA-guided endonuclease, (iii) an optional donor binding site at least partially complementary to the integrating nucleic acid, and (iv) a flap binding site at least partially identical to or complementary to a genomic flap at or adjacent to the genomic locus, and (b) an integrating nucleic acid comprising a 5' end that is ligated to the 3' end of the genomic strand generated by the RNA-guided endonuclease. The components (i), (ii), (iii), or (iv) may be included in a single guide nucleic acid, or may be split among or together in multiple guide nucleic acids.

[0138] A nucleic acid system may include: (a) a guide nucleic acid comprising (i) a spacer complementary to a region of a genomic locus of a genomic strand, (ii) an RNA-guided endonuclease, and (iii) an optional donor binding site that is at least partially complementary to the splint nucleic acid; (b) an integrating nucleic acid comprising a 5' end that is ligated to the 3' end of the genomic strand generated by the RNA-guided endonuclease; and (c) a splint nucleic acid comprising a flap binding site that is at least partially identical or complementary to a genomic flap at or adjacent to the genomic locus and an optional guide binding site that is at least partially complementary to the guide nucleic acid. Components (i), (ii), or (iii) may be included in a single guide nucleic acid, or may be split among multiple guide nucleic acids, or may be included together in multiple guide nucleic acids.

[0139] In some embodiments, the system described herein can be delivered into a cell, and one or more of the components of the system can be delivered into the cell together. In some embodiments, each component of the system can be delivered separately to the cell. In some embodiments, the system can be encoded by a polynucleotide, such as a heterologous polynucleotide, and the polynucleotide is delivered into the cell, and the polynucleotide is expressed by the cell to generate the components of the cell. In some embodiments, the system can be encoded and delivered into the cell via a polynucleotide comprising an mRNA. In some embodiments, the system can be encoded and delivered into the cell via a polynucleotide comprising a vector. In some embodiments, the vector comprises a viral vector. The system can be encapsulated in a lipid or nanoparticle, or in a plurality of lipids or nanoparticles. In some embodiments, the system can be encapsulated in at least one lipid nanoparticle. In some embodiments, the system comprises a ribonucleoprotein (RNP). For example, at least one RNA-guided endonuclease (e.g., Cas9) described herein can be complexed with at least one guide nucleic acid described herein for delivery (e.g., to form a CRISPR ribonucleoprotein). In some embodiments, the system comprises at least one RNP comprising an RNA-guided endonuclease complexed with at least one first guide nucleic acid or complexed with at least one second guide nucleic acid. In some embodiments, the system comprises at least one RNP and at least one integrating nucleic acid (e.g., a single-stranded or double-stranded integrating nucleic acid as described herein). In some embodiments, the system comprises at least one RNP and at least one integrating nucleic acid. In some embodiments, the system comprises at least one RNP and at least one first integrating nucleic acid or at least one second integrating nucleic acid.

[0140] In some aspects, the systems described herein can modify genomic loci or genes in a cell. In some aspects, the cell comprises a bacterial cell, a eukaryotic cell, or a plant cell. In some aspects, the systems described herein can be formulated into a composition, a pharmaceutical composition, a kit, or a combination thereof. In some aspects, the systems described herein can be delivered and propagated in a cell line.

[0141] Some embodiments include an editing system comprising an RNA-guided endonuclease, a guide nucleic acid, and an integrating nucleic acid. Some embodiments include a method of editing comprising contacting a target nucleic acid with the editing system and a DNA ligase.

[0142] Pharmaceutical Compositions Described herein, in some aspects, is a pharmaceutical composition comprising the system or composition described herein. The pharmaceutical composition may include a pharma- ceutically acceptable excipient, carrier, or diluent. The pharmaceutical composition may include a carrier. The pharmaceutical composition may include an excipient. The pharmaceutical composition may be delivered to a subject. The pharmaceutical composition may be delivered to a cell. The pharmaceutical composition may be used in the methods disclosed herein.

[0143] The pharmaceutical compositions described herein include systems, compositions, or cells that are in contact with the systems or in contact with the compositions. The pharmaceutical compositions may include compositions such as proteins or nucleic acids disclosed herein. The pharmaceutical compositions may include cells that include the compositions or systems disclosed herein.

[0144] A pharmaceutical composition may comprise a mixture of a pharmaceutical composition with other chemical components (i.e., pharma- ceutically acceptable inactive ingredients), such as carriers, excipients, binders, fillers, suspending agents, flavoring agents, sweeteners, disintegrants, dispersants, surfactants, lubricants, colorants, diluents, solubilizers, humectants, plasticizers, stabilizers, penetration enhancers, wetting agents, antifoaming agents, antioxidants, preservatives, or one or more combinations thereof. In practicing the methods of treatment or use provided herein, a therapeutically effective amount of the pharmaceutical composition described herein is administered to a mammal having the disease, disorder, or condition to be treated. In some embodiments, the mammal is a human. The therapeutically effective amount may vary widely depending on the severity of the disease, the age and relative health of the subject, the potency of the pharmaceutical composition used, as well as other factors. The pharmaceutical composition may be used alone or in combination with one or more other pharmaceutical compositions, as a component of a mixture.

[0145] The pharmaceutical composition may be formulated for administration to a subject in need thereof intrathecal, intraocular, intravitreal, retinal, intravenous, intramuscular, intraventricular, intracerebral, intracerebellar, intralateral ventricular, intraparenchymal, subcutaneous, intratumor, intrapulmonary, intratracheal, intraperitoneal, intravesical, intravaginal, rectal, oral, sublingual, transdermal, by inhalation, by inhaled aerosol form, by intraluminal GI route, or by a combination thereof.

[0146] The pharmaceutical formulations described herein are administered to a subject by suitable routes of administration, including but not limited to intravenous, intraarterial, oral, parenteral, buccal, topical, transdermal, rectal, intramuscular, subcutaneous, intraosseous, transmucosal, inhalation, or intraperitoneal routes of administration.The pharmaceutical formulations described herein include, but are not limited to, aqueous liquid dispersions, self-emulsifying dispersions, solid solutions, liposomal dispersions, aerosols, solid dosage forms, powders, immediate release formulations, controlled release formulations, fast dissolving formulations, tablets, capsules, pills, delayed release formulations, sustained release formulations, pulsatile release formulations, multiparticulate formulations, and mixed immediate release and controlled release formulations.The pharmaceutical compositions, including pharmaceutical compositions, are prepared in a conventional manner, such as, by way of example only, conventional mixing, dissolving, granulating, dragee making, micronizing, emulsifying, encapsulating, encapsulating, or compressing processes.

[0147] The pharmaceutical composition may contain at least the pharmaceutical composition as the active ingredient in free acid or free base form, or in pharma- ceutical acceptable salt form.Furthermore, the methods and pharmaceutical compositions described herein include the use of N-oxides (where appropriate), crystalline forms, amorphous phases, and active metabolites of these compounds having the same type of activity.In some embodiments, the pharmaceutical composition exists in unsolvated form or in solvated form with pharma-ceutical acceptable solvents such as water, ethanol, etc.Solvated forms of the pharmaceutical composition are also considered to be disclosed herein.

[0148] In some embodiments, pharmaceutical compositions exist as tautomers.All tautomers are included within the scope of the drug presented herein.Therefore, it should be understood that pharmaceutical compositions or their salts can be easily interconverted by exchanging hydrogen atoms between two atoms, and two compounds that form a covalent bond to one another can exhibit the phenomenon of tautomerism.Tautomeric compounds exist in a transfer equilibrium with each other, so they can be considered as different isomeric forms of the same compound.

[0149] In some embodiments, pharmaceutical compositions exist as enantiomers, diastereomers, or other stereoisomeric forms. The agents disclosed herein include all enantiomeric, diastereomeric, and epimeric forms, and mixtures thereof.

[0150] In some aspects, the pharmaceutical compositions described herein can be prepared as prodrugs. "Prodrug" refers to an agent that is converted to the parent drug in vivo. Prodrugs are often useful because in some situations, they may be easier to administer than the parent drug. They may be, for example, bioavailable by oral administration, whereas the parent is not. Prodrugs may also have improved solubility in pharmaceutical compositions over the parent drug. In certain embodiments, when administered in vivo, the prodrug is chemically converted to the biologically, pharma- ceutical, or therapeutically active form of the pharmaceutical composition. In certain embodiments, the prodrug is enzymatically metabolized by one or more steps or processes to the biologically, pharma- ceutical, or therapeutically active form of the pharmaceutical composition.

[0151] kit Described herein, in some aspects, are kits for using the systems, compositions, or pharmaceutical compositions described herein. In some aspects, the kits disclosed herein can be used to treat a disease or condition in a subject. In some aspects, the kits include an assembly of materials or components separate from the systems, compositions, or pharmaceutical compositions. In some aspects, the kits include components for assaying and selecting a suitable guide nucleic acid or donor strand for treating a disease or condition. In some aspects, the kits include components for performing assays such as enzyme-linked immunosorbent assay (ELISA), single molecule array (Simoa), PCR, or qPCR. The exact nature of the components configured in the kit will vary depending on its intended purpose. For example, some embodiments are configured for the purpose of treating a disease or condition disclosed herein in a subject. In some aspects, the kits are configured specifically for the purpose of treating a mammalian subject. In some aspects, the kits are configured specifically for the purpose of treating a human subject.

[0152] Instructions for use may be included in the kit. In some embodiments, the kit includes instructions for administering the composition to a subject in need thereof. In some embodiments, the kit includes instructions for further operating the system described herein. In some embodiments, the kit includes instructions for thawing or otherwise restoring biological activity of at least one component of the system, which may be cryopreserved or lyophilized during storage or transport. In some embodiments, the kit includes instructions for measuring the effectiveness of the kit for its intended purpose (e.g., therapeutic effectiveness when used to treat a subject).

[0153] The kit may include a system or composition disclosed herein and a container. The composition may be a pharmaceutical composition.

[0154] method Described herein are methods, such as the method of modifying target nucleic acid. Described herein are methods, such as the method of gene editing or gene replacement. The method can include the use of any aspect of the composition described herein, such as endonuclease, ligase, guide nucleic acid, integrating nucleic acid, system, kit, or pharmaceutical composition.

[0155] Gene editing or replacement Disclosed herein are editing methods, such as gene editing methods or nucleic acid editing methods. The editing tools and methods disclosed herein may be useful for gene enhancement, gene correction, disease treatment, research tool development, or disease diagnosis. The methods may be performed for therapeutic, agricultural, industrial, and research purposes. The editing method may include contacting a target nucleic acid with an editing system and a ligase. The target nucleic acid may be double-stranded. The target nucleic acid may include a host or cell genome. The target nucleic acid may include a pathogen genome in a host. The target nucleic acid may be part of a gene or may include a non-genic or intergenic sequence. The target nucleic acid may be present in the nucleus of a cell. The target nucleic acid may include chromatin, euchromatin, or heterochromatin. The target nucleic acid may include DNA. The methods referred to herein as gene editing methods or genome editing methods may be useful for nucleic acid editing, without necessarily being limited to editing a particular gene. The method may include replacing a target nucleic acid sequence with a sequence of an integrated nucleic acid. The method may be performed in vitro. The method may be performed in vivo. The method may be performed within a cell. The editing may be performed without homologous recombination. The editing may be performed without prior insertion into the host genome.

[0156] In some aspects, disclosed herein is an editing method. The method may include editing a nucleic acid. The nucleic acid may be in a cell. The editing may be performed using a DNA ligase. The editing may be performed using a CRISPR protein. The editing may be performed using a CRISPR protein or a DNA ligase without any significant chemical interaction with endogenous factors. The editing may be performed using a CRISPR protein or a DNA ligase without any significant chemical interaction with a polymerase, such as a DNA polymerase. In some aspects, the editing may be performed using an endonuclease (e.g., a Cas endonuclease) or a DNA ligase described herein, where the endonuclease and the DNA ligase are coupled. For example, the endonuclease and the DNA ligase may be covalently coupled as a fusion protein to perform the editing. The method may include editing a nucleic acid in a cell, where the editing is performed using a Cas endonuclease without any significant chemical interaction with endogenous factors or polymerase. The method can include editing nucleic acid in a cell, and the editing is performed using Cas endonuclease without any significant chemical interaction with the endogenous cellular components of NHEJ or HDR.The editing method can exclude polymerization or intracellular synthesis of nucleic acid.For example, the method can exclude intracellular synthesis from the template on the guide nucleic acid.

[0157] In some embodiments, editing can only be performed by a factor exogenous to the cell. The exogenous factor can be added to the cell or can be encoded by a nucleic acid added to the cell. In some embodiments, the exogenous factor is added to the cell. In some embodiments, the exogenous factor is encoded by a nucleic acid added to the cell. The factor can include Cas endonuclease and DNA ligase. Cas endonuclease can be or include a DNA binding protein.

[0158] The editing may include replacing a nucleotide or nucleotide sequence in the target nucleic acid. The editing may include replacing a nucleotide. The editing may include replacing a nucleotide sequence. The nucleotide or nucleotide sequence may be replaced with an incorporated nucleic acid. The editing may include replacing a nucleotide or nucleotide sequence of a nucleic acid with an incorporated nucleic acid. In some aspects, replacing a nucleotide includes breaking a phosphodiester bond of the nucleic acid and forming a new phosphodiester bond with the incorporated nucleic acid. In some aspects, the replacement is performed at the replacement site in the nucleic acid without leaving a residual nick or strand break in the nucleic acid at the replacement site. In some aspects, the editing generates an edited nucleic acid that includes an edited region adjacent to a phosphodiester bond in an unedited region of the edited nucleic acid.

[0159] Described herein, in some embodiments, is a method for correcting a gene or modifying gene expression in a cell. In some embodiments, the method includes contacting a cell with a system or composition described herein. In some embodiments, the method includes delivering a heterologous polynucleotide into the cell, the heterologous polynucleotide encoding at least one component of the system. In some embodiments, the system described herein can introduce a donor strand into a genomic locus. In some embodiments, the system can introduce a donor strand without the need for endogenous machinery of the cell. In some embodiments, the system can introduce a donor strand without the need to synchronize the cell cycle. In some embodiments, the system can introduce a donor strand into a non-dividing or slow-dividing cell. Such technical aspects may be particularly useful for correcting genetic mutations in non-dividing or slow-dividing cells to treat a disease or condition.

[0160] The method may include editing the nucleic acid of the cell. In some embodiments, the cell is a quiescent or senescent cell. The cell may be quiescent. The cell may be senescent. In some aspects, the cell is not actively dividing. The cell may have a low dNTP concentration compared to other cells or cell types. Some examples of cells may include neurons, muscle cells, cardiomyocytes, or bone cells. The cell may include neurons. The cell may include muscle cells. The cell may include cardiomyocytes. The cell may include bone cells. The cell may include eye cells.

[0161] The cell may comprise a stem cell, such as an embryonic stem cell, or an adult stem cell, etc. The cell may be a circulating cell, such as a blood cell. The cell may comprise a bone marrow cell. The cell may be an immune cell. The cell may be an innate immune cell.

[0162] The cell can be an airway cell. The cell can be a lung cell. The cell can be a bronchial cell. The cell can be an endothelial cell.

[0163] Described herein is an editing method, comprising, in some aspects, editing nucleic acid in a cell, wherein the editing is performed using CRISPR protein (e.g., RNA-guided endonuclease such as Cas endonuclease) without any significant chemical interaction with endogenous factors or polymerase.In some embodiments, the editing is performed only by factors exogenous to the cell.In some embodiments, the exogenous factors are added to the cell or are encoded by nucleic acids added to the cell.

[0164] In some embodiments, the editing is performed using a DNA ligase. In some embodiments, the editing comprises replacing a nucleotide or nucleotide sequence of the nucleic acid with an incorporated nucleic acid. In some embodiments, replacing the nucleotide comprises breaking a phosphodiester bond of the nucleic acid and forming a new phosphodiester bond with the incorporated nucleic acid. In some embodiments, the replacement is performed at the replacement site in the nucleic acid without leaving a residual nick or strand break in the nucleic acid at the replacement site. In some embodiments, the editing produces an edited nucleic acid that includes an edited region adjacent to a phosphodiester bond in an unedited region of the edited nucleic acid.

[0165] Some embodiments include a method for modifying a cell, comprising contacting the cell with the system or composition, such as the pharmaceutical composition disclosed herein.In some embodiments, the cell is not a dividing cell.The integrated nucleic acid can be inserted into the genomic locus of the cell independent of endogenous non-homologous end joining (NHEJ) and independent of endogenous homology-directed repair (HDR).

[0166] In some aspects, described herein are methods for modifying or replacing a nucleotide or nucleotide sequence in a cell by contacting the cell with a system or composition described herein, the system or composition comprising a guide nucleic acid comprising a spacer complementary to a region of a genomic locus of a genomic strand, a scaffold for complexing with an endonuclease, an optional donor binding site at least partially complementary to the integrating nucleic acid, and a flap binding site at least partially identical to or complementary to a genomic flap at or adjacent to the genomic locus. In some embodiments, the guide nucleic acid comprises a donor binding site complexed with the integrating nucleic acid. The complexing between the guide nucleic acid and the integrating nucleic acid can occur in vivo or in vitro. In some embodiments, the flap binding site can be complexed with a genomic flap generated by an endonuclease that cleaves the genomic strand. The complexing between the flap binding site and the genomic flap can bring the integrating nucleic acid into proximity with the cleaved genomic strand. The reduced proximity between the donor nucleus and the cleaved genomic strand can increase editing efficiency, reduce off-target effects, or reduce the introduction of undesired mutations such as indels. In such cases, the integrating nucleic acid can replace one strand of the cleaved genomic strand, thus editing or correcting the cleaved genomic strand. Figures 1A-1C show complexation between a guide nucleic acid and an integrating nucleic acid as described herein, where the complexation between the guide nucleic acid and the integrating nucleic acid brings the integrating nucleic acid into close proximity to the cleaved genomic strand. In some embodiments, the integrating nucleic acid comprises a 5' end that is ligated to the 3' end of the genomic strand generated by an endonuclease that cleaves the genomic strand. In some embodiments, the integrating nucleic acid comprises a 3' end that is ligated to the 5' end of the genomic strand generated by an endonuclease that cleaves the genomic strand. In some embodiments, the endonuclease can be a fusion protein as described herein.For example, an endonuclease can be fused to a DNA ligase as described herein, and the endonuclease and DNA ligase fusion can cleave a genomic strand and efficiently ligate the integrated nucleic acid to the cleaved genomic strand.

[0167] In some embodiments, the integrating nucleic acid is double-stranded or partially double-stranded, and the integrating nucleic acid can replace both strands of the cleaved genomic strand. In such cases, the integrating nucleic acid can include a single-stranded guide binding site complexed with a guide nucleic acid that includes a donor binding site. The guide binding site can be located at the 5' end of the integrating nucleic acid. The guide binding site can be located at the 3' end of the integrating nucleic acid. The guide binding site can be located at both the 5' and 3' ends of the integrating nucleic acid. Figures 2A-2C show a double-stranded integrating nucleic acid that includes guide binding sites at both the 5' and 3' ends of the integrating nucleic acid, and the integrating nucleic acid can edit and replace the cleaved genomic strand.

[0168] In some embodiments, the integrating nucleic acid is double-stranded or partially double-stranded, and the integrating nucleic acid comprises a flap binding site and a guide binding site. In such cases, the guide binding site can be complexed with the donor binding site of the guide nucleic acid. Figure 3A shows an arrangement in which the integrating nucleic acid (rather than the guide nucleic acid) can be complexed with a genomic flap to bring the integrating nucleic acid in close proximity to the cleaved genomic strand. In some embodiments, the donor nucleic acid comprises two flap binding sites that are complexed with two different genomic flaps. Figure 4A shows an arrangement in which the integrating nucleic acid (rather than the guide nucleic acid) can be complexed with two genomic flaps to bring the integrating nucleic acid in close proximity to the two cleaved genomic strands.

[0169] In some embodiments, the integrating nucleic acid comprises a guide binding site, and the guide binding site can be complexed with the donor binding site of the guide nucleic acid. The guide nucleic acid can comprise a flap binding site that is complexed with a genomic flap in the cleaved genomic strand. As shown in FIG. 5A, the guide nucleic acid brings the integrating nucleic acid into proximity with the cleaved genomic strand to edit the cleaved genomic strand and replace the cleaved genomic strand with the integrating nucleic acid. In some embodiments, the integrating nucleic acid can be double-stranded and comprises two guide binding sites that are complexed with two different guide nucleic acids. FIG. 6A shows an arrangement in which two guide nucleic acids bring the integrating nucleic acid into proximity with two cleaved genomic strands.

[0170] In some aspects, described herein are methods for modifying or replacing a nucleotide or nucleotide sequence in a cell by contacting the cell with a system or composition described herein, the system or composition comprising a guide nucleic acid comprising a spacer complementary to a region of a genomic locus of a genomic strand, a scaffold for complexing with an endonuclease, and an optional donor binding site at least partially complementary to the splint nucleic acid. In some embodiments, the system or composition comprises an integrating nucleic acid, the integrating nucleic acid may be ligated to a cleaved or nicked genomic strand. In some embodiments, the integrating nucleic acid comprises a 5' end that is ligated to the 3' end of the genomic strand generated by the endonuclease. In some embodiments, the integrating nucleic acid comprises a 3' end that is ligated to the 5' end of the genomic strand generated by the endonuclease. In some embodiments, the system or composition comprises a splint nucleic acid comprising a flap binding site at least partially identical or complementary to a genomic flap at or adjacent to the genomic locus, and an optional guide binding site at least partially complementary to the guide nucleic acid. In some embodiments, the splint nucleic acid may comprise a guide binding site. The guide binding site may be complementary to the guide nucleic acid. The guide binding site may be partially complementary to the guide nucleic acid. The splint nucleic acid may comprise a donor binding site. The donor binding site may be complementary to the integrating nucleic acid. The donor binding site may be partially complementary to the integrating nucleic acid. The splint strand may be or may comprise DNA. The splint strand may be or may comprise RNA. The splint nucleic acid may be included as part of the integrating nucleic acid. The splint nucleic acid may be included as a strand of a double stranded integrating nucleic acid.

[0171] In some embodiments, the methods described herein reduce the proximity between the integrating nucleic acid and the cleavage or nick site. In some embodiments, the reduced proximity between the integrating nucleic acid and the cleavage or nick site increases the gene editing rate by at least 0.1-fold, 0.2-fold, 0.5-fold, 1.0-fold, 2.0-fold, 5.0-fold, 10.0-fold, or more, compared to the gene editing rate without the use of the compositions or replacers described herein. In some embodiments, the reduced proximity between the integrating nucleic acid and the cleavage or nick site reduces the introduction of unwanted mutations, such as indels, by at least 0.1-fold, 0.2-fold, 0.5-fold, 1.0-fold, 2.0-fold, 5.0-fold, 10.0-fold, or more, compared to the introduction of unwanted mutations without the use of the compositions or replacers described herein. In some embodiments, the decreased proximity between the incorporated nucleic acid and the cleavage or nick site reduces off-target editing by at least 0.1-fold, 0.2-fold, 0.5-fold, 1.0-fold, 2.0-fold, 5.0-fold, 10.0-fold, or more, compared to off-target editing without the use of a composition or replacer described herein.

[0172] In some embodiments, the method edits a gene. In some embodiments, the method replaces a gene. In some embodiments, the method removes a gene. In some embodiments, the method introduces a methylated nucleotide into the target nucleic acid. In some embodiments, the method introduces an unmethylated nucleotide into the target nucleic acid.

[0173] The method can be used to edit nucleic acid in plant cells. Some embodiments include enhancing plants. Some examples of plant enhancement can include editing disease susceptibility genes or introducing herbicide resistance genes. Examples of disease susceptibility genes can include bacterial leaf stripe disease susceptibility genes OsSULTR3;6 in rice. An example of introducing herbicide resistance genes can include editing acetolactate synthase in potato for herbicide resistance.

[0174] treatment Methods such as gene editing methods can be useful for treating disease or disorder. The disease or disorder can be genetic. The treatment can be of diseased or damaged cells. The disease can include genetic disease, cancer, or infectious disease. The treatment can include administration of the compositions disclosed herein to a subject in need thereof. The subject in need can include a subject identified as having a disease or disorder.

[0175] The methods described herein may be useful for treating genetic diseases. Genetic diseases may be caused by DNA mutations, such as point mutations, deletions, insertions, duplications, or repeats, compared to normal non-disease DNA. Treatment may correct the mutations. Some examples of genetic diseases include Angelman syndrome, Canavan disease, Charcot-Marie-Tooth disease, color blindness, Cri-du-Chat syndrome, cystic fibrosis, DiGeorge syndrome, Duchenne muscular dystrophy, familial hypercholesterolemia, type 1 hemochromatosis, hemophilia, neurofibromatosis, phenylketonuria, polycystic kidney disease, Prader-Willi syndrome, sickle cell disease, spinal muscular atrophy, or Tay-Sachs disease. Some examples of diseases that may be treated using the methods herein include sickle cell disease, beta thalassemia, familial hypercholesterolemia (e.g., PCSK9 disruption), alpha I antitrypsin deficiency, phenylketonuria, cystic fibrosis, tyrosinemia, arginase I deficiency, Wilson's disease, repeat proliferation disorder, hemophilia (e.g., factor IX insertion in the ALB of hepatocytes), Duchenne muscular dystrophy. Some examples of repeat expansion diseases, such as Huntington's disease, amyotrophic lateral sclerosis / frontotemporal dementia, Friedreich's ataxia, and fragile X syndrome. The methods may be included in immuno-oncology, such as T cell engineering or cancer therapy.

[0176] Two non-limiting examples of genetic diseases in which efficient and precise editing of slowly dividing and non-dividing cells would be beneficial for therapeutic gene therapy are sickle cell anemia (SCA) and alpha-1 antitrypsin deficiency (AATD). Sickle cell anemia is caused by an E6V missense mutation in the HBB gene that leads to aggregation of mutant β-globin protein and "sickling" of red blood cells. Autologous gene therapy using hematopoietic stem cells with a corrected HBB allele has been proposed as a curative treatment for SCA. Although expansion of ex vivo HSC cultures can be induced using cytokine cocktails, HSCs in the human body typically reside in a niche within the bone marrow where they exist in a quiescent or slowly dividing state. AATD is most commonly caused by an E366K missense mutation in the SERPINA1 gene that encodes alpha-1 antitrypsin, a serine protease inhibitor secreted by hepatocytes. Mutant AAT is misfolded and forms aggregates in the endoplasmic reticulum of hepatocytes rather than being secreted, ultimately causing liver disease. Although hepatocytes have the ability to rapidly proliferate in response to liver injury, their life cycle typically proceeds in a quiescent state. Highly efficient in vivo editing of these two disorders therefore requires novel gene therapy platforms that can effectively perform precise editing in non-dividing or slowly dividing cells.

[0177] Some embodiments include a method for treating a disease or condition in a subject in need thereof, comprising: (a) contacting the cells of the subject with a system or composition, such as a pharmaceutical composition disclosed herein; and (b) replacing the genomic locus in the cell with an integrated nucleic acid, thereby treating the disease or condition in the subject.In some embodiments, the cell is not a dividing cell.In some embodiments, the integrated nucleic acid is inserted into the genomic locus of the cell independent of endogenous non-homologous end joining (NHEJ) and independent of endogenous homology-directed repair (HDR).

[0178] In some embodiments, the methods described herein reduce the proximity between the integrating nucleic acid and the cleavage or nick site, and the reduced proximity between the integrating nucleic acid and the cleavage or nick site increases the gene editing rate by at least 0.1-fold, 0.2-fold, 0.5-fold, 1.0-fold, 2.0-fold, 5.0-fold, 10.0-fold, or more, compared to the gene editing rate without the use of a composition or replacer described herein. In some embodiments, the reduced proximity between the integrating nucleic acid and the cleavage or nick site increases the therapeutic efficacy (by increasing the gene editing rate) by at least 0.1-fold, 0.2-fold, 0.5-fold, 1.0-fold, 2.0-fold, 5.0-fold, 10.0-fold, or more, compared to the therapeutic efficacy without the use of a composition or replacer described herein.

[0179] delivery Described herein, in some embodiments, is a method of delivering the system described herein to a cell. In some embodiments, the method includes directly or indirectly delivering at least one component of the system to a cell. In some embodiments, the method includes delivering a cell with at least one heterologous polynucleotide, and the cell can then express at least one component of the system. In some embodiments, the at least one heterologous polynucleotide can be delivered to the cell via any of the transfection methods described herein. In some embodiments, the at least one heterologous polynucleotide can be delivered to the cell via the use of an expression vector, such as a viral vector. In the context of an expression vector, the vector can be easily introduced into the cell described herein by any method in the art. For example, the expression vector can be transferred into the cell by physical, chemical, or biological means.

[0180] Physical methods for introducing oligonucleotides or vectors encoding oligonucleotides into cells include calcium phosphate precipitation, lipofection, particle bombardment, microinjection, gene gun, electroporation, etc. Any method for generating cells containing vectors and / or exogenous nucleic acids is suitable for the methods herein. One method for introducing oligonucleotides or vectors encoding oligonucleotides into host cells is calcium phosphate transfection.

[0181] Chemical means for introducing oligonucleotides or vectors encoding oligonucleotides into cells can include colloidal dispersion systems such as macromolecular complexes, nanocapsules, microspheres, beads, and lipid-based systems (including oil-in-water emulsions, micelles, mixed micelles, spherical nucleic acids (SNAs), liposomes, or lipid nanoparticles). An exemplary colloidal system for use as a delivery vehicle in vitro and in vivo is a liposome (e.g., artificial membrane vesicle). Other methods of state-of-the-art targeted delivery of nucleic acids are available, such as delivery of oligonucleotides or vectors encoding oligonucleotides with targeted nanoparticles or other suitable submicron-sized delivery systems.

[0182] In the case where a non-viral delivery system is utilized, an exemplary delivery vehicle is a liposome. The use of lipid formulations is contemplated for the introduction of oligonucleotides or vectors encoding oligonucleotides into cells (in vitro, ex vivo, or in vivo). In another embodiment, the oligonucleotides or vectors encoding oligonucleotides may be associated with lipids. The oligonucleotides or vectors encoding oligonucleotides associated with lipids may in some embodiments be encapsulated in the aqueous interior of liposomes, dispersed within the lipid bilayer of liposomes, attached to liposomes via linking molecules associated with both the liposomes and the oligonucleotides, entrapped in liposomes, complexed with liposomes, dispersed in a solution containing lipids, mixed with lipids, combined with lipids, contained as a suspension in lipids, contained in or complexed with micelles, or otherwise associated with lipids. The lipid, lipid / DNA, or lipid / expression vector associated compositions are not limited to any particular structure in solution. For example, in some embodiments, they exist in a bilayer structure as micelles or have a "collapsed" structure. Alternatively, they may simply be dispersed in solution, and may form aggregates that are not uniform in size or shape.Lipids are fatty substances that, in some aspects, are naturally occurring lipids or synthetic lipids.For example, lipids include the lipid droplets that naturally occur in cytoplasm, as well as the class of compounds that contain long-chain aliphatic hydrocarbons and their derivatives, such as fatty acids, alcohols, amines, aminoalcohols, and aldehydes.

[0183] Lipids suitable for use are obtained from commercial sources. Stock solutions of lipids in chloroform or chloroform / methanol are often stored at about -20°C. Chloroform is used as the only solvent because it evaporates more easily than methanol. "Liposome" is a general term that encompasses a variety of unilamellar and multilamellar lipid vesicles formed by the production of enclosed lipid bilayers or aggregates. Liposomes are often characterized as having a vesicular structure with a phospholipid bilayer membrane and an internal aqueous medium. Multilamellar liposomes have multiple lipid layers separated by aqueous medium. They form spontaneously when phospholipids are suspended in an excess of aqueous solution. The lipid components self-rearrange before forming a closed structure, trapping water and dissolved solutes between the lipid bilayers. However, compositions with structures that differ from the usual vesicular structure are also encompassed. For example, lipids in some embodiments assume a micellar structure or simply exist as heterogeneous aggregates of lipid molecules. Lipofectamine-nucleic acid complexes are also contemplated.

[0184] In some cases, non-viral delivery methods include lipofection, nucleofection, microinjection, biolistics, virosomes, liposomes, immunoliposomes, exosomes, polycation or lipid: cargo conjugates (or aggregates), naked polypeptides (e.g., recombinant polypeptides), naked DNA, artificial virions, and drug-enhanced uptake of polypeptides or DNA. In some aspects, the delivery method includes conjugating or encapsulating the compositions or oligonucleotides described herein with at least one polymer, such as a natural polymer or a synthetic material. The polymer can be biocompatible or biodegradable. Non-limiting examples of suitable biocompatible, biodegradable synthetic polymers include aliphatic polyesters, poly(amino acids), copoly(ether-esters), polyalkylene oxalates, polyamides, poly(iminocarbonates), polyorthoesters, polyoxaesters, polyamide esters, polyoxaesters containing amine groups, and poly(anhydrides). Such synthetic polymers can be homopolymers or copolymers (e.g., random, block, segmented, grafted) of two or more of a number of different monomers, such as lactic acid, lactide, glycolic acid, glycolide, ε-caprolactone, trimethylene carbonate, p-dioxanone, etc. In one example, the scaffold can be composed of a polymer that includes glycolic acid and lactic acid, such as a polymer with a ratio of glycolic acid to lactic acid of 90 / 10 or 5 / 95. Non-limiting examples of naturally occurring biocompatible, biodegradable polymers include glycoproteins, proteoglycans, polysaccharides, glycosaminoglycans (GAGs), and fragment(s) derived from these components, elastin, laminin, dechlorin, fibrinogen / fibrin, fibronectin, osteopontin, tenascin, hyaluronic acid, collagen, chondroitin sulfate, heparin, heparan sulfate, ORC, carboxymethylcellulose, and chitin.

[0185] In some cases, the oligonucleotides or vectors encoding the oligonucleotides described herein can be packaged and delivered to cells via extracellular vesicles. The extracellular vesicles can be any membrane-bound particle. In some embodiments, the extracellular vesicles can be any membrane-bound particle secreted by at least one cell. In some examples, the extracellular vesicles can be any membrane-bound particle synthesized in vitro. In some examples, the extracellular vesicles can be any membrane-bound particle synthesized without cells. In some cases, the extracellular vesicles can be exosomes, microvesicles, retrovirus-like particles, apoptotic bodies, apoptosomes, oncosomes, exosomes, enveloped viruses, exomers, or other very large extracellular vesicles.

[0186] In aspects, the system described herein or at least one heterologous polynucleotide encoding the system described herein can be delivered into a cell as a vector, such as a viral vector. Viral vectors, and in particular retroviral vectors, have become the most widely used method for inserting genes into mammalian, e.g., human cells. In some embodiments, other viral vectors are derived from lentiviruses, poxviruses, herpes simplex virus I, adenoviruses and adeno-associated viruses, and the like. Exemplary viral vectors include retroviral vectors, adenoviral vectors, adeno-associated virus vectors (AAV), pox vectors, parvovirus vectors, baculovirus vectors, measles virus vectors, or herpes simplex virus vectors (HSV). In some examples, retroviral vectors include gamma-retroviral vectors, such as vectors derived from Moloney murine leukemia virus (MoMLV, MMLV, MuLV, or MLV) or murine stem cell virus (MSCV) genomes. In some examples, retroviral vectors also include lentiviral vectors, such as those derived from the human immunodeficiency virus (HIV) genome. In some examples, the AAV vector includes AAV1, AAV2, AAV4, AAV5, AAV6, AAV7, AAV8, or AAV9 serotypes. In some examples, the viral vector is a chimeric viral vector that includes viral portions from two or more viruses. In further examples, the viral vector is a recombinant viral vector.

[0187] In some cases, at least one heterologous polynucleotide encoding the system described herein can be administered to a subject in need thereof through the use of transgenic cells generated by first introducing at least one heterologous polynucleotide into an allogeneic or autologous cell. In some cases, the cells can be isolated. In some embodiments, the cells can be isolated from the subject.

[0188] Subjects and cells The methods described herein may involve a cell. For example, a composition may be delivered to a cell to edit nucleic acid within the cell. The embodiment delivered to the cell may be heterologous to the cell. "Heterologous" may include something that is not present within the cell in its natural state.

[0189] Any cell or cell type may be used. Examples of cells or cell types may include stem cells, red blood cells, white blood cells, platelets, nerve cells, neuroglial cells, muscle cells, chondrocytes, bone cells, skin cells, endothelial cells, epithelial cells, fat cells, or sex cells. The cells may include stem cells. The cells may include bone cells. The cells may include blood cells. The cells may include sperm cells. The cells may include egg cells. The cells may include fat cells. The cells may include nerve cells. The cells may include muscle cells. The cells may include endocrine cells. The cells may include endothelial cells. The cells may include pancreatic cells.

[0190] The cell can be eukaryotic. The cell can be a plant cell. The cell can be an animal cell. The cell can be a protozoan. The cell can be a fungal cell. The cell can be prokaryotic. The cell can be a bacterial cell. The cell can be an archaeal cell. The cell can be from a cell line. The cell can be part of a subject. The cell can be isolated from a subject. The cell can be an autologous cell of the subject. The cell can be an allogeneic cell of the subject.

[0191] The cell may comprise a diseased cell. The cell may comprise a cancer cell. The cell may be infected. The cell may be damaged. The cell may be a pathogen, such as a fungal pathogen.

[0192] The methods described herein may involve a subject. For example, a composition may be delivered to a subject. Some aspects of the methods described herein include treating a subject. Non-limiting examples of subjects include vertebrates, animals, mammals, dogs, cats, cows, rodents, mice, rats, primates, monkeys, and humans. The subject may be an invertebrate. The subject may be an arthropod. The subject may be a vertebrate. The subject may be an animal. The subject may be a fish. The subject may be a reptile. The subject may be a mammal. The subject may be a dog. The subject may be a cat. The subject may be a cow. The subject may be a rodent. The subject may be a mouse. The subject may be a rat. The subject may be a primate. The subject may be a non-human primate. The subject may be a monkey. The subject may be an animal, mammal, dog, cat, cow, rodent, mouse, rat, primate, or monkey. The subject may be a human.

[0193] The subject may be a non-animal subject. For example, the subject may include a plant. Examples of plants may include trees, flowers, shrubs, or grass. The subject may include a crop. Examples of crops may include almonds, apricots, apples, artichokes, bananas, barley, beets, blackberries, blueberries, broccoli, Brussels sprouts, cabbage, cannabis, peppers, carrots, celery, chard, cherries, citrus fruits, corn, cucurbits, dates, figs, garlic, grapes, herbs, spices, kale, lettuce, oil palm, olives, onions, peas, pears, peaches, peanuts, papayas, parsnips, pecans, persimmons, plums, pomegranates, potatoes, quince, radishes, raspberries, roses, rice, sloes, sorghum, soybeans, spinach, strawberries, sweet potatoes, tobacco, tomatoes, turnip vegetables, walnuts, or wheat.

[0194] definition The use of absolute or sequential terms, such as "will," "will not," "shall," "shall not," "must," "must not," "first," "initially," "next," "subsequently," "before," "after," "lastly," and "finally," are not intended to limit the scope of the embodiments disclosed herein, but are exemplary.

[0195] As used herein, the singular forms "a," "an," and "the" are intended to include the plural forms unless the context clearly indicates otherwise. Furthermore, to the extent that the terms "including," "includes," "having," "has," "with," or variations thereof are used anywhere in the detailed description and / or claims, such terms are intended to be inclusive, just as the term "comprising."

[0196] As used herein, the phrases "at least one," "one or more," and "and / or" are open-ended expressions that are both conjunctive and disjunctive in operation. For example, each of the phrases "at least one of A, B, and C," "at least one of A, B, or C," "one or more of A, B, and C," "one or more of A, B, or C," and "A, B, and / or C" means A alone, B alone, C alone, A and B together, A and C together, B and C together, or A, B, and C together.

[0197] As used herein, "or" may refer to "and," "or," or "and / or," and may be used either exclusively or inclusively. For example, the term "A or B" may refer to "A or B," "A but not B," "B but not A," and "A and B." In some cases, the context may dictate a particular meaning.

[0198] Any systems, methods, software, and platforms described herein are modular, and thus terms such as "first" and "second" do not necessarily imply a priority, order of importance, or order of action.

[0199] When referring to a numerical value or numerical range, the term "about" means that the numerical value or numerical range referred to is approximate within experimental variation (or within statistical experimental error) and that the numerical value or numerical range may vary, for example, from 1% to 15% of the stated number or numerical range. In an example, the term "about" refers to ±10% of the stated number or value.

[0200] The terms "increased," "increasing," or "increase" are generally used herein to mean an increase of a statistically significant amount. In some embodiments, the term "increased" or "increase" refers to an increase of at least 10% compared to a reference level, for example, an increase of at least about 10%, at least about 20%, or at least about 30%, or at least about 40%, or at least about 50%, or at least about 60%, or at least about 70%, or at least about 80%, or at least about 90%, or 100%, or any increase between 10-100%, compared to a reference level, standard, or control. Other examples of "increase" include an increase of at least 2-fold, at least 5-fold, at least 10-fold, at least 20-fold, at least 50-fold, at least 100-fold, at least 1000-fold, or more compared to a reference level.

[0201] The terms "decreased", "decreasing", or "decrease" are generally used herein to mean a decrease by a statistically significant amount. In some embodiments, "decreased" or "decrease" means a reduction of at least 10% compared to a reference level, e.g., at least about 20%, or at least about 30%, or at least about 40%, or at least about 50%, or at least about 60%, or at least about 70%, or at least about 80%, or at least about 90%, or up to a 100% decrease compared to a reference level (e.g., an absent or undetectable level compared to a reference level), or any decrease between 10-100% compared to a reference level. In the context of a marker or condition, these terms mean a statistically significant decrease in such level. The decrease can be, for example, at least 10%, at least 20%, at least 30%, at least 40%, or more, and is preferably down to a level that is accepted within the normal range for individuals without the given disease.

[0202] Where sequences are provided, nucleic acids containing phosphorothioate bonds between nucleotides are represented by an asterisk (*). 2'-O-methyl nucleotides are represented by a lower case "m" preceding the nucleotide (e.g., mC instead of C). The code " / 5Phos / " preceding a nucleotide sequence indicates that the sequence is phosphorylated at the 5' end. Locked Nucleic Acid (LNA) nucleotides that contain a methylene bridge connecting the 2' oxygen and the 4' carbon are indicated by a "+" preceding the nucleotide (e.g., +C instead of C).

[0203] Embodiment Some aspects include the embodiments or components thereof provided below.

[0204] Embodiment 1. Described herein, in some aspects, is a method for treating a pulmonary circulation disorder comprising: A composition comprising a DNA binding protein coupled to a DNA ligase.

[0205] Embodiment 2. The composition of embodiment 1, wherein the coupling is a covalent bond.

[0206] Embodiment 3. The composition of embodiment 2, comprising a fusion protein comprising said DNA binding protein and said DNA ligase.

[0207] Embodiment 4. The composition of embodiment 3, wherein the DNA binding protein is amino (N) terminal to the DNA ligase in the fusion protein.

[0208] Embodiment 5. The composition of embodiment 3, wherein the DNA binding protein is carboxy (C) terminal to the DNA ligase in the fusion protein.

[0209] Embodiment 6. A composition according to any one of embodiments 2 to 5, wherein the connection comprises a linker comprising 1 to 100 amino acids.

[0210] Embodiment 7. The composition of embodiment 1, wherein the coupling is a non-covalent bond.

[0211] Embodiment 8. The composition of embodiment 7, wherein the composition comprises a first polypeptide comprising at least a portion of the DNA binding protein and a second polypeptide comprising at least a portion of the DNA ligase, and wherein the first and second polypeptides are non-covalently coupled.

[0212] Embodiment 9. The composition of embodiment 8, wherein the first polypeptide comprises a first heterodimerization domain that binds to a second heterodimerization domain, and the second polypeptide comprises the second heterodimerization domain.

[0213] Embodiment 10. The composition of embodiment 9, wherein the heterodimerization domain comprises a leucine zipper, a PDZ domain, streptavidin, a streptavidin binding protein, a foldon domain, a hydrophobic portion, or a functional binding fragment thereof.

[0214] Embodiment 11. The composition of embodiment 8, wherein the first polypeptide comprises a first intein that binds to a second intein, and the second polypeptide comprises the second intein.

[0215] Embodiment 12. The composition of embodiment 1, wherein the ligase comprises a hairpin binding motif, and the DNA binding protein and the DNA ligase are coupled to a nucleic acid comprising a scaffold that binds to the DNA binding protein and a hairpin that binds to the hairpin binding motif.

[0216] Embodiment 13. The composition of embodiment 12, wherein the hairpin binding motif comprises an MS2 coat protein (MCP) peptide and the hairpin comprises an MS2 hairpin.

[0217] Embodiment 14. The composition of embodiment 1, wherein the DNA binding protein and the DNA ligase are coupled to a heterobifunctional molecule comprising an endonuclease binding domain and a DNA ligase binding domain.

[0218] Embodiment 15 The composition of embodiment 14, wherein the heterobifunctional molecule comprises a small molecule.

[0219] Embodiment 16. Described herein, in some aspects, is a composition comprising a cell containing a DNA binding protein and a DNA ligase, both of which are heterologous to the cell.

[0220] Embodiment 17. The composition of any one of embodiments 1 to 16, wherein the DNA binding protein comprises a class II CRISPR / Cas endonuclease.

[0221] Embodiment 18. The composition of any one of embodiments 1 to 17, wherein the DNA binding protein comprises a Cas9 endonuclease.

[0222] Embodiment 19. The composition of any one of embodiments 1 to 18, wherein the DNA binding protein comprises a nickase.

[0223] Embodiment 20. The composition of any one of embodiments 1 to 19, wherein the DNA binding protein comprises an amino acid sequence that is at least 80% identical to the amino acid sequence of any one of SEQ ID NOs: 1 to 13, or a functional fragment thereof.

[0224] Embodiment 21. The composition of any one of embodiments 1 to 20, wherein the DNA ligase ligates DNA strand bases paired to a DNA splint.

[0225] Embodiment 22. A composition described in any one of embodiments 1 to 20, wherein the DNA ligase ligates DNA strand bases paired to an RNA splint.

[0226] Embodiment 23. The composition of any one of embodiments 1 to 22, wherein the DNA ligase comprises an amino acid sequence at least 80% identical to the amino acid sequence of any one of SEQ ID NOs: 55 to 96, or a functional fragment thereof.

[0227] Embodiment 24. The composition of any one of embodiments 1 to 23, wherein the DNA binding protein or the DNA ligase comprises a nuclear localization signal, a chromatin modifying domain, a cell penetrating peptide, or a tag polypeptide.

[0228] Embodiment 25. The composition of any one of embodiments 1 to 24, further comprising a guide RNA and an integrating nucleic acid.

[0229] Embodiment 26. One or more nucleic acids encoding the composition according to any one of embodiments 1 to 25.

[0230] Embodiment 27. A cell comprising a composition according to any one of embodiments 1 to 25, or comprising one or more nucleic acids according to embodiment 26.

[0231] Embodiment 28. A nucleic acid system comprising: a. a guide nucleic acid, i. a spacer complementary to a region of the genomic locus on the genomic strand; ii. a scaffold for complexing with a DNA-binding protein; iii. an optional donor binding site that is at least partially complementary to the incorporated nucleic acid; and iv. the guide nucleic acid comprises a flap binding site that is at least partially identical to or complementary to a genomic flap at or adjacent to the genomic locus; b. An integrating nucleic acid comprising a 5' end that is ligated to the 3' end of the genomic strand generated by a DNA binding protein.

[0232] Embodiment 29. A nucleic acid system comprising: a. a guide nucleic acid, i. a spacer complementary to a region of the genomic locus on the genomic strand; ii. a scaffold for complexing with a DNA binding protein, and iii. the guide nucleic acid comprising an optional donor binding site that is at least partially complementary to the splint nucleic acid; b. an integrated nucleic acid comprising a 5' end that is ligated to the 3' end of the genomic strand generated by a DNA binding protein; c. a splint nucleic acid comprising a flap binding site that is at least partially identical or complementary to a genomic flap at or adjacent to the genomic locus, and an optional guide binding site that is at least partially complementary to a guide nucleic acid.

[0233] Embodiment 30. The system of embodiment 28 or 29, wherein the genomic strand is within a cell.

[0234] Embodiment 31. The system of any one of embodiments 28 to 30, wherein the splint nucleic acid further comprises a donor binding site that is at least partially identical to or complementary to a portion of the integrating nucleic acid.

[0235] Embodiment 32. The system of any one of embodiments 28 to 31, wherein the guide nucleic acid comprises a sequence of a linking nucleic acid between the scaffold and the donor binding site.

[0236] Embodiment 33. The system of any one of embodiments 28 to 32, wherein the guide nucleic acid, the embedding nucleic acid, or the splint nucleic acid comprises a modified internucleoside linkage.

[0237] Embodiment 34 The system of embodiment 33, wherein the modified internucleoside linkage comprises a phosphorothioate linkage.

[0238] Embodiment 35. The system of embodiment 33 or 34, wherein the modified internucleoside linkage is between any of the four terminal nucleosides at the 5' or 3' end of the guide nucleic acid or the incorporating nucleic acid.

[0239] Embodiment 36. The system of any one of embodiments 28 to 35, wherein the guide nucleic acid, the embedding nucleic acid, or the splint nucleic acid comprises a modified nucleoside.

[0240] Embodiment 37. The system of embodiment 36, wherein the modified nucleoside comprises a locked nucleic acid (LNA), 2' fluoro, 2' O-alkyl, or a combination thereof.

[0241] Embodiment 38. The system of embodiment 36 or 37, wherein the modified nucleoside is any of the three terminal nucleosides at the 5' or 3' end of the guide nucleic acid or the incorporating nucleic acid. EXAMPLES

[0242] Example 1. Editing to convert BFP to GFP with Replacer 1 The components used to edit a stably integrated blue fluorescent protein (BFP) gene in HEK293 cells are co-delivered by lipid nanoparticle (LNP) transfection. The components include a chemically synthesized guide RNA (gRNA), a single-stranded DNA donor, and an mRNA-encoded protein effector for replacer1 editing, including nicking Cas9 (nCas9), SplintR ligase, and a nuclear localization sequence (NLS). The gRNA is synthesized by Agilent, the DNA donor is synthesized by IDT, and the mRNA is synthesized by TriLink or RiboPro. The gRNA, DNA donor, and mRNA are mixed and formulated into lipid nanoparticles before delivery to adherent cells in 96-well plates. After 48 hours, cells are detached from the plate by trypsinization and green fluorescent protein (GFP) fluorescence is measured using an Attune NxT flow cytometer to assess the percentage for BFP-GFP editing. Following the Replacer 1 editing format, the gRNA contains a spacer, a scaffold, a donor binding site (DBS), and a flap binding site (FBS). The gRNA is delivered individually (single-sided Replacer 1) or in pairs with a spacer (double-sided Replacer 1) that targets the opposite strand of the genomic locus. Some of the DBSs contain mutations in the spacer region or the protospacer adjacent motif region (SpPAMmut). The gRNA contains 2'-O-methyl 3'-phosphorothioate nucleotides in the first three and last three positions. The DNA donors are delivered individually (single-sided Replacer 1) or in pairs (double-sided Replacer 1). Some donors have mutations in the spacer or the protospacer adjacent motif (PAM) region (SpPAMmut). Some donors have phosphorothioate linkages in the first three and last three positions. Some donors are recoded with silent mutations that change the nucleotide sequence but retain the amino acid sequence. The DNA donor is phosphorylated at the 5' end. In some conditions, the gRNA and donor DNA are annealed by a thermal cycler annealing reaction prior to LNP formulation. Plasmids can be used instead of mRNA.Table 12 details this experiment. The sequences corresponding to the names in the table can be found herein. [Table 12-1]

[0243] Example 2. Editing to convert BFP to GFP with Replacer 2 The experiment can be performed similarly to Example 1, but can be adjusted to fit the Replacer 2 format. The ligases used herein are T4 ligase, hLIG1(233-919), and hLIG1(119-919). The Replacer 2 gRNA contains a spacer, a scaffold, and a DBS. The gRNAs are delivered individually (single-sided Replacer 2) or in pairs (double-sided Replacer 2), and the gRNAs contain 2'-O-methyl 3'-phosphorothioate nucleotides in the first three and last three positions. The DNA donor contains FBS and a guide binding site (GBS) that can hybridize to the DBS. Some DNA donors contain SpPAM mutations, and some DNA donors have phosphorothioate bonds in the first three and last three positions. Some DNA donors are recoded. The DNA donors are phosphorylated at the 5' end. The DNA donors are delivered as pairs in the Replacer 2 format. Some of the gRNAs and donor DNAs are annealed prior to LNP formulation. Table 13 details this experiment. Sequences corresponding to the names in the table can be found herein. [Table 13-1] [Table 13-2]

[0244] Example 3. Editing to insert mGL before CBX1 with Replacer2 An editing experiment can be performed to insert monomeric green lantern (mGL) into the genome of HEK293T cells in front of the CBX1 gene so that a fusion protein is formed that exhibits green fluorescence. This fluorescence can be detected by flow cytometry as in Examples 1 and 2. The experiment is performed in a similar manner to Example 2, except that the sequences of the gRNA and DNA donor are different, allowing the insertion of mGL into the genome rather than the insertion of a sequence that changes the blue fluorescent protein (BFP) to green fluorescent protein (GFP). The DNA donor in Example 3 is longer than in Example 2 and is synthesized by GenScript. The DNA donor is phosphorylated at the 5' end. Table 14 details this experiment. The sequences corresponding to the names in the table can be found herein. [Table 14-1] [Table 14-2]

[0245] Example 4. Treatment of genetic disorders in patients A human patient with sickle cell disease visits a physician for treatment. The patient is identified as having a hemoglobin gene mutation. Hematopoietic stem and progenitor cells are collected from the patient's peripheral blood. The cells are edited by contacting the cell's genome with a nCas9-DNA ligase fusion protein, a gRNA, and donor DNA containing a corrected hemoglobin gene. The gRNA recruits the fusion protein to the gene mutation, and nCas9 nicks the patient's DNA on one side adjacent to the mutation. The gRNA binds to the genomic flap generated by the nick, and to the donor DNA, forming an RNA splint for the ligase to ligate the genomic flap to the donor DNA. Another fusion protein nicks the opposite strand of the mutated hemoglobin gene using a second gRNA on the opposite side of the mutation and ligates the other side of the donor DNA. Thus, replacing the mutated DNA with donor DNA, the cells with the donor DNA are returned to the patient, thus treating the patient's genetic disease.

[0246] Example 5. Enhancement of crops In soybean plants, germ cells are microinjected with an expression vector encoding an nCas9-DNA ligase fusion protein, a gRNA, and a donor DNA encoding an herbicide resistance gene. The gRNA recruits the fusion protein to a suitable spot in the soybean genome that does not already contain a gene. The nCas9 nicks the soybean DNA on one side adjacent to the spot. The gRNA also recruits the donor DNA to bind to the genomic flap created by the nick, and the ligase seals the nick using the donor DNA itself as a splint. Another fusion protein nicks the opposite strand of the soybean DNA on the other side adjacent to the spot and ligates the other side of the donor DNA, thus integrating the herbicide resistance gene into the germ cells. The germ cells eventually produce seeds, which are harvested to grow herbicide-resistant soybeans.

[0247] Example 6. In vitro one-sided replacer 2 using T4 ligase In vitro experiments were performed to demonstrate the usefulness of the components and methods described herein for editing nucleic acids. The experiments in this example specifically evaluated the feasibility of one-sided replacer 2. The experiments used a 100 bp, 5'-Cy5-labeled double-stranded DNA (dsDNA) substrate (IDT) corresponding to the blue fluorescent protein (BFP) target region (see Examples 1 and 2), with the nicking site located in the middle of base pair 50. A 5'-phosphorylated dsDNA donor (IDT) containing a variable GBS, a 13 nt flap binding site (FBS), and a protospacer adjacent motif (PAM) mutation was used in conjunction with a gRNA (Agilent) containing the corresponding variable DBS. The 5'-Cy5-labeled dsDNA substrate and the 5'-phosphorylated dsDNA donor were annealed separately using complementary oligonucleotides by heating to 95C for 5 minutes and then slowly cooling to room temperature.

[0248] In vitro one-sided replacer 2 reactions were performed by first incubating gRNA (30 nM final) and dsDNA donor (30 nM final) with recombinant S. pyogenes nicking Cas9 (Cas9n; IDT; 30 nM final) for 10 minutes at room temperature, followed by the addition of T4 ligase (NEB; 200 U final), ATP (1 mM final), and 5'-Cy5 labeled dsDNA substrate (3 nM final). Reactions were carried out for 1 hour at 37C in the presence of NEB buffer 3.1 (10 ul final volume). Reactions were terminated by the addition of 0.5% SDS and 100 ug / ml proteinase K and incubated at 37C for 30 minutes. The reaction products were then combined with 2x formamide gel loading buffer (90% formamide; 10% glycerol; 0.01% bromophenol blue), denatured at 95°C for 10 min, and separated on denaturing urea PAGE gels (15% TBE-urea, 55°C, 200 V). DNA products were visualized by Cy5 fluorescent signal using a LI-COR Odyssey CLx imager.

[0249] In addition to the intact 100bp 5'-Cy5-labeled dsDNA substrate, a nicked 5'-Cy5-labeled dsDNA substrate and the final ligation product were included as size controls. The nicked 5'-Cy5-labeled dsDNA control was annealed using two 50mers corresponding to the top strand oligos of the 100bp 5'-Cy5-labeled dsDNA substrate (5'-Cy5-labeled 50mer and 5'-phosphorylated 50mer) and their complementary 100mer bottom strand oligos. The final ligation product control was annealed and ligated using the 5'-Cy5-labeled 50mer and bottom 100mer from the nicked control along with a 150nt top strand donor oligo.

[0250] FIG. 8A shows an exemplary nicking and ligation pattern of the integrated nucleic acid. FIG. 8B shows an exemplary nucleic acid gel showing the pattern associated with in vitro one-sided replacer 2 using 30 nt GBS / DBS and thermostable T4 ligase. Using a 30 nt GBS / DBS combination, a donor containing a PAM mutation, and thermostable T4 ligase (Hi-T4, NEB), we were able to generate a final replacer product (lane 3) that corresponds in size to our control product (lane 1). In the absence of nicking Cas9 (Cas9n) (lane 2) or the absence of a bottom donor acting as a splint (lanes 4 and 5), no replacer product was detected. FIG. 8C shows an exemplary nucleic acid gel showing the pattern associated with in vitro one-sided replacer 2 using variable length GBS / DBS combinations and T4 ligase. Using regular T4 ligase (NEB), multiple GBS / DBS combinations, including no GBS / DBS, 20nt GBS / DBS, and 30nt GBS / DBS, were used to generate final replacer products that corresponded to the size of the control. Furthermore, in this experiment, the recoded dsDNA donor containing the PAM mutation was more efficient in generating the final replacer product compared to the non-recoded PAM mutant dsDNA donor. The results indicate that DNA ligase can be used together with RNA-guided endonucleases to edit target nucleic acids.

[0251] Example 7. Use of one-sided replacer 2 with nicking Cas9 and multiple DNA ligases in various coupling architectures in mammalian cells The components used to edit the stably integrated blue fluorescent protein (BFP) gene in HEK293T cells were co-delivered by Lipofectamine 2000 transfection. The components were a chemically synthesized guide RNA (SEQ ID NO: 166, mG*mC*mU*GAAGCACUGCACGCCAUGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCGACUUGAAAAAGUCGGACCGAGUCGGUCCAGCUGCGGUAUUGUGGmC*mG*mU) with 2'-O-methyl and phosphorothioate chemical modifications at the 5' and 3' ends, an integrated nucleic acid with a 5' phosphate end modification (SEQ ID NO: 167 , / 5Phos / cgtaTgtcagggtggtcacGAGgg), a locked nucleic acid and a split nucleic acid with phosphorothioate modifications (SEQ ID NO: 169, +c*c*+CT+CG+TG+AC+CA+CC+CT+GA+CA+TA+CGGCGTGCAgtgcttACGCCA+CA+AT+AC+CG+CA+G*C*+T), and either a single mRNA encoding a nicking Cas9 fused to a ligase or a pair of mRNAs encoding a nicking Cas9 and a ligase.

[0252] The integrating and splinting nucleic acids were synthesized by Integrated DNA Technologies (IDT). All mRNAs corresponding to Cas9n (H840A) and all ligases are generated via in vitro transcription (IVT) reactions using the HiScribe T7 High Yield RNA Synthesis Kit (NEB). The coding sequence is cloned into an IVT vector that contains a single copy of the 5' UTR and two copies of the 3' UTR from the human β-globin gene in addition to a 152 nt polyA tail. Plasmid DNA containing the coding sequence is linearized using an XbaI restriction enzyme site located immediately downstream of the polyA tail. The linearized plasmid is then purified via phenol:chloroform extraction followed by ethanol precipitation. The mRNA is generated via an IVT reaction containing N1-methylpseudouridine-5'-triphosphate (TriLink BioTech) instead of uridine-triphosphate and is co-transcriptionally capped with CleanCap Reagent AG (3'OMe) (TriLink BioTech). The IVT reaction is incubated at 37°C for 2 hours, followed by DNAse I digestion of the template DNA. Finally, the mRNA product is purified using LiCl precipitation, quantified (Qubit Fluorometric Quantification; ThermoFisher), and checked for integrity by denaturing gel electrophoresis. "Ligase in trans" refers to Cas9 H840A nickase combined with T4 ligase fused at its C-terminus to a leucine zipper (T4-LZ, SEQ ID NO: 145). "LZ; C-terminal ligase" refers to Cas9 H840A nickase fused to a C-terminal leucine zipper (nCas9-LZ, SEQ ID NO: 133) in combination with a ligase fused to the N-terminal leucine zipper of T4 (LZ-T4, SEQ ID NO: 142), SplintR (LZ-SplintR, SEQ ID NO: 141), or hLIG4(1-620) (LZ-hLIG4(1-620), SEQ ID NO: 146)."LZ; N-terminal ligase" refers to Cas9 H840A nickase fused to a leucine zipper at its N-terminus (LZ-nCas9, SEQ ID NO: 147) in combination with a ligase fused to a leucine zipper at the C-terminus of T4 (T4-LZ, SEQ ID NO: 145), SplintR (SplintR-LZ, SEQ ID NO: 148), or hLIG4(1-620) (hLIG4(1-620)-LZ, SEQ ID NO: 149). "Fused; C-terminal ligase" refers to Cas9 H840A nickase fused to a ligase with a ligase at the C-terminus of T4 (nCas9-T4, SEQ ID NO: 131), SplintR (nCas9-SplintR, SEQ ID NO: 129), or hLIG4(1-620) (nCas9-hLIG4(1-620) SEQ ID NO: 150). "Fusion; N-terminal ligase" refers to Cas9 H840A nickase fused to a ligase with a ligase at the N-terminus of T4 (T4-nCas9, SEQ ID NO: 151), SplintR (SplintR-nCas9, SEQ ID NO: 152), or hLIG4(1-620) (hLIG4(1-620)-nCas9, SEQ ID NO: 153). The gRNA contained a spacer, scaffold, and donor binding site. The splint-incorporated nucleic acid contained a guide binding site and a flap binding site. The ligation-incorporated nucleic acid and the splint-incorporated nucleic acid were partially complementary.

[0253] The embedding and splint nucleic acids were hybridized using an annealing reaction, then mixed with guide RNA and mRNA and formulated in Lipofectamine 2000 in OptiMEM before delivery to adherent HEK293 cells in 96-well plates. After 24-48 hours, cells were detached with 0.05% trypsin-EDTA and run through a flow cytometer to measure the percentage of cells expressing green fluorescent protein (GFP), indicating gene editing from BFP to GFP (Figure 9). Gene editing was observed with T4, SplintR, and hLIG4(1-620) ligases when fused to nCas9, when interacting with nCas9 via the leucine zipper, or when delivered in trans without the leucine zipper interaction.

[0254] The results herein demonstrate the utility of using a DNA ligase with an RNA-guided endonuclease to edit target nucleic acids in cells. The experiments in this example specifically demonstrated the feasibility of including a one-sided replacer 2 component to edit target nucleic acids in mammalian cells. This example shows the effectiveness of including a DNA ligase coupled to an RNA-guided endonuclease (e.g., nicking Cas9) via a heterodimerization domain (here, leucine zipper) in nucleic acid editing, such as gene editing. It also shows that nucleic acid editing is possible in mammalian cells with a DNA ligase fused to an RNA-guided endonuclease (e.g., T4 ligase fused to Cas9 H840A nickase), and that nucleic acid editing can be achieved by delivering the DNA ligase and the RNA-guided endonuclease as separate, uncoupled components.

[0255] Example 8. Use of one-sided replacer 2 with nicking Cas9 and T4 DNA ligase to perform differential edits at multiple genomic targets The components used to edit genome targets in HEK293T cells were co-delivered by Lipofectamine 2000 transfection. The components included a chemically synthesized guide with 2'-O-methyl and phosphorothioate chemical modifications at the 5' and 3' ends, an integrating nucleic acid with a 5' phosphate end modification, a locked nucleic acid and a splint nucleic acid with a phosphorothioate modification, an mRNA encoding a nicking Cas9 (LZ-nCas9, SEQ ID NO: 147), and an mRNA encoding a ligase (T4-LZ, SEQ ID NO: 145). The target-specific guide, splint, and integrating nucleic acids are listed in Table 15. The integrating and splint nucleic acids were synthesized by Integrated DNA Technologies (IDT), and both mRNAs were generated via in vitro transcription reactions using the method described in Example 7. The gRNA contained a spacer, a scaffold, and a donor binding site. The splint integrating nucleic acid contained a guide binding site and a flap binding site. The ligated integrating and splinting nucleic acids were partially complementary. The integrating and splinting nucleic acids were hybridized using an annealing reaction, then mixed with the guide RNA and mRNA and formulated in Lipofectamine 2000 in OptiMEM before delivery to adherent HEK293 cells in 96-well plates. After 24-48 hours, genomic DNA was extracted from the cells using QuickExtract, and the genomic targets were amplified using Q5 DNA polymerase. The PCR program was run at 98C for 30 seconds, then 35 cycles at 98C for 5 seconds, 67C for 20 seconds, and 72C for 20 seconds, then finally at 72C for 2 minutes. PCR primers are listed in Table 15. The PCR products were cleaned up with ExoCIP treatment and submitted for next generation sequencing (NGS) by Azenta using Amplicon-EZ services. Sequencing reads were merged and aligned to the amplicon of interest, and the percentage of total reads that matched the intended edit was calculated (Figure 10). This example shows the efficacy of gene editing with one-sided replacer2 in mammalian cells at various genomic targets.The types of edits herein include single point mutations (HEK3 F+5 G to T), paired point mutations (VEGFA R+5 G to T and +2 A to T, VEGFA F+5 G to T and +2 G to C, and AAVS1 R+5 G to T), or trinucleotide insertions using one-sided replacer 2 (HEK3 F CAC insertion and AAVS1 R CAC insertion). [Table 15-1] [Table 15-2] [Table 15-3]

[0256] Example 9. Use of double-sided replacer 2 with nicking Cas9 and T4 DNA ligase to perform deletions and sequence replacements at multiple genomic targets The components used to edit genome targets in HEK293T cells were co-delivered by Lipofectamine 2000 transfection. The components included two chemically synthesized guides with 2'-O-methyl and phosphorothioate chemical modifications at the 5' and 3' ends, two integrated nucleic acids with 5' phosphate end modifications, two splint nucleic acids with locked and phosphorothioate modifications, an mRNA encoding a nicking Cas9 (LZ-nCas9, SEQ ID NO: 147), and an mRNA encoding a ligase (T4-LZ, SEQ ID NO: 145). For both "VEGFA 175nt replacement with attB" and "VEGFA 175nt deletion", the two guide RNAs used were VEGFA_R (SEQ ID NO: 170) and VEGFA_F (SEQ ID NO: 171). For both the "AAVS1 replacement of 117 nt with attB" and the "AAVS1 117 nt deletion", the two guide RNAs used were AAVS1_R (SEQ ID NO: 173) and AAVS1_F (SEQ ID NO: 192, mG*mC*mU*ggccccccaccgccccaGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCGACUUGAAAAAGUCGGACCGAGUCGGUCCGUGGUUCCGGGCUGCAmU*mG*mA). For "VEGFA replacement of 175nt with attB", the splint nucleic acids used were SEQ ID NO: 193 (+g*g*+ag+ac+cg+cc+gt+cg+tc+ga+ca+ag+cctctggcctgcagaTCATGC+AG+CC+CG+GA+AC+C*A*+C) and SEQ ID NO: 194 (+g*g*+cg+gt+ct+cc+gt+cg+tc+ag+ga+tc+attagccagagccggACGCCA+CA+AT+AC+CG+CA+G*C*+T) and the integrate nucleic acids used were SEQ ID NO: 195 ( / 5Phos / ggcttgtcgacgacggcggtctcc) and SEQ ID NO: 196 ( / 5Phos / atgatcctgacgacggagaccgcc).For the "VEGFA 175nt deletion", the splint nucleic acids used were SEQ ID NO: 197 (+C*C*+GT+CT+GC+AC+AC+CC+CG+GC+TC+TG+GC+TAtctggcctgcagaTCATGC+AG+CC+CG+GA+AC+C*A*+C) and SEQ ID NO: 198 (+G*C*+TC+AC+TT+TG+AT+GT+CT+GC+AG+GC+CA+GAtagccagagccggACGCCA+CA+AT+AC+CG+CA+G*C*+T) and the integrate nucleic acids used were SEQ ID NO: 199 ( / 5Phos / TAGCCAGAGCCGGGGTGTGCAGACGG) and SEQ ID NO: 200 ( / 5Phos / TCTGGCCTGCAGACATCAAAGTGAGC). For "AAVS1 replacement of 117 nt with attB", the splint nucleic acids used were SEQ ID NO: 201 (+g*g*+ag+ac+cg+cc+gt+cg+tc+ga+ca+ag+ccggcggtgggTCATGC+AG+CC+CG+GA+AC+C*A*+C) and SEQ ID NO: 202 (+g*g*+cg+gt+ct+cc+gt+cg+tc+ag+ga+tc+atccacttccaggACGCCA+CA+AT+AC+CG+CA+G*C*+T) and the integrating nucleic acids used were SEQ ID NO: 195 and SEQ ID NO: 196. For the "AAVS1 117nt deletion", the splint nucleic acids used were SEQ ID NO: 203 (+C*G*+GG+GC+AC+AG+CG+AC+TC+CT+GG+AA+GT+GGggcggtgggTCATGC+AG+CC+CG+GA+AC+C*A*+C) and SEQ ID NO: 204 (+G*G*+AA+CT+GC+CG+CT+GG+CC+CC+CC+AC+CG+CCccacttccaggACGCCA+CA+AT+AC+CG+CA+G*C*+T) and the integrate nucleic acids used were SEQ ID NO: 205 ( / 5Phos / CCACTTCCAGGAGTCGCTGTGCCCCG) and SEQ ID NO: 206 ( / 5Phos / GGCGGTGGGGGGCCAGCGGCAGTTCC). The embedding and splint nucleic acids were synthesized by Integrated DNA Technologies (IDT) and both mRNAs were generated via in vitro transcription reactions using the methods described in Example 7.The gRNA contained a spacer, scaffold, and donor binding site. The splint-integrating nucleic acid contained a guide-binding site and a flap-binding site. There were two pairs of integrating and ligating integrating and splint nucleic acids, each pair being partially complementary to each other. The integrating and splint nucleic acids were hybridized using an annealing reaction, then mixed with the guide RNA and mRNA and formulated with Lipofectamine 2000 in OptiMEM before delivery to adherent HEK293 cells in 96-well plates. After 24-48 hours, genomic DNA was extracted from the cells using QuickExtract and the genomic target was amplified using Q5 DNA polymerase. The PCR program was run at 98C for 30 seconds, then 35 cycles at 98C for 5 seconds, 67C for 20 seconds, and 72C for 20 seconds, then finally at 72C for 2 minutes. The PCR primers used for both "VEGFA replacement of 175 nt with attB" and "VEGFA 175 nt deletion" are SEQ ID NO: 186 and SEQ ID NO: 187. The PCR primers used for both "AAVS1 replacement of 117 nt with attB" and "AAVS1 117 nt deletion" are SEQ ID NO: 190 and SEQ ID NO: 191. The PCR products were cleaned with ExoCIP treatment and submitted for next generation sequencing (NGS). Sequencing reads were merged and aligned to the amplicons of interest, and the percentage of total reads that matched the intended edit was calculated (Figure 11). This example shows that when Replacer 2 is delivered as two complete sets of guide RNA, splint, and donor, it can delete the entire region of DNA between the nicking sites of each guide RNA and optionally replace that region of DNA with a new DNA sequence. Since the Replacer is now creating two separate flaps that can hybridize to each other, this gene editing mechanism would not be dependent on the MMR pathway. After the attB sequence has been inserted into the target site in the genome by the replacer, the entire synthetic gene, if delivered along with the Bxb1 integrase, can be inserted into the attB site.Thus, the attB sequence replacement described herein could be used for targeted insertion of large 1 kb+ DNA fragments into the genome without gene editing via double-strand breaks or mismatch repair.

[0257] Example 10. Use of one-sided replacer 2 with nicking Cas9 and T4 DNA ligase to integrate methylated DNA into genomic targets The components used to edit genomic targets in HEK293T cells were co-delivered by Lipofectamine 2000 transfection. The components included a chemically synthesized guide (SEQ ID NO: 166) with 2'-O-methyl and phosphorothioate chemical modifications at the 5' and 3' ends, an integrating nucleic acid, a splint nucleic acid, an mRNA encoding a nicking Cas9 (LZ-nCas9, SEQ ID NO: 147), and an mRNA encoding a ligase (T4-LZ, SEQ ID NO: 145). The condition with the "non-methylated donor" used an integrating nucleic acid with a 5' phosphate end modification (SEQ ID NO: 207, / 5Phos / CGTATGTCAGGGTGGTCACG). The condition with "donor with all cytosines methylated" used an incorporated nucleic acid with a 5' phosphate end modification and a methylated cytosine (SEQ ID NO: 207, 5Phos / / 5Me-dC / gtaTgt / iMe-dC / agggtggt / iMe-dC / a / iMe-dC / G). The condition under "splint is LNA" used a locked nucleic acid and a splint nucleic acid with a phosphorothioate modification (SEQ ID NO: 208, +C*g*+tg+ac+ca+cc+ct+ga+cA+TA+CGGCGTGCAgtgcttACGCCA+CA+AT+AC+CG+CA+G*C*+T). In the condition under "Splint is OMe", a splint nucleic acid with locked nucleic acid, 2'-O-methyl, and phosphorothioate modifications was used (SEQ ID NO: 209, mC*g*mUgmacmcamccmctmgamcAmUAmCGGCGTGCAgtgcttACGCCA+CA+AT+AC+CG+CA+G*C*+T). The embedding and splint nucleic acids were synthesized by Integrated DNA Technologies (IDT) and both mRNAs were generated via in vitro transcription reactions using the method described in Example 7. The gRNA contained a spacer, scaffold, and donor binding site. The splint embedding nucleic acid contained a guide binding site and a flap binding site. The ligation embedding and splint nucleic acids were partially complementary.The integrating and splinting nucleic acids were hybridized using an annealing reaction, then mixed with guide RNA and mRNA and formulated in Lipofectamine 2000 in OptiMEM before delivery to adherent HEK293 cells in 96-well plates. After 24-48 hours, cells were detached with 0.05% trypsin-EDTA and run through a flow cytometer to measure the percentage of cells expressing green fluorescent protein (GFP), indicating gene editing from BFP to GFP (Figure 12). This example shows that when the splint has LNA bases, methylated DNA can be used for the integrating nucleic acid and does not negatively affect editing efficiency under ideal conditions. When the splint has OMe bases instead of LNA and therefore has low affinity to the donor, methylated DNA in the donor increases efficiency, indicating that DNA methylation can improve the system by stabilizing the nucleic acid components. Methylated donors can also be used to specifically introduce DNA methylation into the genome at functional epigenetic sites such as promoters to modulate gene expression. Follow-up experiments can be performed by performing bisulfite sequencing on the genomic region where the replacer has introduced methylated DNA to confirm that epigenetic editing has occurred. If the replacer successfully introduced DNA methylation in this genomic region and the methylation status of the region is thought to control gene expression, quantitative PCR can be performed to confirm that the gene of interest has reduced mRNA expression after editing.

[0258] While preferred embodiments of the present invention have been shown and described herein, it will be apparent to those skilled in the art that such embodiments are provided by way of example only. It is not intended that the present invention be limited by the specific examples provided herein. The present invention has been described with reference to the foregoing specification, but the description and illustration of the embodiments herein are not intended to be construed in a limiting sense. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the present invention. It will be further understood that all aspects of the present invention are not limited to the specific depictions, configurations, or relative proportions described herein, which depend upon a variety of conditions and variables. It will be understood that various alternatives to the embodiments of the present invention described herein may be employed in the practice of the present invention. Thus, the present invention is also intended to cover any such alternatives, modifications, variations, or equivalents. It is intended that the following claims define the scope of the present invention, and that methods and structures within the scope of these claims, and their equivalents, are covered thereby.

[0259] Although the foregoing disclosure has been described in some detail for purposes of clarity and understanding, it will be apparent to those skilled in the art from a reading of this disclosure that various changes in form and detail can be made without departing from the true scope of the disclosure. For example, all of the techniques and apparatus described above can be used in various combinations. All publications, patents, patent applications, and / or other documents cited in this application are incorporated herein by reference in their entirety for all purposes to the same extent as if each individual publication, patent, patent application, and / or other document was individually indicated to be incorporated by reference for all purposes.

Claims

1. 1. A system comprising: an endonuclease coupled to a DNA ligase; an integrating nucleic acid configured to be ligated by the DNA ligase to a strand break generated by the endonuclease in a target nucleic acid.

2. The system of claim 1 , wherein the coupling is a covalent bond.

3. The system of claim 2 comprising a fusion protein comprising said endonuclease and said DNA ligase.

4. The system of claim 3 , wherein the endonuclease is amino (N) terminal to the DNA ligase in the fusion protein.

5. The system of claim 3 , wherein the endonuclease is carboxy (C) terminal to the DNA ligase in the fusion protein.

6. The system of claim 3, wherein the fusion protein comprises a linker comprising 1 to 100 amino acids connecting the endonuclease and the DNA ligase.

7. The system of claim 1 , wherein the coupling is a non-covalent bond.

8. 8. The system of claim 7, wherein the endonuclease coupled to the DNA ligase comprises a first polypeptide comprising at least a portion of the endonuclease and a second polypeptide comprising at least a portion of the DNA ligase, wherein the first and second polypeptides are non-covalently coupled.

9. The system of claim 8, wherein the first polypeptide comprises a first heterodimerization domain that binds to a second heterodimerization domain, and the second polypeptide comprises the second heterodimerization domain.

10. The system of claim 9 , wherein the heterodimerization domain comprises a leucine zipper, a PDZ domain, streptavidin, a streptavidin binding protein, a foldon domain, a hydrophobic portion, or a functional binding fragment thereof.

11. 9. The system of claim 8, wherein the first polypeptide comprises a first intein that binds to a second intein, and the second polypeptide comprises the second intein.

12. 2. The system of claim 1, wherein the ligase comprises a hairpin binding motif, and the endonuclease and the DNA ligase are coupled to a nucleic acid comprising a scaffold that binds to the endonuclease and a hairpin that binds to the hairpin binding motif.

13. The system of claim 12 , wherein the hairpin binding motif comprises an MS2 coat protein (MCP) peptide and the hairpin comprises an MS2 hairpin.

14. The system of claim 1 , wherein the endonuclease and the DNA ligase are coupled to a heterobifunctional molecule comprising an endonuclease binding domain and a DNA ligase binding domain.

15. The system of claim 14 , wherein the heterobifunctional molecule comprises a small molecule.

16. A system comprising a cell containing an RNA-guided endonuclease and a DNA ligase, both of which are heterologous to the cell, and an integrated nucleic acid configured to be ligated by the DNA ligase to a strand break generated by the endonuclease in a target nucleic acid.

17. A system comprising a cell containing a heterologous RNA-guided endonuclease, an endogenous DNA ligase, and an integrated nucleic acid configured to be ligated by the DNA ligase to a strand break generated by the endonuclease in a target nucleic acid.

18. The system of any one of claims 1 to 17, wherein the endonuclease comprises an RNA-guided endonuclease.

19. 20. The system of claim 18, wherein the endonuclease comprises a class II CRISPR / Cas endonuclease.

20. 20. The system of claim 19, wherein the endonuclease comprises a Cas9 endonuclease.

21. The system of claim 18 , wherein the endonuclease comprises a nickase.

22. 22. The system of claim 21 , wherein the endonuclease comprises a Cas9 nickase.

23. The system of any one of claims 1 to 17, wherein the DNA ligase ligates DNA strand bases paired to a DNA splint.

24. The system of any one of claims 1 to 17, wherein the DNA ligase ligates DNA strand bases paired to an RNA splint.

25. The system according to any one of claims 1 to 17, wherein the endonuclease or the DNA ligase comprises a nuclear localization signal, a chromatin modifying domain, a cell penetrating peptide, or a tag polypeptide.

26. 20. The system of claim 18, further comprising a guide RNA.

27. One or more nucleic acids encoding the endonuclease or DNA ligase according to any one of claims 1 to 16.

28. A cell comprising the system according to any one of claims 1 to 15.

29. A nucleic acid system comprising: a. a guide nucleic acid, i. a spacer complementary to a region of the genomic locus on the genomic strand; ii. a scaffold for complexing with an endonuclease; iii. an optional donor binding site that is at least partially complementary to the incorporated nucleic acid; and iv. the guide nucleic acid comprises a flap binding site that is at least partially identical to or complementary to a genomic flap at or adjacent to the genomic locus; and b. an integrating nucleic acid comprising a 5' end that is ligated to the 3' end of the genomic strand generated by the endonuclease.

30. A nucleic acid system comprising: a. a guide nucleic acid, i. a spacer complementary to a region of the genomic locus on the genomic strand; ii. a scaffold for complexing with an endonuclease, and iii. The guide nucleic acid includes an optional donor binding site that is at least partially complementary to the splint nucleic acid; b. an integrating nucleic acid comprising a 5' end that is ligated to the 3' end of the genomic strand generated by the endonuclease; and a splint nucleic acid comprising a flap binding site that is at least partially identical to or complementary to a genomic flap at or adjacent to the genomic locus, and an optional guide binding site that is at least partially complementary to a guide nucleic acid.

31. The system of claim 29 or 30, wherein the genomic strand is within a cell.

32. The system of claim 29 or 30, wherein the splint nucleic acid further comprises a donor binding site that is at least partially identical to or complementary to a portion of the integrating nucleic acid.

33. 31. The system of claim 29 or 30, wherein the guide nucleic acid comprises a sequence of a linking nucleic acid between the scaffold and the donor binding site.

34. 31. The system of Claim 29 or 30, wherein the guide nucleic acid, the embedding nucleic acid, or the splint nucleic acid comprises a modified internucleoside linkage.

35. 35. The system of claim 34, wherein the modified internucleoside linkage comprises a phosphorothioate linkage.

36. 31. The system of Claim 29 or 30, wherein the guide nucleic acid, the embedding nucleic acid, or the splint nucleic acid comprises a modified nucleoside.

37. 37. The system of claim 36, wherein the modified nucleosides comprise locked nucleic acid (LNA), 2'fluoro, 2'O-alkyl, methylated cytosine, inverted thymidine, or a combination thereof.

38. 31. The system of claim 29 or 30, wherein the endonuclease comprises an RNA-guided endonuclease.

39. 39. The system of claim 38, wherein the endonuclease comprises a class II CRISPR / Cas endonuclease.

40. 40. The system of claim 39, wherein the endonuclease comprises a Cas9 endonuclease.

41. The system of claim 38 , wherein the endonuclease comprises a nickase.

42. 42. The system of claim 41 , wherein the endonuclease comprises a Cas9 nickase.

Citation Information

Patent Citations

  • Methods for generating nucleic acid libraries and compositions and kits for carrying them out

    JP2021526798A

  • Scarless DNA assembly and genome editing using crispr / cpf1 and DNA ligase

    US20190330659A1

  • Methods of synthesizing RNA molecules

    WO2021108647A1

  • Ligation-based gene editing using crispr nickase

    WO2021127238A1

  • Programmable DNA nuclease-associated ligase and methods of use thereof

    WO2021133977A1